

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number
WO 01/49097 A2

(51) International Patent Classification: Not classified

(21) International Application Number: PCT/IB01/00797

(22) International Filing Date: 9 May 2001 (09.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 09/416,901 (CON)
Filed on 10 March 1999 (10.03.1999)

(71) Applicants and

(72) Inventors: BIENKOWSKI, Michael, Jerome [US/US]; Global Intellectual Property, Building 209, 301 Henrietta Street, Kalamazoo, MI 49001-0199 (US). GURNEY, Mark, E. [US/IS]; Lyngghals 1, IS-110 Rey Kavik (IS). HEINRIKSON, Robert, Leroy [US/US]; Global Intellectual Property, Building 209, 301 Henrietta Street, Kalamazoo, MI 49001-0199 (US). PARODI, Luis, A.

[US/SE]; Grevgafan 24, S-115 43 Stockholm (SE). YAN, Riqiang [US/US]; Global Intellectual Property, Building 209, 301 Henrietta Street, Kalamazoo, MI 49001-0199 (US).

(74) Agent: GASS, David, A.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).

(81) Designated State (*national*): US.

Published:

- Upon request of the applicant under Article 64(3)(c)(i).
- Upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a).
- Without international search report and to be republished upon receipt of that report.
- Without classification; title and abstract not checked by the International Searching Authority.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/49097 A2

(54) Title: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES THEREFOR

(57) Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the B secretase cleavage site off the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.

Alzheimer's Disease Secretase, APP Substrates Therefor, and Uses Therefor

The present application is a continuation of United States Application Serial No. 09/416,901, filed October 13, 1999 which claims priority benefit of United States Provisional Patent Application No. 60/155,493, filed September 23, 1999. The present application also claims priority benefit as a continuation-in-part of United States Patent Application Serial No. 09/404,133 and PCT/US99/20881, both filed September 23, 1999, both of which in turn claim priority benefit of United States Provisional Patent Application No. 60/101,594, filed September 24, 1998. All of these priority applications are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to Alzheimer's Disease, amyloid protein precursor, amyloid beta peptide, and human aspartyl proteases, as well as a method for the identification of agents that modulate the activity of these polypeptides and thereby are candidates to modulate the progression of Alzheimer's disease.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) causes progressive dementia with consequent formation of amyloid plaques, neurofibrillary tangles, gliosis and neuronal loss. The disease occurs in both genetic and sporadic forms whose clinical course and pathological features are quite similar. Three genes have been discovered to date which, when mutated, cause an autosomal dominant form of Alzheimer's disease. These encode the amyloid protein precursor (APP) and two related proteins, presenilin-1 (PS1) and presenilin-2 (PS2), which, as their names suggest, are structurally and functionally related. Mutations in any of the three proteins have been observed to enhance proteolytic processing of APP via an intracellular pathway that produces amyloid beta peptide (A β peptide, or sometimes here as Abeta), a 40-42 amino acid long peptide that is the primary component of amyloid plaque in AD.

Dysregulation of intracellular pathways for proteolytic processing may be central to the pathophysiology of AD. In the case of plaque formation, mutations in APP, PS1 or PS2 consistently alter the proteolytic processing of APP so as to enhance formation of A β 1-42, a form of the A β peptide which seems to be particularly amyloidogenic, and thus very important in AD. Different forms of APP range in size from 695-770 amino acids, localize to the cell surface, and have a single C-terminal transmembrane domain. Examples of specific isoforms of APP which are currently known to exist in humans are the 695-amino acid polypeptide described by Kang *et al.* (1987), *Nature* 325: 733-736 which is designated as the "normal" APP; the 751 amino acid polypeptide described by Ponte *et al.* (1988), *Nature* 331: 525-527 (1988) and Tanzi *et al.* (1988), *Nature* 331: 528-530; and the 770 amino acid polypeptide described by Kitaguchi *et al.* (1988), *Nature* 331: 530-532. The Abeta peptide is derived from a region of APP adjacent to and containing a portion of the transmembrane domain. Normally, processing of APP at the α -secretase site cleaves the midregion of the A β sequence adjacent to the membrane and releases the soluble, extracellular domain of APP from the cell surface. This α -secretase APP processing creates soluble APP- α , which is normal and not thought to contribute to AD. Pathological processing of APP at the β - and γ -secretase sites, which are located N-terminal and C-terminal to the α -secretase site, respectively, produces a very different result than processing at the α site. Sequential processing at the β - and γ -secretase sites releases the A β peptide, a peptide possibly very important in AD pathogenesis. Processing at the β - and γ -secretase sites can occur in both the endoplasmic reticulum (in neurons) and in the endosomal/lysosomal pathway after reinternalization of cell surface APP (in all cells). Despite intense efforts, for 10 years or more, to identify the enzymes responsible for processing APP at the β and γ sites, to produce the A β peptide, those proteases remained unknown until this disclosure.

SUMMARY OF THE INVENTION

Here, for the first time, we report the identification and characterization of the β secretase enzyme, termed Aspartyl Protease 2 (Asp2). We disclose some known

and some novel human aspartic proteases that can act as β -secretase proteases and, for the first time, we explain the role these proteases have in AD. We describe regions in the proteases critical for their unique function and for the first time characterize their substrate. This is the first description of expressed isolated purified active protein of this type, assays that use the protein, in addition to the identification and creation of useful cell lines and inhibitors.

Here we disclose a number of variants of the Asp2 gene and peptide.

In one aspect, the invention provides any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of nucleic acids is the first special nucleic acid, and where the second set of nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of nucleic acids is the last special nucleic acid, with the proviso that the nucleic acids disclosed in SEQ ID NO. 1 and SEQ ID NO. 3 are not included. In a preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 125 to 222 amino acid positions, which may be any amino acids. In a highly preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 150 to 196, or 150-190, or 150 to 172 amino acid positions, which may be any amino acids. In a particular preferred embodiment, the two sets are separated by nucleic acids that code for about 172 amino acid positions, which may be any amino acids. An exemplary nucleic acid polynucleotide comprises the acid nucleotide sequence in SEQ ID NO. 5. In another particular preferred embodiment, the two sets are separated by nucleic acids that code for about 196 amino acids. An exemplary polynucleotide comprises the nucleotide sequence in SEQ ID NO. 5. In another particular embodiment, the two sets of nucleotides are separated by nucleic acids that code for about 190 amino acids. An exemplary polynucleotide

comprises the nucleotide sequence in SEQ ID NO. 1. Preferably, the first nucleic acid of the first special set of amino acids, that is, the first special nucleic acid, is operably linked to any codon where the nucleic acids of that codon codes for any peptide comprising from 1 to 10,000 amino acid (positions). In one variation, the first special
5 nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. For example, the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green
10 Fluorescent protein, and ubiquitin. In another variation, the last nucleic acid of the second set of special amino acids, that is, the last special nucleic acid, is operably linked to nucleic acid polymers that code for any peptide comprising any amino acids from 1 to 10,000 amino acids. In still another variation, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the
15 group consisting of: any reporter proteins or proteins which facilitate purification. For example, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

20 In a related aspect, the invention provides any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino
25 acids, where the first set of special nucleic acids consists of the nucleic acids that code for DTG, where the first nucleic acid of the first special set of nucleic acids is the first special nucleic acid, and where the second set of nucleic acids code for either DSG or DTG, where the last nucleic acid of the second set of special nucleic acids is the last special nucleic acid, where the first special nucleic acid is operably linked to nucleic
30 acids that code for any number of amino acids from zero to 81 amino acids and where

each of those codons may code for any amino acid. In a preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 64 to 77 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 71 amino acids. For example, the first special nucleic acid is operably linked to 71 amino acids and where the first of those 71 amino acids is the amino acid T. In a preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to a human Asp1 or Asp2 sequence as taught herein. In another preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 30 to 54 amino acids, or 35 to 47 amino acids, or 40 to 54 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 47 amino acids. For example, the first special nucleic acid is operably linked to 47 codons where the first those 47 amino acids is the amino acid E.

In another related aspect, the invention provides for any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP and that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of amino acids is, the first special nucleic acid, and where the second set of special nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of special nucleic acids, the last special nucleic acid, is operably linked to nucleic acids that code for any number of codons from 50 to 170 codons. In a preferred embodiment, the last special nucleic acid is operably linked to nucleic acids comprising from 100 to 170 codons. In a highly preferred embodiment, the last special nucleic acid is operably linked to nucleic acids comprising from 142 to 163 codons. In a particular embodiment, the last special nucleic acid is operably linked to nucleic acids comprising about 142 codons, or about 163 codons, or about 170

codons. In a highly preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to aspartyl-protease encoding sequences taught herein. In one variation, the second set of special nucleic acids code for the peptide DSG. In another variation, the first set of nucleic acid polynucleotide is operably linked to a peptide purification tag. For example, the nucleic acid polynucleotide is operably linked to a peptide purification tag which is six histidine. In still another variation, the first set of special nucleic acids are on one polynucleotide and the second set of special nucleic acids are on a second polynucleotide, where both first and second polynucleotides have at least 50 codons. In one embodiment of this type, both of the polynucleotides are in the same solution. In a related aspect, the invention provides a vector which contains a polynucleotide as described above, or a cell or cell line which is transformed or transfected with a polynucleotide as described above or with a vector containing such a polynucleotide.

In still another aspect, the invention provides an isolated or purified peptide or protein comprising an amino acid polymer that is a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid position can be any amino acid, where the first set of special amino acids consists of the peptide DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, where the second set of amino acids is selected from the peptide comprising either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, with the proviso that the proteases disclosed in SEQ ID NO. 2 and SEQ ID NO. 4 are not included. In preferred embodiments, the two sets of amino acids are separated by about 125 to 222 amino acid positions or about 150 to 196 amino acids, or about 150-190 amino acids, or about 150 to 172 amino acids, where in each position it may be any amino acid. In a particular embodiment, the two sets of amino acids are separated by about 172 amino acids. For example, the protease has the amino acid sequence described in SEQ ID NO 6. In another particular embodiment, the two sets of amino acids are separated by about 196 amino acids. For example, the two sets of amino

acids are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 4. In another particular embodiment, the two sets of nucleotides are separated by about 190 amino acids. For example, the two sets of nucleotides are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 2. In one embodiment, the first amino acid of the first special set of amino acids, that is, the first special amino acid, is operably linked to any peptide comprising from 1 to 10,000 amino acids. In another embodiment, the first special amino acid is operably linked to any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. In particular embodiments, the first special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin. In still another variation, the last amino acid of the second set of special amino acids, that is, the last special amino acid, is operably linked to any peptide comprising any amino acids from 1 to 10,000 amino acids. By way of nonlimiting example, the last special amino acid is operably linked any peptide selected from the group consisting of any reporter proteins or proteins which facilitate purification. In particular embodiments, the last special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

In a related aspect, the invention provides any isolated or purified peptide or protein comprising an amino acid polypeptide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids is either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, where the first special amino acid is operably linked to amino acids that code for any

number of amino acids from zero to 81 amino acid positions where in each position it may be any amino acid. In a preferred embodiment, the first special amino acid is operably linked to a peptide from about 30-77 or about 64 to 77 amino acids positions where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to a peptide 35, 47, 71, or 77 amino acids. In a very particular embodiment, the first special amino acid is operably linked to 71 amino acids and the first of those 71 amino acids is the amino acid T. For example, the polypeptide comprises a sequence that is at least 95% identical to an aspartyl protease sequence as described herein. In another embodiment, the first special amino acid is operably linked to any number of from 40 to 54 amino acids (positions) where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to amino acids that code for a peptide of 47 amino acids. In a very particular embodiment, the first special amino acid is operably linked to a 47 amino acid peptide where the first those 47 amino acids is the amino acid E. In another particular embodiment, the first special amino acid is operably linked to the same corresponding peptides from SEQ ID NO. 3 that are 35, 47, 71, or 77 peptides in length, beginning counting with the amino acids on the first special sequence, DTG, towards the N-terminal of SEQ ID NO. 3. In another particular embodiment, the polypeptide comprises a sequence that is at least 95% identical to the same corresponding amino acids in SEQ ID NO. 4, that is, identical to that portion of the sequences in SEQ ID NO. 4, including all the sequences from both the first and or the second special nucleic acids, toward the – terminal, through and including 71, 47, 35 amino acids before the first special amino acids. For example, the complete polypeptide comprises the peptide of 71 amino acids, where the first of the amino acid is T and the second is Q.

In still another related aspect, the invention provides any isolated or purified amino acid polypeptide that is a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special

amino acids consists of the amino acids that code for DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids are either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, which is operably
5 linked to any number of amino acids from 50 to 170 amino acids, which may be any amino acids. In preferred embodiments, the last special amino acid is operably linked to a peptide of about 100 to 170 amino acids or about 142-163 amino acids. In particular embodiments, the last special amino acid is operably linked to a peptide of about 142 amino acids, or about 163 amino acids, or about 170 amino acids. For
10 example, the polypeptide comprises a sequence that is at least 95% identical (and preferably 100% identical) to an aspartyl protease sequence as described herein. In one particular embodiment, the second set of special amino acids is comprised of the peptide with the amino acid sequence DSG. Optionally, the amino acid polypeptide is operably linked to a peptide purification tag, such as purification tag which is six
15 histidine. In one variation, the first set of special amino acids are on one polypeptide and the second set of special amino acids are on a second polypeptide, where both first and second polypeptide have at least 50 amino acids, which may be any amino acids. In one embodiment of this type, both of the polypeptides are in the same vessel. The invention further includes a process of making any of the polynucleotides,
20 vectors, or cells described herein; and a process of making any of the polypeptides described herein.

In yet another related aspect, the invention provides a purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide having aspartyl protease activity, wherein the polypeptide has an amino acid sequence characterized by: (a) a
25 first tripeptide sequence DTG; (b) a second tripeptide sequence selected from the group consisting of DSG and DTG; and (c) about 100 to 300 amino acids separating the first and second tripeptide sequences, wherein the polypeptide cleaves the beta secretase cleavage site of amyloid protein precursor. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4,
30 whereas in another embodiment, the polypeptide comprises an amino acid sequence

other than the amino acid sequences set forth in SEQ ID NOs: 2 and 4. Similarly, the invention provides a purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide that cleaves the beta secretase cleavage site of amyloid protein precursor; wherein the polynucleotide includes a strand that hybridizes to one or more of SEQ ID NOs: 3, 5, and 7 under the following hybridization conditions: hybridization overnight at 42°C for 2.5 hours in 6 X SSC/0.1% SDS, followed by washing in 1.0 X SSC at 65°C, 0.1% SDS. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4, whereas in another embodiment, the polypeptide comprises an amino acid sequence other than the amino acid sequences set forth in SEQ ID NOs: 2 and 4. Likewise, the invention provides a purified polypeptide having aspartyl protease activity, wherein the polypeptide is encoded by polynucleotides as described in the preceding sentences. The invention also provides a vector or host cell comprising such polynucleotides, and a method of making the polypeptides using the vectors or host cells to recombinantly express the polypeptide.

In yet another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide, said polynucleotide encoding a Hu-Asp polypeptide and having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), wherein said Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) polypeptides have the complete amino acid sequence of SEQ ID NO. 2, SEQ ID NO. 4, and SEQ ID NO. 6, respectively; and
- (b) a nucleotide sequence complementary to the nucleotide sequence of (a).

Several species are particularly contemplated. For example, the invention provides a nucleic acid and molecule wherein said Hu-Asp polypeptide is Hu-Asp1, and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 1; and a nucleic acid molecule wherein said Hu-Asp polypeptide is Hu-Asp2(a), and said polynucleotide molecule of 1(a) comprises the nucleotide

sequence of SEQ ID NO. 4; and a nucleic acid molecule wherein said Hu-Asp polypeptide is Hu-Asp2(b), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 5. In addition to the foregoing, the invention provides an isolated nucleic acid molecule comprising polynucleotide which
5 hybridizes under stringent conditions to a polynucleotide having the nucleotide sequence in (a) or (b) as described above.

Additionally, the invention provides a vector comprising a nucleic acid molecule as described in the preceding paragraph. In a preferred embodiment, the nucleic acid molecule is operably linked to a promoter for the expression of a Hu-Asp
10 polypeptide. Individual vectors which encode Hu-Asp1, and Hu-Asp2(a), and Hu-Asp2(b) are all contemplated. Likewise, the invention contemplates a host cell comprising any of the foregoing vectors, as well as a method of obtaining a Hu-Asp polypeptide comprising culturing such a host cell and isolating the Hu-Asp polypeptide. Host cells of the invention include bacterial cells, such as *E. coli*, and
15 eukaryotic cells. Among the eukaryotic cells that are contemplated are insect cells, such as sf9 or High 5 cells; and mammalian cells, such as human, rodent, lagomorph, and primate. Preferred human cells include HEK293, and IMR-32 cells. Other preferred mammalian cells include COS-7, CHO-K1, Neuro-2A, and 3T3 cells. Also among the eukaryotic cells that are contemplated are a yeast cell and an avian cell.

20 In a related aspect, the invention provides an isolated Hu-Asp1 polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 2. The invention also provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 4. The invention also
25 provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 8.

In still another aspect, the invention provides an isolated antibody that binds specifically to any Hu-Asp polypeptide described herein, especially the polypeptide
30 described in the preceding paragraphs.

The invention also provides several assays involving aspartyl protease enzymes of the invention. For example, the invention provides

a method to identify a cell that can be used to screen for inhibitors of β secretase activity comprising:

- 5 (a) identifying a cell that expresses a protease capable of cleaving APP at the β secretase site, comprising:
 - i) collect the cells or the supernatant from the cells to be identified
 - 10 ii) measure the production of a critical peptide, where the critical peptide is selected from the group consisting of either the APP C-terminal peptide or soluble APP,
 - iii) select the cells which produce the critical peptide.

In one variation, the cells are collected and the critical peptide is the APP C-terminal peptide created as a result of the β secretase cleavage. In another
15 variation, the supernatant is collected and the critical peptide is soluble APP, where the soluble APP has a C-terminus created by β secretase cleavage. In preferred embodiments, the cells contain any of the nucleic acids or polypeptides described above and the cells are shown to cleave the β secretase site of any peptide having the following peptide structure, P2, P1, P1', P2', where P2 is K or N, where P1 is M or
20 L, where P1' is D, where P2' is A. The method of claim 111 where P2 is K and P1 is M. The method of claim 112 where P2 is N and P1 is L.

In still another aspect, the invention provides novel isoforms of amyloid protein precursor (APP) where the last two carboxy terminus amino acids of that isoform are both lysine residues. In this context, the term "isoform" is defined as any
25 APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans, such as those described in US 5,766,846, col 7, lines 45-67, incorporated into this document by reference, modified as described herein by the inclusion of two C-terminal lysine residues. For example, the invention provides a polypeptide comprising the isoform known as APP695, modified to include two lysine
30 residues as its last two carboxy terminus amino acids. An exemplary polypeptide

comprises the amino acid sequence set forth in SEQ ID NO. 16. The invention further includes APP isoform variants as set forth in SEQ ID NOs. 18 and 20. The invention further includes all polynucleotides that encode an APP protein that has been modified to include two C-terminal lysines; as well as any eukaryotic cell line comprising such nucleic acids or polypeptides. Preferred cell lines include a mammalian cell line (*e.g.*, HEK293, Neuro2a).

Thus, in one embodiment, the invention provides a polypeptide comprising the amino acid sequence of a mammalian amyloid protein precursor (APP) or fragment thereof containing an APP cleavage site recognizable by a mammalian β -secretase, and further comprising two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian APP or APP fragment. As taught herein in detail, the addition of two additional lysine residues to APP sequences has been found to greatly increase $A\beta$ processing of the APP in APP processing assays. Thus, the di-lysine modified APP reagents of the invention are particularly useful in assays to identify modulators of $A\beta$ production, for use in designing therapeutics for the treatment or prevention of Alzheimer's disease. In one embodiment, the polypeptide comprises the complete amino acid sequence of a mammalian amyloid protein precursor (APP), and further comprises the two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian amyloid protein precursor. In an alternative embodiment, the polypeptide comprises only a fragment of the APP, the fragment containing at least that portion of APP that is cleaved by a mammalian β -secretase in the formation of $A\beta$ peptides.

The practice of assays that monitor cleavage of APP can be facilitated by attaching a marker to a portion of the APP. Measurement of retained or liberated marker can be used to quantitate the amount of APP cleavage that occurs in the assay, *e.g.*, in the presence or absence of a putative modulator of cleavage activity. Thus, in one preferred embodiment, the polypeptide of the invention further includes a marker. For example, the marker comprises a reporter protein amino acid sequence attached to the APP amino acid sequence. Exemplary reporter proteins include a fluorescing protein (*e.g.*, green fluorescing proteins, luciferase) or an enzyme that is used to

cleave a substrate to produce a colorimetric cleavage product. Also contemplated are tag sequences which are commonly used as epitopes for quantitative immunoassays.

In a preferred embodiment, the di-lysine-modified APP of the invention is a human APP. For example, human APP isoforms such as APP695, APP751, and APP770, modified to include the two lysines, are contemplated. In a preferred embodiment, the APP isoform comprises at least one variation selected from the group consisting of a Swedish KM-NL mutation and a London V717-F mutation, or any other mutation that has been observed in a subpopulation that is particularly prone to development of Alzheimer's disease. These mutations are recognized as mutations that influence APP processing into A β . In a highly preferred embodiment, the APP protein or fragment thereof comprises the APP-Sw β -secretase peptide sequence NLDA (SEQ ID NO: 66), which is associated with increased levels of A β processing and therefore is particularly useful in assays relating to Alzheimer's research. More particularly, the APP protein or fragment thereof preferably comprises the APP-Sw β -secretase peptide sequence SEVNLDAEFR (SEQ ID NO: 63).

In one preferred embodiment, the APP protein or fragment thereof further includes an APP transmembrane domain carboxy-terminal to the APP-Sw β -secretase peptide sequence. Polypeptides that include the TM domain are particularly useful in cell-based APP processing assays. In contrast, embodiments lacking the TM domain are useful in cell-free assays of APP processing.

In addition to working with APP from humans and various animal models, researchers in the field of Alzheimer's also have construct chimeric APP polypeptides which include stretches of amino acids from APP of one species (e.g., humans) fused to stretches of APP from one or more other species (e.g., rodent). Thus, in another embodiment of the polypeptide of the invention, the APP protein or fragment thereof comprises a chimeric APP, the chimeric APP including partial APP amino acid sequences from at least two species. A chimeric APP that includes amino acid sequence of a human APP and a rodent APP is particularly contemplated.

In a related aspect, the invention provides a polynucleotide comprising a nucleotide sequence that encodes a polypeptide as described in the preceding

paragraphs. Such a polynucleotide is useful for recominant expression of the polypeptide of the invention for use in APP processing assays. In addition, the polynucleotide is useful for transforming into cells to produce recombinant cells that express the polypeptide of the invention, which cells are useful in cell-based assays to
5 identify modulators of APP processing. Thus, in addition to polynucleotides, the invention provides a vector comprising such polynucleotides, especially expression vectors where the polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell. The invention further provides a host cell transformed or transfected with a polynucleotide
10 according to claim 14 or a vector according to claim 15 or 16. Among the preferred host cells are mammalian cells, especially human cells.

In another, related embodiment, the invention provides a polypeptide useful for assaying for modulators of β -secretase activity, said polypeptide comprising an amino acid sequence of the formula $\text{NH}_2\text{-X-Y-Z-KK-COOH}$; wherein X, Y, and Z
15 each comprise an amino acid sequence of at least one amino acid; wherein $\text{NH}_2\text{-X}$ comprises an amino-terminal amino acid sequence having at least one amino acid residue; wherein Y comprises an amino acid sequence of a β -secretase recognition site of a mammalian amyloid protein precursor (APP); and wherein Z-KK-COOH comprises a carboxy-terminal amino acid sequence ending in two lysine (K) residues.
20 In one preferred variation, the carboxyl-terminal amino acid sequence Z includes a hydrophobic domain that is a transmembrane domain in host cells that express the polypeptide. Host cells that express such a polypeptide are particularly useful in assays described herein for identifying modulators of APP processing. In another preferred variation, the amino-terminal amino acid sequence X includes an amino acid
25 sequence of a reporter or marker protein, as described above. In still another preferred variation, the β -secretase recognition site Y comprises the human APP-Sw β -secretase peptide sequence NLDA (SEQ ID NO: 66). It will be apparent that these preferred variations are not mutually exclusive of each other -- they may be combined in a single polypeptide. The invention further provides a polynucleotide comprising a
30 nucleotide sequence that encodes such polypeptides, vectors which comprise such

polynucleotides, and host cells which comprises such vectors, polynucleotides, and/or polypeptides.

In yet another aspect, the invention provides a method for identifying inhibitors of an enzyme that cleaves the beta secretase cleavable site of APP comprising:

- a) culturing cells in a culture medium under conditions in which the enzyme causes processing of APP and release of amyloid beta-peptide into the medium and causes the accumulation of CTF99 fragments of APP in cell lysates,
- b) exposing the cultured cells to a test compound; and specifically determining whether the test compound inhibits the function of the enzyme by measuring the amount of amyloid beta-peptide released into the medium and/or the amount of CTF99 fragments of APP in cell lysates;
- c) identifying test compounds diminishing the amount of soluble amyloid beta peptide present in the culture medium and diminution of CTF99 fragments of APP in cell lysates as Asp2 inhibitors. In preferred embodiments, the cultured cells are a human, rodent or insect cell line. It is also preferred that the human or rodent cell line exhibits β secretase activity in which processing of APP occurs with release of amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates. Among the contemplated test compounds are antisense oligomers directed against the enzyme that exhibits β secretase activity, which oligomers reduce release of soluble amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates.

In yet another aspect, the invention provides a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising:

- a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and
- b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent; whereby a lower level of activity in the presence of said

test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide.

In a related aspect, the invention provides a method for assaying for modulators of β -secretase activity, comprising the steps of:

- 5 (a) contacting a first composition with a second composition both in the presence and in the absence of a putative modulator compound, wherein the first composition comprises a mammalian β -secretase polypeptide or biologically active fragment thereof, and wherein the second composition comprises a substrate polypeptide having an amino acid sequence comprising a β -secretase cleavage site;
- 10 (b) measuring cleavage of the substrate polypeptide in the presence and in the absence of the putative modulator compound; and (c) identifying modulators of β -secretase activity from a difference in cleavage in the presence versus in the absence of the putative modulator compound. A modulator that is a β -secretase antagonist (inhibitor) reduces such cleavage, whereas a modulator that is a β -secretase agonist
- 15 increases such cleavage. Since such assays are relevant to development of Alzheimer's disease therapeutics for humans, it will be readily apparent that, in one preferred embodiment, the first composition comprises a purified human Asp2 polypeptide. In one variation, the first composition comprises a soluble fragment of a human Asp2 polypeptide that retains Asp2 β -secretase activity. Several such
- 20 fragments (including Δ TM fragments) are described herein in detail. Thus, in a particular embodiment, the soluble fragment is a fragment lacking an Asp2 transmembrane domain.

The β -secretase cleavage site in APP is known, and it will be appreciated that the assays of the invention can be performed with either intact APP

25 or fragments or analogs of APP that retain the β -secretase recognition and cleavage site. Thus, in one variation, the substrate polypeptide of the second composition comprises the amino acid sequence SEVNLDAEFR (SEQ ID NO: 63), which includes the β -secretase recognition site of human APP that contains the "Swiss" mutation. In another variation, the substrate polypeptide of the second composition

30 comprises the amino acid sequence EVKMDAEF (SEQ ID NO: 67). In another

variation, the second composition comprises a polypeptide having an amino acid sequence of a human amyloid precursor protein (APP). For example, the human amyloid precursor protein is selected from the group consisting of: APP695, APP751, and APP770. Preferably, the human amyloid precursor protein (irrespective of

5 isoform selected) includes at least one mutation selected from a KM→NL Swiss mutation and a V→F London mutation. As explained elsewhere, one preferred embodiment involves a variation wherein the polypeptide having an amino acid sequence of a human APP further comprises an amino acid sequence comprising a marker sequence attached amino-terminal to the amino acid sequence of the human

10 amyloid precursor protein. Preferably, the polypeptide having an amino acid sequence of a human APP further comprises two lysine residues attached to the carboxyl terminus of the amino acid sequence of the human APP. The assays can be performed in a cell free setting, using cell-free enzyme and cell-free substrate, or can be performed in a cell-based assay wherein the second composition comprises a

15 eukaryotic cell that expresses amyloid precursor protein (APP) or a fragment thereof containing a β -secretase cleavage site. Preferably, the APP expressed by the host cell is an APP variant that includes two carboxyl-terminal lysine residues. It will also be appreciated that the β -secretase enzyme can be an enzyme that is expressed on the surface of the same cells.

20 The present invention provides isolated nucleic acid molecules comprising a polynucleotide that codes for a polypeptide selected from the group consisting of human aspartyl proteases. In particular, human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), a "long" (L) form designated herein as Hu-Asp2(a) and a "short" (S) form designated Hu-Asp2(b).

25 As used herein, all references to "Hu-Asp" should be understood to refer to all of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b). In addition, as used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain

tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

In a preferred embodiment, the nucleic acid molecules comprise a polynucleotide having a nucleotide sequence selected from the group consisting of residues 1-1554 of SEQ ID NO. 1, encoding Hu-Asp1, residues 1-1503 of SEQ ID NO. 3, encoding Hu-Asp2(a), and residues 1-1428 of SEQ ID NO.5, encoding Hu-Asp2(b). In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide encoding Hu-Asp1, Hu-Asp2(a), Hu-Asp-2(b), or fragments thereof. European patent application EP 0 848 062 discloses a polypeptide referred to as "Asp 1," that bears substantial homology to Hu-Asp1, while international application WO 98/22597 discloses a polypeptide referred to as "Asp 2," that bears substantial homology to Hu-Asp2(a).

The present invention also provides vectors comprising the isolated nucleic acid molecules of the invention, host cells into which such vectors have been introduced, and recombinant methods of obtaining a Hu-Asp1, Hu-Asp2(a), or Hu-Asp2(b) polypeptide comprising culturing the above-described host cell and isolating the relevant polypeptide.

In another aspect, the invention provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof. In a preferred embodiment, the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides have the amino acid sequence given in SEQ ID NO. 2, SEQ ID NO. 4, or SEQ ID NO.6, respectively. The present invention also describes active forms of Hu-Asp2, methods for preparing such active forms, methods for preparing soluble forms, methods for measuring Hu-Asp2 activity, and substrates for Hu-Asp2 cleavage. The invention also describes antisense oligomers targeting the Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) mRNA transcripts and the use of such antisense reagents to decrease such mRNA and consequently the production of the corresponding polypeptide. Isolated antibodies, both polyclonal and monoclonal, that binds specifically to any of the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides of the invention are also provided.

The invention also provides a method for the identification of an agent that modulates the activity of any of Hu-Asp-1, Hu-Asp2(a), and Hu-Asp2(b). The inventions

describes methods to test such agents in cell-free assays to which Hu-Asp2 polypeptide is added, as well as methods to test such agents in human or other mammalian cells in which Hu-Asp2 is present.

5 Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the drawing and detailed description, and all such features are intended as aspects of the invention. Likewise, features of the invention described herein can be re-combined into additional embodiments that are also intended as aspects of the invention, irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment
10 of the invention. Also, only such limitations which are described herein as critical to the invention should be viewed as such; variations of the invention lacking limitations which have not been described herein as critical are intended as aspects of the invention.

In addition to the foregoing, the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations
15 specifically mentioned above. Although the applicant(s) invented the full scope of the claims appended hereto, the claims appended hereto are not intended to encompass within their scope the prior art work of others. Therefore, in the event that statutory prior art within the scope of a claim is brought to the attention of the applicants by a Patent Office or other entity or individual, the applicant(s) reserve the right to exercise
20 amendment rights under applicable patent laws to redefine the subject matter of such a claim to specifically exclude such statutory prior art or obvious variations of statutory prior art from the scope of such a claim. Variations of the invention defined by such amended claims also are intended as aspects of the invention.

25 BRIEF DESCRIPTION OF THE SEQUENCE LISTING

Sequence ID No. 1: Human Asp-1, nucleotide sequence.

Sequence ID No. 2: Human Asp-1, predicted amino acid sequence.

Sequence ID No. 3: Human Asp-2(a), nucleotide sequence.

Sequence ID No. 4: Human Asp-2(a), predicted amino acid sequence. The
30 Asp2(a) amino acid sequence includes a putative signal peptide comprising residues 1

to 21; and a putative pre-propeptide after the signal peptide that extends through residue 45 (as assessed by processing observed of recombinant Asp2(a) in CHO cells), and a putative propeptide that may extend to at least about residue 57, based on the observation of an observed GRRIGS (SEQ ID NO: 68) sequence which has characteristics of a protease recognition sequence. The Asp2(a) further includes a transmembrane domain comprising residues 455-477, a cytoplasmic domain comprising residues 478-501, and a putative alpha-helical spacer region, comprising residues 420-454, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

Sequence ID No. 5: Human Asp-2(b), nucleotide sequence.

Sequence ID No. 6: Human Asp-2(b), predicted amino acid sequence. The Asp2(b) amino acid sequence includes a putative signal peptide, pre-propeptide, and propeptide as described above for Asp2(a). The Asp2(b) further includes a transmembrane domain comprising residues 430-452, a cytoplasmic domain comprising residues 453-476, and a putative alpha-helical spacer region, comprising residues 395-429, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

Sequence ID No. 7: Murine Asp-2(a), nucleotide sequence.

Sequence ID No. 8: Murine Asp-2(a), predicted amino acid sequence. The proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically contemplated as a murine Asp2(b) polypeptide.

Sequence ID No. 9: Human APP695, nucleotide sequence.

Sequence ID No.10: Human APP695, predicted amino acid sequence.

Sequence ID No.11: Human APP695-Sw, nucleotide sequence.

Sequence ID No.12: Human APP695-Sw, predicted amino acid sequence. In the APP695 isoform, the Sw mutation is characterized by a KM-NL alteration at positions 595-596 (compared to normal APP695).

Sequence ID No.13: Human APP695-VF, nucleotide sequence.

Sequence ID No.14: Human APP695-VF, predicted amino acid sequence. In the APP 695 isoform, the VF mutation is characterized by a V→F alteration at position 642 (compared to normal APP 695).

Sequence ID No.15: Human APP695-KK, nucleotide sequence.

5 Sequence ID No.16: Human APP695-KK, predicted amino acid sequence.
(APP695 with two carboxy-terminal lysine residues.)

Sequence ID No.17: Human APP695-Sw-KK, nucleotide sequence.

Sequence ID No.18: Human APP695-Sw-KK, predicted amino acid sequence

Sequence ID No.19: Human APP695-VF-KK, nucleotide sequence

10 Sequence ID No.20: Human APP695-VF-KK, predicted amino acid sequence

Sequence ID No.21: T7-Human-pro-Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.22: T7-Human-pro-Asp-2(a)ΔTM, amino acid sequence

Sequence ID No.23: T7-Caspase-Human-pro-Asp-2(a)ΔTM, nucleotide
sequence

15 Sequence ID No.24: T7-Caspase-Human-pro-Asp-2(a)ΔTM, amino acid
sequence

Sequence ID No.25: Human-pro-Asp-2(a)ΔTM (low GC), nucleotide
sequence

Sequence ID No.26: Human-pro-Asp-2(a)ΔTM, (low GC), amino acid
20 sequence

Sequence ID No.27: T7-Caspase-Caspase 8
cleavage-Human-pro-Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.28: T7-Caspase-Caspase 8
cleavage-Human-pro-Asp-2(a)ΔTM, amino acid sequence

25 Sequence ID No.29: Human Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.30: Human Asp-2(a)ΔTM, amino acid sequence

Sequence ID No.31: Human Asp-2(a)ΔTM(His)₆, nucleotide sequence

Sequence ID No. 32: Human Asp-2(a)ΔTM(His)₆, amino acid sequence

Sequence ID Nos. 33-49 are short synthetic peptide and oligonucleotide
30 sequences that are described below in the Detailed Description of the Invention.

Sequence ID No. 50: Human Asp2(b) Δ TM polynucleotide sequence.

Sequence ID No. 51: Human Asp2(b) Δ TM polypeptide sequence (exemplary variant of Human Asp2(b) lacking transmembrane and intracellular domains of Human Asp2(b) set forth in SEQ ID NO: 6.

5 Sequence ID No. 52: Human Asp2(b) Δ TM(His)₆ polynucleotide sequence.

Sequence ID No. 53: Human Asp2(b) Δ TM(His)₆ polypeptide sequence (Human Asp2(b) Δ TM with six histidine tag attached to C-terminus).

Sequence ID No. 54: Human APP770-encoding polynucleotide sequence.

Sequence ID No. 55: Human APP770 polypeptide sequence. To introduce the KM→NL Swedish mutation, residues KM at positions 670-71 are changed to NL. To introduce the V→F London mutation, the V residue at position 717 is changed to F.

Sequence ID No. 56: Human APP751 encoding polynucleotide sequence.

Sequence ID No. 57: Human APP751 polypeptide sequence (Human APP751 isoform).

15 Sequence ID No. 58: Human APP770-KK encoding polynucleotide sequence.

Sequence ID No. 59: Human APP770-KK polypeptide sequence. (Human APP770 isoform to which two C-terminal lysines have been added).

Sequence ID No. 60: Human APP751-KK encoding polynucleotide sequence.

Sequence ID No. 61: Human APP751-KK polypeptide sequence (Human APP751 isoform to which two C-terminal lysines have been added).

Sequence ID No. 62-65: Various short peptide sequences described in detail in detailed description.

BRIEF DESCRIPTION OF THE FIGURES

25 Figure 1: Figure 1 shows the nucleotide (SEQ ID NO:1) and predicted amino acid sequence (SEQ ID NO:2) of human Asp1.

Figure 2: Figure 2 shows the nucleotide (SEQ ID NO:3) and predicted amino acid sequence (SEQ ID NO:4) of human Asp2(a).

Figure 3: Figure 3 shows the nucleotide (SEQ ID NO:5) and predicted amino acid sequence (SEQ ID NO:6) of human Asp2(b). The predicted transmembrane domain of Hu-Asp2(b) is enclosed in brackets.

Figure 4: Figure 4 shows the nucleotide (SEQ ID No. 7) and predicted amino acid sequence (SEQ ID No. 8) of murine Asp2(a)

Figure 5: Figure 5 shows the BestFit alignment of the predicted amino acid sequences of Hu-Asp2(a) (SEQ ID NO: 4) and murine Asp2(a) (SEQ ID NO: 8).

Figure 6: Figure 6 shows the nucleotide (SEQ ID No. 21) and predicted amino acid sequence (SEQ ID No. 22) of T7-Human-pro-Asp-2(a) Δ TM

Figure 7: Figure 7 shows the nucleotide (SEQ ID No. 23) and predicted amino acid sequence (SEQ ID No. 24) of T7-caspase-Human-pro-Asp-2(a) Δ TM

Figure 8: Figure 8 shows the nucleotide (SEQ ID No. 25) and predicted amino acid sequence (SEQ ID No. 26) of Human-pro-Asp-2(a) Δ TM (low GC)

Figure 9: Western blot showing reduction of CTF99 production by HEK125.3 cells transfected with antisense oligomers targeting the Hu-Asp2 mRNA.

Figure 10: Western blot showing increase in CTF99 production in mouse Neuro-2a cells cotransfected with APP-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2. A further increase in CTF99 production is seen in cells cotransfected with APP-Sw-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2

Figure 11: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a) Δ TM

Figure 12: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a) Δ TM(His)₆

DETAILED DESCRIPTION OF THE INVENTION

A few definitions used in this invention follow, most definitions to be used are those that would be used by one ordinarily skilled in the art.

The term " β amyloid peptide" means any peptide resulting from beta secretase cleavage of APP. This includes peptides of 39, 40, 41, 42 and 43 amino acids, extending

from the β -secretase cleavage site to 39, 40, 41, 42 and 43 amino acids C-terminal to the β -secretase cleavage site. β amyloid peptide also includes sequences 1-6, SEQ ID NOs. 1-6 of US 5,750,349, issued 12 May 1998 (incorporated into this document by reference). A β -secretase cleavage fragment disclosed here is called CTF-99, which extends from
5 β -secretase cleavage site to the carboxy terminus of APP.

When an isoform of APP is discussed then what is meant is any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans such as those described in US 5,766,846, col 7, lines 45-67, incorporated into this document by reference.

10 The term " β -amyloid precursor protein" (APP) as used herein is defined as a polypeptide that is encoded by a gene of the same name localized in humans on the long arm of chromosome 21 and that includes " β AP – here " β -amyloid protein" see above, within its carboxyl third. APP is a glycosylated, single-membrane spanning protein expressed in a wide variety of cells in many mammalian tissues. Examples of
15 specific isotypes of APP which are currently known to exist in humans are the 695 amino acid polypeptide described by Kang et. al. (1987) Nature 325:733-736 which is designated as the "normal" APP (SEQ ID NOs: 9-10); the 751 amino acid polypeptide described by Ponte et al. (1988) Nature 331:525-527 (1988) and Tanzi et al. (1988) Nature 331:528-530 (SEQ ID NOs: 56-57); and the 770-amino acid polypeptide
20 described by Kitaguchi et. al. (1988) Nature 331:530-532 (SEQ ID NOs: 54-55). Examples of specific variants of APP include point mutation which can differ in both position and phenotype (for review of known variant mutation see Hardy (1992) Nature Genet. 1:233-234). All references cited here incorporated by reference. The
25 term "APP fragments" as used herein refers to fragments of APP other than those which consist solely of β AP or β AP fragments. That is, APP fragments will include amino acid sequences of APP in addition to those which form intact β AP or a fragment of β AP.

When the term "any amino acid" is used, the amino acids referred to are to be selected from the following, three letter and single letter abbreviations - which may
30 also be used, are provided as follows:

Alanine, Ala, A; Arginine, Arg, R; Asparagine, Asn, N; Aspartic acid, Asp, D; Cysteine, Cys, C; Glutamine, Gln, Q; Glutamic Acid, Glu, E; Glycine, Gly, G; Histidine, His, H; Isoleucine, Ile, I; Leucine, Leu, L; Lysine, Lys, K; Methionine, Met, M; Phenylalanine, Phe, F; Proline, Pro, P; Serine, Ser, S; Threonine, Thr, T; 5 Tryptophan, Trp, W; Tyrosine, Tyr, Y; Valine, Val, V; Aspartic acid or Asparagine, Asx, B; Glutamic acid or Glutamine, Glx, Z; Any amino acid, Xaa, X.

The present invention describes a method to scan gene databases for the simple active site motif characteristic of aspartyl proteases. Eukaryotic aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to 10 bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. Most aspartyl proteases occur as proenzyme whose N-terminus must be cleaved for activation. The DTG or DSG active site motif appears at about residue 65-70 in the proenzyme (prorenin, pepsinogen), but at about residue 25-30 in the active enzyme after cleavage of the 15 N-terminal prodomain. The limited length of the active site motif makes it difficult to search collections of short, expressed sequence tags (EST) for novel aspartyl proteases. EST sequences typically average 250 nucleotides or less, and so would encode 80-90 amino acid residues or less. That would be too short a sequence to span the two active site motifs. The preferred method is to scan databases of hypothetical 20 or assembled protein coding sequences. The present invention describes a computer method to identify candidate aspartyl proteases in protein sequence databases. The method was used to identify seven candidate aspartyl protease sequences in the *Caenorhabditis elegans* genome. These sequences were then used to identify by 25 homology search Hu-Asp1 and two alternative splice variants of Hu-Asp2, designated herein as Hu-Asp2(a) and Hu-Asp2(b).

In a major aspect of the invention disclosed here we provide new information about APP processing. Pathogenic processing of the amyloid precursor protein (APP) via the A β pathway requires the sequential action of two proteases referred to as β -secretase and γ -secretase. Cleavage of APP by the β -secretase and γ -secretase 30 generates the N-terminus and C-terminus of the A β peptide, respectively. Because

over production of the A β peptide, particularly the A β_{1-42} , has been implicated in the initiation of Alzheimer's disease, inhibitors of either the β -secretase and/or the γ -secretase have potential in the treatment of Alzheimer's disease. Despite the importance of the β -secretase and γ -secretase in the pathogenic processing of APP, molecular definition of these enzymes has not been accomplished to date. That is, it was not known what enzymes were required for cleavage at either the β -secretase or the γ -secretase cleavage site. The sites themselves were known because APP was known and the A β_{1-42} peptide was known, see US 5,766,846 and US 5,837,672, (incorporated by reference, with the exception to reference to "soluble" peptides). But what enzyme was involved in producing the A β_{1-42} peptide was unknown.

Alignment of the amino acid sequences of Hu-Asp2 with other known aspartyl proteases reveals a similar domain organization. All of the sequences contain a signal sequence followed by a pro-segment and the catalytic domain containing 2 copies of the aspartyl protease active site motif (DTG/DSG) separated by approximately 180 amino acid residues. Comparison of the processing site for proteolytic removal of the pro-segment in the mature forms of pepsin A, pepsin C, cathepsin D, cathepsin E and renin reveals that the mature forms of these enzymes contain between 31-35 amino acid residues upstream of the first DTG motif. Inspection of this region in the Hu-Asp-2 amino acid sequence indicates a preferred processing site within the sequence GRR↓GS (SEQ ID NO: 68) as proteolytic processing of pro-protein precursors commonly occurs at site following dibasic amino acid pairs (*eg.* RR). Also, processing at this site would yield a mature enzyme with 35 amino acid residues upstream of the first DTG, consistent with the processing sites for other aspartyl proteases. In the absence of self-activation of Hu-Asp2 or a knowledge of the endogenous protease that processes Hu-Asp2 at this site, a recombinant form was engineered by introducing a recognition site for the PreSission protease (LEVLFQ↓GP; SEQ ID NO: 62) into the expression plasmids for bacterial, insect cell, and mammalian cell expression of pro-Hu-Asp2. In each case, the Gly residue in P1' position corresponds to the Gly residue 35 amino acids upstream of the first DTG motif in Hu-Asp2.

The present invention involves the molecular definition of several novel human aspartyl proteases and one of these, referred to as Hu-Asp-2(a) and Hu-Asp2(b), has been characterized in detail. Previous forms of asp1 and asp 2 have been disclosed, see EP 0848062 A2 and EP 0855444A2, inventors David Powel et al.,
5 assigned to Smith Kline Beecham Corp. (incorporated by reference). Herein are disclosed old and new forms of Hu-Asp 2. For the first time they are expressed in active form, their substrates are disclosed, and their specificity is disclosed. Prior to this disclosure cell or cell extracts were required to cleave the β -secretase site, now purified protein can be used in assays, also described here. Based on the results of (1)
10 antisense knock out experiments, (2) transient transfection knock in experiments, and (3) biochemical experiments using purified recombinant Hu-Asp-2, we demonstrate that Hu-Asp-2 is the β -secretase involved in the processing of APP. Although the nucleotide and predicted amino acid sequence of Hu-Asp-2(a) has been reported, see above, see EP 0848062 A2 and EP 0855444A2, no functional characterization of the
15 enzyme was disclosed. Here the authors characterize the Hu-Asp-2 enzyme and are able to explain why it is a critical and essential enzyme required in the formation of $A\beta_{1-42}$, peptide and possible a critical step in the development of AD.

In another embodiment the present invention also describes a novel splice variant of Hu-Asp2, referred to as Hu-Asp-2(b), that has never before been disclosed.
20 In another embodiment, the invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a polypeptide selected from the group consisting of human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), designated herein as Hu-Asp2(a) and Hu-Asp2(b). As used herein, all references to "Hu-Asp2" should be understood to
25 refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

The predicted amino acid sequences of Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) share significant homology with previously identified mammalian aspartyl proteases such as pepsinogen A, pepsinogen B, cathepsin D, cathepsin E, and renin. P.B.Szezs, *Scand. J. Clin. Lab. Invest.* 52:(Suppl. 210 5-22 (1992)). These enzymes are
5 characterized by the presence of a duplicated DTG/DSG sequence motif. The Hu-Asp1 and HuAsp2 polypeptides disclosed herein also exhibit extremely high homology with the ProSite consensus motif for aspartyl proteases extracted from the SwissProt database.

The nucleotide sequence given as residues 1-1554 of SEQ ID NO:1
10 corresponds to the nucleotide sequence encoding Hu-Asp1, the nucleotide sequence given as residues 1-1503 of SEQ ID NO:3 corresponds to the nucleotide sequence encoding Hu-Asp2(a), and the nucleotide sequence given as residues 1-1428 of SEQ ID NO:5 corresponds to the nucleotide sequence encoding Hu-Asp2(b). The isolation and sequencing of DNA encoding Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) is
15 described below in Examples 1 and 2.

As is described in Examples 1 and 2, automated sequencing methods were used to obtain the nucleotide sequence of Hu-Asp1, Hu-Asp2(a), and Hu-Asp-2(b). The Hu-Asp nucleotide sequences of the present invention were obtained for both DNA strands, and are believed to be 100% accurate. However, as is known in the art,
20 nucleotide sequence obtained by such automated methods may contain some errors. Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known
25 in the art. An error in sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation. The Hu-Asp DNA of the present invention includes cDNA, chemically synthesized
30 DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic

Hu-Asp DNA may be obtained by screening a genomic library with the Hu-Asp2 cDNA described herein, using methods that are well known in the art, or with oligonucleotides chosen from the Hu-Asp2 sequence that will prime the polymerase chain reaction (PCR). RNA transcribed from Hu-Asp DNA is also encompassed by
5 the present invention.

Due to the degeneracy of the genetic code, two DNA sequences may differ and yet encode identical amino acid sequences. The present invention thus provides isolated nucleic acid molecules having a polynucleotide sequence encoding any of the Hu-Asp polypeptides of the invention, wherein said polynucleotide sequence encodes
10 a Hu-Asp polypeptide having the complete amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or fragments thereof.

Also provided herein are purified Hu-Asp polypeptides, both recombinant and non-recombinant. Most importantly, methods to produce Hu-Asp2 polypeptides in active form are provided. These include production of Hu-Asp2 polypeptides and
15 variants thereof in bacterial cells, insect cells, and mammalian cells, also in forms that allow secretion of the Hu-Asp2 polypeptide from bacterial, insect or mammalian cells into the culture medium, also methods to produce variants of Hu-Asp2 polypeptide incorporating amino acid tags that facilitate subsequent purification. In a preferred embodiment of the invention the Hu-Asp2 polypeptide is converted to a
20 proteolytically active form either in transformed cells or after purification and cleavage by a second protease in a cell-free system, such active forms of the Hu-Asp2 polypeptide beginning with the N-terminal sequence TQHGIR (SEQ ID NO: 69) or ETDEEP (SEQ ID NO: 70). The sequence TQHGIR (SEQ ID NO: 69) represents the amino-terminus of Asp2(a) or Asp2(b) beginning with residue 22 of SEQ ID NO: 4 or
25 6, after cleavage of a putative 21 residue signal peptide. Recombinant Asp2(a) expressed in and purified from insect cells was observed to have this amino terminus, presumably as a result of cleavage by a signal peptidase. The sequence ETDEEP (SEQ ID NO: 70) represents the amino-terminus of Asp2(a) or Asp2(b) beginning with residue 46 of SEQ ID NO: 4 or 6, as observed when Asp2(a) has been
30 recombinantly produced in CHO cells (presumably after cleavage by both a rodent

signal peptidase and another rodent peptidase that removes a propeptide sequence).

The Asp2(a) produced in the CHO cells possesses β -secretase activity, as described in greater detail in Examples 11 and 12. Variants and derivatives, including fragments,

of Hu-Asp proteins having the native amino acid sequences given in SEQ ID Nos: 2,

5 4, and 6 that retain any of the biological activities of Hu-Asp are also within the scope of the present invention. Of course, one of ordinary skill in the art will readily be able

to determine whether a variant, derivative, or fragment of a Hu-Asp protein displays Hu-Asp activity by subjecting the variant, derivative, or fragment to a standard

aspartyl protease assay. Fragments of Hu-Asp within the scope of this invention

10 include those that contain the active site domain containing the amino acid sequence

DTG, fragments that contain the active site domain amino acid sequence DSG,

fragments containing both the DTG and DSG active site sequences, fragments in

which the spacing of the DTG and DSG active site sequences has been lengthened,

fragments in which the spacing has been shortened. Also within the scope of the

15 invention are fragments of Hu-Asp in which the transmembrane domain has been

removed to allow production of Hu-Asp2 in a soluble form. In another embodiment of

the invention, the two halves of Hu-Asp2, each containing a single active site DTG or

DSG sequence can be produced independently as recombinant polypeptides, then

combined in solution where they reconstitute an active protease.

20 Thus, the invention provides a purified polypeptide comprising a fragment of a

mammalian Asp2 protein, wherein said fragment lacks the Asp2 transmembrane

domain of said Asp2 protein, and wherein the polypeptide and the fragment retain the

β -secretase activity of said mammalian Asp2 protein. In a preferred embodiment, the

purified polypeptide comprises a fragment of a human Asp2 protein that retains the β -

25 secretase activity of the human Asp2 protein from which it was derived. Examples

include:

a purified polypeptide that comprises a fragment of Asp2(a) having the amino acid sequence set forth in SEQ ID NO: 4, wherein the polypeptide lacks transmembrane domain amino acids 455 to 477 of SEQ ID NO: 4;

a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 478 to 501 of SEQ ID NO: 4;

5 a purified polypeptide as described in either of the preceding paragraphs that further lacks amino acids 420-454 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;

10 a purified polypeptide that comprises an amino acid sequence that includes amino acids 58 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;

a purified polypeptide that comprises an amino acid sequence that includes amino acids 46 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4;

15 a purified polypeptide that comprises an amino acid sequence that includes amino acids 22 to 454 of SEQ ID NO: 4.

a purified polypeptide that comprises a fragment of Asp2(b) having the amino acid sequence set forth in SEQ ID NO: 6, and wherein said polypeptide lacks transmembrane domain amino acids 430 to 452 of SEQ ID NO: 6;

20 a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 453 to 476 of SEQ ID NO: 6;

a purified polypeptide as described in either of the preceding two paragraphs that further lacks amino acids 395-429 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;

25 a purified polypeptide comprising an amino acid sequence that includes amino acids 58 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;

a purified polypeptide comprising an amino acid sequence that includes amino acids 46 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4; and

5 a purified polypeptide comprising an amino acid sequence that includes amino acids 22 to 429 of SEQ ID NO: 4.

Also included as part of the invention is a purified polynucleotide comprising a nucleotide sequence that encodes such polypeptides; a vector comprising a polynucleotide that encodes such polypeptides; and a host cell transformed or transfected with such a polynucleotide or vector.

10 Hu-Asp variants may be obtained by mutation of native Hu-Asp-encoding nucleotide sequences, for example. A Hu-Asp variant, as referred to herein, is a polypeptide substantially homologous to a native Hu-Asp polypeptide but which has an amino acid sequence different from that of native Hu-Asp because of one or more deletions, insertions, or substitutions in the amino acid sequence. The variant amino
15 acid or nucleotide sequence is preferably at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical, to a native Hu-Asp sequence. Thus, a variant nucleotide sequence which contains, for example, 5 point mutations for every one hundred nucleotides, as compared to a native Hu-Asp gene, will be 95% identical to the native protein. The
20 percentage of sequence identity, also termed homology, between a native and a variant Hu-Asp sequence may also be determined, for example, by comparing the two sequences using any of the computer programs commonly employed for this purpose, such as the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wisconsin), which
25 uses the algorithm of Smith and Waterman (*Adv. Appl. Math.* 2: 482-489 (1981)).

Alterations of the native amino acid sequence may be accomplished by any of a number of known techniques. For example, mutations may be introduced at particular locations by procedures well known to the skilled artisan, such as oligonucleotide-directed mutagenesis, which is described by Walder *et al.* (*Gene*
30 42:133 (1986)); Bauer *et al.* (*Gene* 37:73 (1985)); Craik (*BioTechniques*, January

1985, pp. 12-19); Smith *et al.* (*Genetic Engineering: Principles and Methods*, Plenum Press (1981)); and U.S. Patent Nos. 4,518,584 and 4,737,462.

Hu-Asp variants within the scope of the invention may comprise conservatively substituted sequences, meaning that one or more amino acid residues of a Hu-Asp polypeptide are replaced by different residues that do not alter the secondary and/or tertiary structure of the Hu-Asp polypeptide. Such substitutions may include the replacement of an amino acid by a residue having similar physicochemical properties, such as substituting one aliphatic residue (Ile, Val, Leu or Ala) for another, or substitution between basic residues Lys and Arg, acidic residues Glu and Asp, amide residues Gln and Asn, hydroxyl residues Ser and Tyr, or aromatic residues Phe and Tyr. Further information regarding making phenotypically silent amino acid exchanges may be found in Bowie *et al.*, *Science* 247:1306-1310 (1990). Other Hu-Asp variants which might retain substantially the biological activities of Hu-Asp are those where amino acid substitutions have been made in areas outside functional regions of the protein.

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a portion of the nucleic acid molecules described above, *e.g.*, to at least about 15 nucleotides, preferably to at least about 20 nucleotides, more preferably to at least about 30 nucleotides, and still more preferably to at least about from 30 to at least about 100 nucleotides, of one of the previously described nucleic acid molecules. Such portions of nucleic acid molecules having the described lengths refer to, *e.g.*, at least about 15 contiguous nucleotides of the reference nucleic acid molecule. By stringent hybridization conditions is intended overnight incubation at about 42°C for about 2.5 hours in 6 X SSC/0.1% SDS, followed by washing of the filters four times for 15 minutes in 1.0 X SSC at 65°C, 0.1% SDS.

Fragments of the Hu-Asp encoding nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR). Such probes may be used, *e.g.*, to detect the presence of Hu-Asp nucleic acids in *in vitro* assays, as well

as in Southern and northern blots. Cell types expressing Hu-Asp may also be identified by the use of such probes. Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application. For PCR, 5' and 3' primers corresponding to the termini of a desired Hu-Asp nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques.

Other useful fragments of the Hu-Asp nucleic acid molecules are antisense or sense oligonucleotides comprising a single stranded nucleic acid sequence capable of binding to a target Hu-Asp mRNA (using a sense strand), or Hu-Asp DNA (using an antisense strand) sequence. In a preferred embodiment of the invention these Hu-Asp antisense oligonucleotides reduce Hu-Asp mRNA and consequent production of Hu-Asp polypeptides.

In another aspect, the invention includes Hu-Asp polypeptides with or without associated native pattern glycosylation. Both Hu-Asp1 and Hu-Asp2 have canonical acceptor sites for Asn-linked sugars, with Hu-Asp1 having two of such sites, and Hu-Asp2 having four. Hu-Asp expressed in yeast or mammalian expression systems (discussed below) may be similar to or significantly different from a native Hu-Asp polypeptide in molecular weight and glycosylation pattern. Expression of Hu-Asp in bacterial expression systems will provide non-glycosylated Hu-Asp.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. Hu-Asp polypeptides may be recovered and purified from tissues, cultured cells, or recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, and high performance liquid chromatography (HPLC). In a preferred embodiment, an amino acid tag is added to the Hu-Asp polypeptide using genetic engineering techniques that are well known to practitioners of the art which include addition of six histidine amino acid residues to allow purification by binding to nickel immobilized on a suitable support, epitopes for

polyclonal or monoclonal antibodies including but not limited to the T7 epitope, the myc epitope, and the V5a epitope, and fusion of Hu-Asp2 to suitable protein partners including but not limited to glutathione-S-transferase or maltose binding protein. In a preferred embodiment these additional amino acid sequences are added to the
5 C-terminus of Hu-Asp but may be added to the N-terminus or at intervening positions within the Hu-Asp2 polypeptide.

The present invention also relates to vectors comprising the polynucleotide molecules of the invention, as well as host cell transformed with such vectors. Any of the polynucleotide molecules of the invention may be joined to a vector, which
10 generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides Hu-Asp polypeptides expressed from the polynucleotide molecules described above, vectors for the expression of Hu-Asp are preferred. The vectors include DNA encoding any of the Hu-Asp polypeptides described above or below, operably linked to suitable transcriptional or translational
15 regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding Hu-Asp.
20 Thus, a promoter nucleotide sequence is operably linked to a Hu-Asp DNA sequence if the promoter nucleotide sequence directs the transcription of the Hu-Asp sequence.

Selection of suitable vectors to be used for the cloning of polynucleotide molecules encoding Hu-Asp, or for the expression of Hu-Asp polypeptides, will of course depend upon the host cell in which the vector will be transformed, and, where
25 applicable, the host cell from which the Hu-Asp polypeptide is to be expressed. Suitable host cells for expression of Hu-Asp polypeptides include prokaryotes, yeast, and higher eukaryotic cells, each of which is discussed below.

The Hu-Asp polypeptides to be expressed in such host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be
30 included to allow, *e.g.*, secretion, improved stability, or facilitated purification of the

polypeptide. For example, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused inframe to the Hu-Asp sequence so that Hu-Asp is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cell promotes extracellular secretion of the Hu-Asp polypeptide.

Preferably, the signal sequence will be cleaved from the Hu-Asp polypeptide upon secretion of Hu-Asp from the cell. Nonlimiting examples of signal sequences that can be used in practicing the invention include the yeast Ifactor and the honeybee melatin leader in sf9 insect cells.

In a preferred embodiment, the Hu-Asp polypeptide will be a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. For example, the Hu-Asp polypeptide may be modified to comprise a peptide to form a fusion protein which specifically binds to a binding partner, or peptide tag. Nonlimiting examples of such peptide tags include the 6-His tag, thioredoxin tag, hemagglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any molecule or compound including metal ions (*e.g.*, metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide, such as the FLAG tag.

Suitable host cells for expression of Hu-Asp polypeptides includes prokaryotes, yeast, and higher eukaryotic cells. Suitable prokaryotic hosts to be used for the expression of Hu-Asp include bacteria of the genera *Escherichia*, *Bacillus*, and *Salmonella*, as well as members of the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. For expression in, *e.g.*, *E. coli*, a Hu-Asp polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host. The N-terminal Met may optionally then be cleaved from the expressed Hu-Asp polypeptide. Other N-terminal amino acid residues can be added to the Hu-Asp polypeptide to facilitate expression in *Escherichia coli* including but not limited to the T7 leader sequence, the T7-caspase 8

leader sequence, as well as others leaders including tags for purification such as the 6-His tag (Example 9). Hu-Asp polypeptides expressed in *E. coli* may be shortened by removal of the cytoplasmic tail, the transmembrane domain, or the membrane proximal region. Hu-Asp polypeptides expressed in *E. coli* may be obtained in either
5 a soluble form or as an insoluble form which may or may not be present as an inclusion body. The insoluble polypeptide may be rendered soluble by guanidine HCl, urea or other protein denaturants, then refolded into a soluble form before or after purification by dilution or dialysis into a suitable aqueous buffer. If the inactive proform of the Hu-Asp was produced using recombinant methods, it may be rendered
10 active by cleaving off the prosegment with a second suitable protease such as human immunodeficiency virus protease.

Expression vectors for use in prokaryotic hosts generally comprises one or more phenotypic selectable marker genes. Such genes generally encode, *e.g.*, a protein that confers antibiotic resistance or that supplies an auxotrophic requirement.
15 A wide variety of such vectors are readily available from commercial sources. Examples include pSPORT vectors, pGEM vectors (Promega), pPROEX vectors (LTI, Bethesda, MD), Bluescript vectors (Stratagene), pET vectors (Novagen) and pQE vectors (Qiagen).

Hu-Asp may also be expressed in yeast host cells from genera including
20 *Saccharomyces*, *Pichia*, and *Kluveromyces*. Preferred yeast hosts are *S. cerevisiae* and *P. pastoris*. Yeast vectors will often contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Vectors replicable in both yeast and *E. coli* (termed shuttle
25 vectors) may also be used. In addition to the above-mentioned features of yeast vectors, a shuttle vector will also include sequences for replication and selection in *E. coli*. Direct secretion of Hu-Asp polypeptides expressed in yeast hosts may be accomplished by the inclusion of nucleotide sequence encoding the yeast I-factor leader sequence at the 5' end of the Hu-Asp-encoding nucleotide sequence.

Insect host cell culture systems may also be used for the expression of Hu-Asp polypeptides. In a preferred embodiment, the Hu-Asp polypeptides of the invention are expressed using an insect cell expression system (*see* Example 10). Additionally, a baculovirus expression system can be used for expression in insect cells as reviewed
5 by Luckow and Summers, *Bio/Technology* 6:47 (1988).

In another preferred embodiment, the Hu-Asp polypeptide is expressed in mammalian host cells. Nonlimiting examples of suitable mammalian cell lines include the COS7 line of monkey kidney cells (Gluzman *et al.*, *Cell* 23:175 (1981)), human embryonic kidney cell line 293, and Chinese hamster ovary (CHO) cells.
10 Preferably, Chinese hamster ovary (CHO) cells are used for expression of Hu-Asp proteins (Example 11).

The choice of a suitable expression vector for expression of the Hu-Asp polypeptides of the invention will of course depend upon the specific mammalian host cell to be used, and is within the skill of the ordinary artisan. Examples of suitable
15 expression vectors include pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). A preferred vector for expression of Hu-Asp polypeptides is pcDNA3.1-Hygro (Invitrogen). Expression vectors for use in mammalian host cells may include transcriptional and translational control sequences derived from viral genomes. Commonly used promoter sequences and enhancer sequences which may be used in
20 the present invention include, but are not limited to, those derived from human cytomegalovirus (CMV), Adenovirus 2, Polyoma virus, and Simian virus 40 (SV40). Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg (*Mol. Cell. Biol.* 3:280 (1983)); Cosman *et al.* (*Mol. Immunol.* 23:935 (1986)); Cosman *et al.* (*Nature* 312:768 (1984)); EP-A-0367566;
25 and WO 91/18982.

The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting Hu-Asp polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example, *Antibodies: A Laboratory Manual*, Harlow and Land
30 (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988);

Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet *et al.* (eds.), Plenum Press, New York (1980). Synthetic peptides comprising portions of Hu-Asp containing 5 to 20 amino acids may also be used for the production of polyclonal or monoclonal antibodies after linkage to a suitable carrier protein including but not limited to keyhole limpet hemacyanin (KLH), chicken ovalbumin, or bovine serum albumin using various cross-linking reagents including carbodimides, glutaraldehyde, or if the peptide contains a cysteine, N-methylmaleimide. A preferred peptide for immunization when conjugated to KLH contains the C-terminus of Hu-Asp1 or Hu-Asp2 comprising

5

10 QRRPRDPEVVNDESSLVRHRWK (SEQ ID NO: 2, residues 497-518) or LRQQHDDFADDISLLK (SEQ ID NO:4, residues 486-501), respectively. See SEQ ID Nos. 33-34.

The Hu-Asp nucleic acid molecules of the present invention are also valuable for chromosome identification, as they can hybridize with a specific location on a human chromosome. Hu-Asp1 has been localized to chromosome 21, while Hu-Asp2 has been localized to chromosome 11q23.3-24.1. There is a current need for identifying particular sites on the chromosome, as few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region can then be identified through linkage analysis, wherein the coinheritance of physically adjacent genes is determined. Whether a gene appearing to be related to a particular disease is in fact the cause of the disease can then be determined by comparing the nucleic acid sequence between affected and unaffected individuals.

15

20

25

In another embodiment, the invention relates to a method of assaying Hu-Asp function, specifically Hu-Asp2 function which involves incubating in solution the Hu-Asp polypeptide with a suitable substrate including but not limited to a synthetic peptide containing the β -secretase cleavage site of APP, preferably one containing the

30

mutation found in a Swedish kindred with inherited AD in which KM is changed to NL, such peptide comprising the sequence SEVNLDAEFR (SEQ ID NO: 63) in an acidic buffering solution, preferably an acidic buffering solution of pH5.5 (see Example 12) using cleavage of the peptide monitored by high performance liquid chromatography as a measure of Hu-Asp proteolytic activity. Preferred assays for proteolytic activity utilize internally quenched peptide assay substrates. Such suitable substrates include peptides which have attached a paired fluorphore and quencher including but not limited to 7-amino-4-methyl coumarin and dinitrophenol, respectively, such that cleavage of the peptide by the Hu-Asp results in increased fluorescence due to physical separation of the fluorphore and quencher. Other paired fluorphores and quenchers include bodipy-tetramethylrhodamine and QSY-5 (Molecular Probes, Inc.). In a variant of this assay, biotin or another suitable tag may be placed on one end of the peptide to anchor the peptide to a substrate assay plate and a fluorphore may be placed at the other end of the peptide. Useful fluorphores include those listed above as well as Europium labels such as W8044 (EG&g Wallac, Inc.). Cleavage of the peptide by Asp2 will release the fluorphore or other tag from the plate, allowing compounds to be assayed for inhibition of Asp2 proteolytic cleavage as shown by an increase in retained fluorescence. Preferred colorimetric assays of Hu-Asp proteolytic activity utilize other suitable substrates that include the P2 and P1 amino acids comprising the recognition site for cleavage linked to o-nitrophenol through an amide linkage, such that cleavage by the Hu-Asp results in an increase in optical density after altering the assay buffer to alkaline pH.

In another embodiment, the invention relates to a method for the identification of an agent that increases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

- (a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and
- (b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent;

whereby a higher level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has increased the activity of said Hu-Asp polypeptide. Such tests can be performed with Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

In another embodiment, the invention relates to a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

(a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and

(b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent;

whereby a lower level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide. Such tests can be performed with Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

In another embodiment, the invention relates to a novel cell line (HEK125.3 cells) for measuring processing of amyloid β peptide ($A\beta$) from the amyloid protein precursor (APP). The cells are stable transformants of human embryonic kidney 293 cells (HEK293) with a bicistronic vector derived from pIRES-EGFP (Clontech) containing a modified human APP cDNA, an internal ribosome entry site and an enhanced green fluorescent protein (EGFP) cDNA in the second cistron. The APP cDNA was modified by adding two lysine codons to the carboxyl terminus of the APP coding sequence. This increases processing of $A\beta$ peptide from human APP by 2-4 fold. This level of $A\beta$ peptide processing is 60 fold higher than is seen in nontransformed HEK293 cells. HEK125.3 cells will be useful for assays of compounds that inhibit $A\beta$ peptide processing. This invention also includes addition of two lysine residues to the C-terminus of other APP isoforms including the 751 and

770 amino acid isoforms, to isoforms of APP having mutations found in human AD including the Swedish KM-NL and V717-F mutations, to C-terminal fragments of APP, such as those beginning with the β -secretase cleavage site, to C-terminal fragments of APP containing the β -secretase cleavage site which have been operably
 5 linked to an N-terminal signal peptide for membrane insertion and secretion, and to C-terminal fragments of APP which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion and a reporter sequence including but not limited to green fluorescent protein or alkaline phosphatase, such that β -secretase cleavage releases the reporter protein from the surface of cells expressing
 10 the polypeptide.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

15

Example 1

Development of a Search Algorithm Useful for the Identification of Aspartyl Proteases, and Identification of *C. elegans* Aspartyl Protease Genes in Wormpep 12


Materials and Methods:

20 Classical aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. The DTG or DSG active site motif appears at about residue 25-30 in the enzyme, but at about 65-70 in the proenzyme (prorenin, pepsinogen). This motif appears again about
 25 150-200 residues downstream. The proenzyme is activated by cleavage of the N-terminal prodomain. This pattern exemplifies the double domain structure of the modern day aspartyl enzymes which apparently arose by gene duplication and divergence. Thus;



30 where X denotes the beginning of the enzyme, following the N-terminal prodomain, and Y denotes the center of the molecule where the gene repeat begins again.

In the case of the retroviral enzymes such as the HIV protease, they represent only a half of the two-domain structures of well-known enzymes like pepsin, cathepsin D, renin, etc. They have no prosegment, but are carved out of a polypeptide precursor containing the *gag* and *pol* proteins of the virus. They can be represented by:



This "monomer" only has about 100 aa, so is extremely parsimonious as compared to the other aspartyl protease "dimers" which have of the order of 330 or so aa, not counting the N-terminal prodomain.

The limited length of the eukaryotic aspartyl protease active site motif makes it difficult to search EST collections for novel sequences. EST sequences typically average 250 nucleotides, and so in this case would be unlikely to span both aspartyl protease active site motifs. Instead, we turned to the *C. elegans* genome. The *C. elegans* genome is estimated to contain around 13,000 genes. Of these, roughly 12,000 have been sequenced and the corresponding hypothetical open reading frame (ORF) has been placed in the database Wormpep12. We used this database as the basis for a whole genome scan of a higher eukaryote for novel aspartyl proteases, using an algorithm that we developed specifically for this purpose. The following AWK script for locating proteins containing two DTG or DSG motifs was used for the search, which was repeated four times to recover all pairwise combinations of the aspartyl motif.

```
BEGIN{RS=">"}          /* defines ">" as record separator for FASTA format */
{
  pos = index($0,"DTG")  /* finds "DTG" in record*/
  if (pos>0) {
    rest = substr($0,pos+3) /*get rest of record after first DTG*/
    pos2 = index(rest,"DTG") /*find second DTG*/
    if (pos2>0) printf ("%s%s\n", ">", $0)} /*report hits*/
  }
}
```

The AWK script shown above was used to search Wormpep12, which was downloaded from <ftp.sanger.ac.uk/pub/databases/wormpep>, for sequence entries

containing at least two DTG or DSG motifs. Using AWK limited each record to 3000 characters or less. Thus, 35 or so larger records were eliminated manually from Wormpep12 as in any case these were unlikely to encode aspartyl proteases.

Results and Discussion:

- 5 The Wormpep 12 database contains 12,178 entries, although some of these (<10%) represent alternatively spliced transcripts from the same gene. Estimates of the number of genes encoded in the *C. elegans* genome is on the order of 13,000 genes, so Wormpep12 may be estimated to cover greater than 90% of the *C. elegans* genome.
- 10 Eukaryotic aspartyl proteases contain a two-domain structure, probably arising from ancestral gene duplication. Each domain contains the active site motif D(S/T)G located from 20-25 amino acid residues into each domain. The retroviral (e.g., HIV protease) or retrotransposon proteases are homodimers of subunits which are homologous to a single eukaryotic aspartyl protease domain. An AWK script was
- 15 used to search the Wormpep12 database for proteins in which the D(S/T)G motif occurred at least twice. This identified >60 proteins with two DTG or DSG motifs. Visual inspection was used to select proteins in which the position of the aspartyl domains was suggestive of a two-domain structure meeting the criteria described above.
- 20 In addition, the PROSITE eukaryotic and viral aspartyl protease active site pattern PS00141 was used to search Wormpep12 for candidate aspartyl proteases. (Bairoch A., Bucher P., Hofmann K., The PROSITE database: its status in 1997, *Nucleic Acids Res.* 24:217-221(1997)). This generated an overlapping set of
- 25 Wormpep12 sequences. Of these, seven sequences contained two DTG or DSG motifs and the PROSITE aspartyl protease active site pattern. Of these seven, three were found in the same cosmid clone (F21F8.3, F21F8.4, and F21F8.7) suggesting that they represent a family of proteins that arose by ancestral gene duplication. Two other ORFs with extensive homology to F21F8.3, F21F8.4 and F21F8.7 are present in the same gene cluster (F21F8.2 and F21F8.6), however, these contain only a single
- 30 DTG motif. Exhaustive BLAST searches with these seven sequences against

Wormpep12 failed to reveal additional candidate aspartyl proteases in the *C. elegans* genome containing two repeats of the DTG or DSG motif.

BLASTX search with each *C. elegans* sequence against SWISS-PROT, GenPep and TREMBL revealed that R12H7.2 was the closest worm homologue to the known mammalian aspartyl proteases, and that T18H9.2 was somewhat more distantly related, while CEASP1, F21F8.3, F21F8.4, and F21F8.7 formed a subcluster which had the least sequence homology to the mammalian sequences.

Discussion:

APP, the presenilins, and p35, the activator of cdk5, all undergo intracellular proteolytic processing at sites which conform to the substrate specificity of the HIV protease. Dysregulation of a cellular aspartyl protease with the same substrate specificity, might therefore provide a unifying mechanism for causation of the plaque and tangle pathologies in AD. Therefore, we sought to identify novel human aspartyl proteases. A whole genome scan in *C. elegans* identified seven open reading frames that adhere to the aspartyl protease profile that we had identified. These seven aspartyl proteases probably comprise the complete complement of such proteases in a simple, multicellular eukaryote. These include four closely related aspartyl proteases unique to *C. elegans* which probably arose by duplication of an ancestral gene. The other three candidate aspartyl proteases (T18H9.2, R12H7.2 and C11D2.2) were found to have homology to mammalian gene sequences.

Example 2

Identification of Novel Human Aspartyl Proteases Using Database Mining by Genome Bridging

Materials and Methods:

Computer-assisted analysis of EST databases, cDNA, and predicted polypeptide sequences:

Exhaustive homology searches of EST databases with the CEASP1, F21F8.3, F21F8.4, and F21F8.7 sequences failed to reveal any novel mammalian homologues. TBLASTN searches with R12H7.2 showed homology to cathepsin D, cathepsin E,

pepsinogen A, pepsinogen C and renin, particularly around the DTG motif within the active site, but also failed to identify any additional novel mammalian aspartyl proteases. This indicates that the *C. elegans* genome probably contains only a single lysosomal aspartyl protease which in mammals is represented by a gene family that
5 arose through duplication and consequent modification of an ancestral gene.

TBLASTN searches with T18H9.2, the remaining *C. elegans* sequence, identified several ESTs which assembled into a contig encoding a novel human aspartyl protease (Hu-ASP1). As is described above in Example 1, BLASTX search with the Hu-ASP1 contig against SWISS-PROT revealed that the active site motifs in
10 the sequence aligned with the active sites of other aspartyl proteases. Exhaustive, repetitive rounds of BLASTN searches against LifeSeq, LifeSeqFL, and the public EST collections identified 102 EST from multiple cDNA libraries that assembled into a single contig. The 51 sequences in this contig found in public EST collections also have been assembled into a single contig (THC213329) by The Institute for Genome
15 Research (TIGR). The TIGR annotation indicates that they failed to find any hits in the database for the contig. Note that the TIGR contig is the reverse complement of the LifeSeq contig that we assembled. BLASTN search of Hu-ASP1 against the rat and mouse EST sequences in ZooSeq revealed one homologous EST in each database (Incyte clone 700311523 and IMAGE clone 313341, GenBank accession number
20 W10530, respectively).

TBLASTN searches with the assembled DNA sequence for Hu-ASP1 against both LifeSeqFL and the public EST databases identified a second, related human sequence (Hu-Asp2) represented by a single EST (2696295). Translation of this partial cDNA sequence reveals a single DTG motif which has homology to the active
25 site motif of a bovine aspartyl protease, NM1.

BLAST searches, contig assemblies and multiple sequence alignments were performed using the bioinformatics tools provided with the LifeSeq, LifeSeqFL and LifeSeq Assembled databases from Incyte. Predicted protein motifs were identified using either the ProSite dictionary (Motifs in GCG 9) or the Pfam database.

30

Full-length cDNA cloning of Hu-Asp1

The open reading frame of *C. elegans* gene T18H9.2CE was used to query Incyte LifeSeq and LifeSeq-FL databases and a single electronic assembly referred to as 1863920CE1 was detected. The 5' most cDNA clone in this contig, 1863920, was
5 obtained from Incyte and completely sequenced on both strands. Translation of the open reading frame contained within clone 1863920 revealed the presence of the duplicated aspartyl protease active site motif (DTG/DSG) but the 5' end was incomplete. The remainder of the Hu-Asp1 coding sequence was determined by 5' Marathon RACE analysis using a human placenta Marathon ready cDNA template
10 (Clontech). A 3'-antisense oligonucleotide primer specific for the 5' end of clone 1863920 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clone 1863920 to yield the complete coding sequence of Hu-Asp-1 (SEQ ID No. 1).

15 Several interesting features are present in the primary amino acid sequence of Hu-Asp1 (Figure 1, SEQ ID No. 2). The sequence contains a signal peptide (residues 1-20 in SEQ ID No. 2), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is about 200 residues which should correspond to the
20 expected size of a single, eukaryotic aspartyl protease domain. More interestingly, the sequence contains a predicted transmembrane domain (residues 469-492 in SEQ ID No.2) near its C-terminus which suggests that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease.

25 *Cloning of a full-length Hu-Asp-2 cDNAs:*

As is described above in Example 1, genome wide scan of the *Caenorhabditis elegans* database WormPep12 for putative aspartyl proteases and subsequent mining of human EST databases revealed a human ortholog to the *C. elegans* gene T18H9.2 referred to as Hu-Asp1. The assembled contig for Hu-Asp1 was used to query for
30 human paralogs using the BLAST search tool in human EST databases and a single

significant match (2696295CE1) with approximately 60% shared identity was found in the LifeSeq FL database. Similar queries of either gb105PubEST or the family of human databases available from TIGR did not identify similar EST clones. cDNA clone 2696295, identified by single pass sequence analysis from a human uterus

5 cDNA library, was obtained from Incyte and completely sequence on both strands. This clone contained an incomplete 1266 bp open-reading frame that encoded a 422 amino acid polypeptide but lacked an initiator ATG on the 5' end. Inspection of the predicted sequence revealed the presence of the duplicated aspartyl protease active site motif DTG/DSG, separated by 194 amino acid residues. Subsequent queries of

10 later releases of the LifeSeq EST database identified an additional ESTs, sequenced from a human astrocyte cDNA library (4386993), that appeared to contain additional 5' sequence relative to clone 2696295. Clone 4386993 was obtained from Incyte and completely sequenced on both strands. Comparative analysis of clone 4386993 and clone 2696295 confirmed that clone 4386993 extended the open-reading frame by 31

15 amino acid residues including two in-frame translation initiation codons. Despite the presence of the two in-frame ATGs, no in-frame stop codon was observed upstream of the ATG indicating that the 4386993 may not be full-length. Furthermore, alignment of the sequences of clones 2696295 and 4386993 revealed a 75 base pair insertion in clone 2696295 relative to clone 4386993 that results in the insertion of 25 additional

20 amino acid residues in 2696295. The remainder of the Hu-Asp2 coding sequence was determined by 5' Marathon RACE analysis using a human hippocampus Marathon ready cDNA template (Clontech). A 3'-antisense oligonucleotide primer specific for the shared 5'-region of clones 2696295 and 4386993 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific

25 PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clones 2696295 and 4386993 to yield the complete coding sequence of Hu-Asp2(a) (SEQ ID No. 3) and Hu-Asp2(b) (SEQ ID No. 5), respectively.

Several interesting features are present in the primary amino acid sequence of

30 Hu-Asp2(a) (Figure 2 and SEQ ID No. 4) and Hu-Asp-2(b) (Figure 3, SEQ ID No. 6).

Both sequences contain a signal peptide (residues 1-21 in SEQ ID No. 4 and SEQ ID No. 6), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is variable due to the 25 amino acid residue deletion in Hu-Asp-2(b) and consists of 168-*versus*-194 amino acid residues, for Hu-Asp2(b) and Hu-Asp-2(a), respectively. More interestingly, both sequences contains a predicted transmembrane domain (residues 455-477 in SEQ ID No.4 and 430-452 in SEQ ID No. 6) near their C-termini which indicates that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease except Hu-Asp1.

Example 3

Molecular cloning of mouse Asp2 cDNA and genomic DNA.

Cloning and characterization of murine Asp2 cDNA.

The murine ortholog of Hu-Asp2 was cloned using a combination of cDNA library screening, PCR, and genomic cloning. Approximately 500,000 independent clones from a mouse brain cDNA library were screened using a ³²P-labeled coding sequence probe prepared from Hu-Asp2. Replicate positives were subjected to DNA sequence analysis and the longest cDNA contained the entire 3' untranslated region and 47 amino acids in the coding region. PCR amplification of the same mouse brain cDNA library with an antisense oligonucleotide primer specific for the 5'-most cDNA sequence determined above and a sense primer specific for the 5' region of human Asp2 sequence followed by DNA sequence analysis gave an additional 980 bp of the coding sequence. The remainder of the 5' sequence of murine Asp-2 was derived from genomic sequence (see below).

Isolation and sequence analysis of the murine Asp-2 gene.

A murine EST sequence encoding a portion of the murine Asp2 cDNA was identified in the GenBank EST database using the BLAST search tool and the Hu-Asp2 coding sequence as the query. Clone g3160898 displayed 88% shared identity to the human sequence over 352 bp. Oligonucleotide primer pairs specific for

this region of murine Asp2 were then synthesized and used to amplify regions of the murine gene. Murine genomic DNA, derived from strain 129/SvJ, was amplified in the PCR (25 cycles) using various primer sets specific for murine Asp2 and the products analyzed by agarose gel electrophoresis. The primer set Zoo-1 and Zoo-4 amplified a 750 bp fragment that contained approximately 600 bp of intron sequence based on comparison to the known cDNA sequence. This primer set was then used to screen a murine BAC library by PCR, a single genomic clone was isolated and this cloned was confirmed contain the murine Asp2 gene by DNA sequence analysis. Shotgun DNA sequencing of this Asp2 genomic clone and comparison to the cDNA sequences of both Hu-Asp2 and the partial murine cDNA sequences defined the full-length sequence of murine Asp2 (SEQ ID No. 7). The predicted amino acid sequence of murine Asp2 (SEQ ID No. 8) showed 96.4% shared identity (GCG BestFit algorithm) with 18/501 amino acid residue substitutions compared to the human sequence (Figure 4). The proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically contemplated as a murine Asp2(b) polypeptide. All forms of murine Asp2(b) gene and protein are intended as aspects of the invention.

Example 4

Tissue Distribution of Expression of Hu-Asp2 Transcripts

Materials and Methods:

The tissue distribution of expression of Hu-Asp-2 was determined using multiple tissue Northern blots obtained from Clontech (Palo Alto, CA). Incyte clone 2696295 in the vector pINCY was digested to completion with *EcoRI/NotI* and the 1.8 kb cDNA insert purified by preparative agarose gel electrophoresis. This fragment was radiolabeled to a specific activity $> 1 \times 10^9$ dpm/ μ g by random priming in the presence of [α - 32 P-dATP] (>3000 Ci/mmol, Amersham, Arlington Heights, IL) and Klenow fragment of DNA polymerase I. Nylon filters containing denatured, size fractionated poly A⁺ RNAs isolated from different human tissues were hybridized

with 2×10^6 dpm/ml probe in ExpressHyb buffer (Clontech, Palo Alto, CA) for 1 hour at 68 °C and washed as recommended by the manufacture. Hybridization signals were visualized by autoradiography using BioMax XR film (Kodak, Rochester, NY) with intensifying screens at -80 °C.

5

Results and Discussion:

Limited information on the tissue distribution of expression of Hu-Asp-2 transcripts was obtained from database analysis due to the relatively small number of ESTs detected using the methods described above (< 5). In an effort to gain further information on the expression of the Hu-Asp2 gene, Northern analysis was employed to determine both the size(s) and abundance of Hu-Asp2 transcripts. PolyA⁺ RNAs isolated from a series of peripheral tissues and brain regions were displayed on a solid support following separation under denaturing conditions and Hu-Asp2 transcripts were visualized by high stringency hybridization to radiolabeled insert from clone 2696295. The 2696295 cDNA probe visualized a constellation of transcripts that migrated with apparent sizes of 3.0kb, 4.4 kb and 8.0 kb with the latter two transcript being the most abundant.

Across the tissues surveyed, Hu-Asp2 transcripts were most abundant in pancreas and brain with lower but detectable levels observed in all other tissues examined except thymus and PBLs. Given the relative abundance of Hu-Asp2 transcripts in brain, the regional expression in brain regions was also established. A similar constellation of transcript sizes were detected in all brain regions examined [cerebellum, cerebral cortex, occipital pole, frontal lobe, temporal lobe and putamen] with the highest abundance in the medulla and spinal cord.

25

Example 5

Northern Blot Detection of HuAsp-1 and HuAsp-2 Transcripts in Human Cell Lines

A variety of human cell lines were tested for their ability to produce Hu-Asp1 and Asp2 mRNA. Human embryonic kidney (HEK-293) cells, African green monkey (Cos-7) cells, Chinese hamster ovary (CHO) cells, HELA cells, and the

30

neuroblastoma cell line IMR-32 were all obtained from the ATCC. Cells were cultured in DME containing 10% FCS except CHO cells which were maintained in α -MEM/10% FCS at 37 °C in 5% CO₂ until they were near confluence. Washed monolayers of cells (3 X 10⁷) were lysed on the dishes and poly A⁺ RNA extracted using the Qiagen Oligotex Direct mRNA kit. Samples containing 2 µg of poly A⁺ RNA from each cell line were fractionated under denaturing conditions (glyoxal-treated), transferred to a solid nylon membrane support by capillary action, and transcripts visualized by hybridization with random-primed labeled (³²P) coding sequence probes derived from either Hu-Asp1 or Hu-Asp2. Radioactive signals were detected by exposure to X-ray film and by image analysis with a PhosphorImager.

The Hu-Asp1 cDNA probe visualized a similar constellation of transcripts (2.6 kb and 3.5 kb) that were previously detected in human tissues. The relative abundance determined by quantification of the radioactive signal was Cos-7 > HEK 292 = HELA > IMR32.

The Hu-Asp2 cDNA probe also visualized a similar constellation of transcripts compared to tissue (3.0 kb, 4.4 kb, and 8.0 kb) with the following relative abundance; HEK 293 > Cos 7 > IMR32 > HELA.

Example 6

Modification of APP to increase A β processing for in vitro screening

Human cell lines that process A β peptide from APP provide a means to screen in cellular assays for inhibitors of β - and γ -secretase. Production and release of A β peptide into the culture supernatant is monitored by an enzyme-linked immunosorbent assay (EIA). Although expression of APP is widespread and both neural and non-neuronal cell lines process and release A β peptide, levels of endogenous APP processing are low and difficult to detect by EIA. A β processing can be increased by expressing in transformed cell lines mutations of APP that enhance A β processing. We made the serendipitous observation that addition of two lysine residues to the carboxyl terminus of APP695 increases A β processing still further. This allowed us

to create a transformed cell line that releases A β peptide into the culture medium at the remarkable level of 20,000 pg/ml.

Materials And Methods

Materials:

5 Human embryonic kidney cell line 293 (HEK293 cells) were obtained internally. The vector pIRES-EGFP was purchased from Clontech. Oligonucleotides for mutation using the polymerase chain reaction (PCR) were purchased from Genosys. A plasmid containing human APP695 (SEQ ID No. 9 [nucleotide] and SEQ ID No. 10 [amino acid]) was obtained from Northwestern University Medical School.
10 This was subcloned into pSK (Stratagene) at the *Not*I site creating the plasmid pAPP695.

Mutagenesis protocol:

The Swedish mutation (K670N, M671L) was introduced into pAPP695 using the Stratagene Quick Change Mutagenesis Kit to create the plasmid pAPP695NL
15 (SEQ ID No. 11 [nucleotide] and SEQ ID No. 12 [amino acid]). To introduce a di-lysine motif at the C-terminus of APP695, the forward primer #276 5' GACTGACCACTCGACCAGGTTC (SEQ ID No. 47) was used with the "patch" primer #274 5' CGAATTAAATTCCAGCACACTGGCTACTTCTTGTTCTGCATCTCAAAGAAC
20 (SEQ ID No. 48) and the flanking primer #275 CGAATTAAATTCCAGCACACTGGCTA (SEQ ID No. 49) to modify the 3' end of the APP695 cDNA (SEQ ID No. 15 [nucleotide] and SEQ ID No. 16 [amino acid]). This also added a BstX1 restriction site that will be compatible with the BstX1 site in the multiple cloning site of pIRES-EGFP. PCR amplification was performed with a
25 Clontech HF Advantage cDNA PCR kit using the polymerase mix and buffers supplied by the manufacturer. For "patch" PCR, the patch primer was used at 1/20th the molar concentration of the flanking primers. PCR amplification products were purified using a QIAquick PCR purification kit (Qiagen). After digestion with restriction enzymes, products were separated on 0.8% agarose gels and then excised
30 DNA fragments were purified using a QIAquick gel extraction kit (Qiagen).

To reassemble a modified APP695-Sw cDNA, the 5' Not1-Bgl2 fragment of the APP695-Sw cDNA and the 3' Bgl2-BstX1 APP695 cDNA fragment obtained by PCR were ligated into pIRES-EGFP plasmid DNA opened at the Not1 and BstX1 sites. Ligations were performed for 5 minutes at room temperature using a Rapid
5 DNA Ligation kit (Boehringer Mannheim) and transformed into Library Efficiency DH5a Competent Cells (GibcoBRL Life Technologies). Bacterial colonies were screened for inserts by PCR amplification using primers #276 and #275. Plasmid DNA was purified for mammalian cell transfection using a QIAprep Spin Miniprep kit (Qiagen). The construct obtained was designated pMG125.3 (APPSW-KK, SEQ
10 ID No. 17 [nucleotide] and SEQ ID No. 18 [amino acid]).

Mammalian Cell Transfection:

HEK293 cells for transfection were grown to 80% confluence in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. Cotransfections were performed using LipofectAmine (Gibco-BRL) with 3 µg pMG125.3 DNA and 9
15 µg pcDNA3.1 DNA per 10 x 10⁶ cells. Three days posttransfection, cells were passaged into medium containing G418 at a concentration of 400 µg/ml. After three days growth in selective medium, cells were sorted by their fluorescence.

Clonal Selection of 125.3 cells by FACS:

Cell samples were analyzed on an EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL) equipped with a 488 nm excitation line supplied by an air-cooled argon
20 laser. EGFP emission was measured through a 525 nm band-pass filter and fluorescence intensity was displayed on a 4-decade log scale after gating on viable cells as determined by forward and right angle light scatter. Single green cells were separated into each well of one 96 well plate containing growth medium without
25 G418. After a four day recovery period, G418 was added to the medium to a final concentration of 400 µg/ml. After selection, 32% of the wells contained expanding clones. Wells with clones were expanded from the 96 well plate to a 24 well plate and then a 6 well plate with the fastest growing colonies chosen for expansion at each passage. The final cell line selected was the fastest growing of the final six passaged.
30 This clone, designated 125.3, has been maintained in G418 at 400 µg/ml with passage

every four days into fresh medium. No loss of A β production or EGFP fluorescence has been seen over 23 passages.

A β EIA Analysis (Double Antibody Sandwich ELISA for hA β 1-40/42):

Cell culture supernatants harvested 48 hours after transfection were analyzed in a standard A β EIA as follows. Human A β 1-40 or 1-42 was measured using monoclonal antibody (mAb) 6E10 (Senetek, St. Louis, MO) and biotinylated rabbit antiserum 162 or 164 (New York State Institute for Basic Research, Staten Island, NY) in a double antibody sandwich ELISA. The capture antibody 6E10 is specific to an epitope present on the N-terminal amino acid residues 1-16 of hA β . The conjugated detecting antibodies 162 and 164 are specific for hA β 1-40 and 1-42, respectively. Briefly, a Nunc Maxisorp 96 well immunoplate was coated with 100 μ l/well of mAb 6E10 (5 μ g/ml) diluted in 0.1M carbonate-bicarbonate buffer, pH 9.6 and incubated at 4°C overnight. After washing the plate 3x with 0.01M DPBS (Modified Dulbecco's Phosphate Buffered Saline (0.008M sodium phosphate, 0.002M potassium phosphate, 0.14M sodium chloride, 0.01 M potassium chloride, pH 7.4) from Pierce, Rockford, IL) containing 0.05% of Tween-20 (DPBST), the plate was blocked for 60 minutes with 200 μ l of 10% normal sheep serum (Sigma) in 0.01M DPBS to avoid non-specific binding. Human A β 1-40 or 1-42 standards 100 μ l/well (Bachem, Torrance, CA) diluted, from a 1mg/ml stock solution in DMSO, in culture medium was added after washing the plate, as well as 100 μ l/well of sample, *e.g.*, conditioned medium of transfected cells.

The plate was incubated for 2 hours at room temperature and 4°C overnight. The next day, after washing the plate, 100 μ l/well biotinylated rabbit antiserum 162 1:400 or 164 1:50 diluted in DPBST + 0.5% BSA was added and incubated at room temperature for 1 hour, 15 minutes. Following washes, 100 μ l/well neutravidin-horseradish peroxidase (Pierce, Rockford, IL) diluted 1:10,000 in DPBST was applied and incubated for 1 hour at room temperature. After the last washes 100 μ l/well of o-phenylenediamine dihydrochloride (Sigma Chemicals, St. Louis, MO) in 50mM citric acid/100mM sodium phosphate buffer (Sigma Chemicals, St. Louis, MO), pH 5.0, was added as substrate and the color development was monitored at

450nm in a kinetic microplate reader for 20 minutes using Soft max Pro software. All standards and samples were run in triplicates. The samples with absorbance values falling within the standard curve were extrapolated from the standard curves using Soft max Pro software and expressed in pg/ml culture medium.

5 *Results:*

 Addition of two lysine residues to the carboxyl terminus of APP695 greatly increases A β processing in HEK293 cells as shown by transient expression (Table 1). Addition of the di-lysine motif to APP695 increases A β processing to that seen with the APP695 containing the Swedish mutation. Combining the di-lysine motif with the
10 Swedish mutation further increases processing by an additional 2.8 fold.

 Cotransformation of HEK293 cells with pMG125.3 and pcDNA3.1 allowed dual selection of transformed cells for G418 resistance and high level expression of EGFP. After clonal selection by FACS, the cell line obtained, produces a remarkable 20,000 pg A β peptide per ml of culture medium after growth for 36 hours in 24 well
15 plates. Production of A β peptide under various growth conditions is summarized in Table 2.

20

25

30

TABLE 1

Release of A β peptide into the culture medium 48 hours after transient
 5 transfection of HEK293 cells with the indicated vectors containing wildtype or
 modified APP. Values tabulated are mean + SD and P-value for pairwise comparison
 using Student's t-test assuming unequal variances.

10	APP Construct	A β 1-40 peptide (pg/ml)	Fold Increase	P-value
	pIRES-EGFP vector	147 + 28	1.0	
	wt APP695 (142.3)	194 + 15	1.3	0.051
15	wt APP695-KK (124.1)	424 + 34	2.8	3 x 10 ⁻⁵
	APP695-Sw (143.3)	457 + 65	3.1	2 x 10 ⁻³
20	APP695-SwKK (125.3)	1308 + 98	8.9	3 x 10 ⁻⁴

25

TABLE 2Release of A β peptide from HEK125.3 cells under various growth conditions.

5	Type of Culture Plate	Volume of Medium	Duration of Culture	A β 1-40 (pg/ml)	A β 1-42 (pg/ml)
10	24 well plate	400 ul	36 hr	28,036	1,439

Example 7**Antisense oligomer inhibition of Abeta processing in HEK125.3 cells**

15 The sequences of Hu-Asp1 and Hu-Asp2 were provided to Sequitur, Inc (Natick, MA) for selection of targeted sequences and design of 2nd generation chimeric antisense oligomers using proprietary technology (Sequitur Ver. D Pat pending #3002). Antisense oligomers Lot# S644, S645, S646 and S647 were targeted against Asp1. Antisense oligomers Lot# S648, S649, S650 and S651 were targeted against Asp2. Control antisense oligomers Lot# S652, S653, S655, and S674 were

20 targeted against an irrelevant gene and antisense oligomers Lot #S656, S657, S658, and S659 were targeted against a second irrelevant gene.

For transfection with the antisense oligomers, HEK125.3 cells were grown to about 50% confluence in 6 well plates in Minimal Essential Medium (MEM)

25 supplemented with 10% fetal calf serum. A stock solution of oligofectin G (Sequitur Inc., Natick, MA) at 2 mg/ml was diluted to 50 μ g/ml in serum free MEM. Separately, the antisense oligomer stock solution at 100 μ M was diluted to 800 nM in Opti-MEM (GIBCO-BRL, Grand Island, NY). The diluted stocks of oligofectin G and antisense oligomer were then mixed at a ratio of 1:1 and incubated at room

30 temperature. After 15 minutes incubation, the reagent was diluted 10 fold into MEM

containing 10% fetal calf serum and 2 ml was added to each well of the 6 well plate after first removing the old medium. After transfection, cells were grown in the continual presence of the oligofectin G/antisense oligomer. To monitor A β peptide release, 400 μ l of conditioned medium was removed periodically from the culture well and replaced with fresh medium beginning 24 hours after transfection. A β peptides in the conditioned medium were assayed via immunoprecipitation and Western blotting. Data reported are from culture supernatants harvested 48 hours after transfection.

The 16 different antisense oligomers obtained from Sequitur Inc. were transfected separately into HEK125.3 cells to determine their affect on A β peptide processing. Only antisense oligomers targeted against Asp2 significantly reduced Abeta processing by HEK125.3 cells. Both A β (1-40) and A β (1-42) were inhibited by the same degree. In Table 3, percent inhibition is calculated with respect to untransfected cells. Antisense oligomer reagents giving greater than 50% inhibition are marked with an asterisk. For ASP2, 4 of 4 antisense oligomers gave greater than 50% inhibition with an average inhibition of 62% for A β 1-40 processing and 60% for A β 1-42 processing.

TABLE 3

Inhibition of A β peptide release from HEK125.3 cells treated with antisense oligomers.

5	Gene Targeted	Antisense Oligomer	Abeta (1-40)	Abeta (1-42)
	Asp2-1	S648	71%*	67%*
10	Asp2-2	S649	83%*	76%*
	Asp2-3	S650	46%*	50%*
	Asp2-4	S651	47%*	46%*
15	Con1-1	S652	13%	18%
	Con1-2	S653	35%	30%
20	Con1-3	S655	9%	18%
	Con1-4	S674	29%	18%
	Con2-1	S656	12%	18%
25	Con2-2	S657	16%	19%
	Con2-3	S658	8%	35%
30	Con2-4	S659	3%	18%

Since HEK293 cells derive from kidney, the experiment was extended to human IMR-32 neuroblastoma cells which express all three APP isoforms and which release A β peptides into conditioned medium at measurable levels. [See Neill *et al.*,

J. NeuroSci. Res., (1994) 39: 482-93; and Asami-Odaka *et al.*, *Biochem.*, (1995) 34:10272-8.] Essentially identical results were obtained in the neuroblastoma cells as the HEK293 cells. As shown in Table 3B, the pair of Asp2 antisense oligomers reduced Asp2 mRNA by roughly one-half, while the pair of reverse control oligomers lacked this effect (Table 3B).

Table 3B

Reduction of A β 40 and A β 42 in human neuroblastoma IMR-32 cells and mouse neuroblastoma Neuro-2A cells treated with Asp2 antisense and control oligomers as indicated. Oligomers were transfected in quadruplicate cultures. Values tabulated are normalized against cultures treated with oligofectin-GTM only (mean + SD, ** p<0.001 compared to reverse control oligomer).

		IMR-32 cells		Neuro-2A cells	
	Asp2 mRNA	A β 40	A β 42	A β 40	A β 42
Asp2-1A	-75%	-49 + 2%**	-42 + 14%**	-70 + 7%**	-67 + 2%**
Asp2-1R	0.16	-0 + 3%	21.26	-9 + 15%	1.05
Asp2-2A	-39%	-43 + 3%**	-44 + 18%**	-61 + 12%**	-61 + 12%**
Asp2-2R	0.47	12.2	19.22	6.15	-8 + 10%

Together with the reduction in Asp2 mRNA there was a concomitant reduction in the release of A β 40 and A β 42 peptides into the conditioned medium. Thus, Asp2 functions directly or indirectly in a human kidney and a human neuroblastoma cell line to facilitate the processing of APP into A β peptides. Molecular cloning of the mouse Asp2 cDNA revealed a high degree of homology to human (>96% amino acid identity, see Example 3), and indeed, complete nucleotide identity at the sites targeted by the Asp2-1A and Asp2-2A antisense oligomers. Similar results were obtained in mouse Neuro-2a cells engineered to express APP-Sw-KK. The Asp2 antisense

oligomers reduced release of A β peptides into the medium while the reverse control oligomers did not (Table 3B). Thus, the three antisense experiments with HEK293, IMR-32 and Neuro-2a cells indicate that Asp2 acts directly or indirectly to facilitate A β processing in both somatic and neural cell lines.

5

Example 8

Demonstration of Hu-Asp2 β -Secretase Activity in Cultured Cells

Several mutations in APP associated with early onset Alzheimer's disease have been shown to alter A β peptide processing. These flank the – and C-terminal cleavage sites that release A β from APP. These cleavage sites are referred to as the β -secretase and γ -secretase cleavage sites, respectively. Cleavage of APP at the β -secretase site creates a C-terminal fragment of APP containing 99 amino acids of 11,145 daltons molecular weight. The Swedish KM \rightarrow NL mutation immediately upstream of the β -secretase cleavage site causes a general increase in production of both the 1-40 and 1-42 amino acid forms of A β peptide. The London VF mutation (V717 \rightarrow F in the APP770 isoform) has little effect on total A β peptide production, but appears to preferentially increase the percentage of the longer 1-42 amino acid form of A β peptide by affecting the choice of β -secretase cleavage site used during APP processing. Thus, we sought to determine if these mutations altered the amount and type of A β peptide produced by cultured cells cotransfected with a construct directing expression of Hu-Asp2.

Two experiments were performed which demonstrate Hu-Asp2 β -secretase activity in cultured cells. In the first experiment, treatment of HEK125.3 cells with antisense oligomers directed against Hu-Asp2 transcripts as described in Example 7 was found to decrease the amount of the C-terminal fragment of APP created by β -secretase cleavage (CTF99) (Figure 9). This shows that Hu-Asp2 acts directly or indirectly to facilitate β -secretase cleavage. In the second experiment, increased expression of Hu-Asp2 in transfected mouse Neuro2A cells is shown to increase accumulation of the CTF99 β -secretase cleavage fragment (Figure 10). This increase is seen most easily when a mutant APP-KK clone containing a C-terminal di-lysine

30

motif is used for transfection. A further increase is seen when Hu-Asp2 is cotransfected with APP-Sw-KK containing the Swedish mutation KM →NL. The Swedish mutation is known to increase cleavage of APP by the β-secretase.

5 A second set of experiments demonstrate Hu-Asp2 facilitates γ-secretase activity in cotransfection experiments with human embryonic kidney HEK293 cells. Cotransfection of Hu-Asp2 with an APP-KK clone greatly increases production and release of soluble Aβ1-40 and Aβ1-42 peptides from HEK293 cells. There is a proportionately greater increase in the release of Aβ1-42. A further increase in production of Aβ1-42 is seen when Hu-Asp2 is cotransfected with APP-VF (SEQ ID
10 No. 13 [nucleotide] and SEQ ID No. 14 [amino acid]) or APP-VF-KK SEQ ID No. 19 [nucleotide] and SEQ ID No. 20 [amino acid]) clones containing the London mutation V717→F. The V717→F mutation is known to alter cleavage specificity of the APP γ-secretase such that the preference for cleavage at the Aβ42 site is increased. Thus, Asp2 acts directly or indirectly to facilitate γ-secretase processing of APP at the β42
15 cleavage site.

Materials

Antibodies 6E10 and 4G8 were purchased from Senetek (St. Louis, MO). Antibody 369 was obtained from the laboratory of Paul Greengard at the Rockefeller University. Antibody C8 was obtained from the laboratory of Dennis Selkoe at the
20 Harvard Medical School and Brigham and Women's Hospital.

APP Constructs used

The APP constructs used for transfection experiments comprised the following APP: wild-type APP695 (SEQ ID No. 9 and No. 10)

APP-Sw: APP695 containing the Swedish KM→NL mutation (SEQ ID No. 11
25 and No. 12), wherein the lysine (K) at residue 595 of APP695 is changed to asparagine (N) and the methionine (M) at residue 596 of APP695 is changed to leucine (L).),

APP-VF: APP695 containing the London V→F mutation (SEQ ID Nos. 13 & 14) (Affected residue 717 of the APP770 isoform corresponds with residue 642 of the

APP695 isoform. Thus, APP-VF as set in SEQ ID NO: 14 comprises the APP695 sequence, wherein the valine (V) at residue 642 is changed to phenylalanine (F).)

APP-KK: APP695 containing a C-terminal KK motif (SEQ ID Nos. 15 & 16),

APP-Sw-KK: APP695-Sw containing a C-terminal KK motif (SEQ ID No. 17
5 & 18),

APP-VF-KK: APP695-VF containing a C-terminal KK motif (SEQ ID Nos.
19 & 20).

These were inserted into the vector pIRES-EGFP (Clontech, Palo Alto CA)
between the *Not*1 and *Bst*X1 sites using appropriate linker sequences introduced by
10 PCR.

*Transfection of antisense oligomers or plasmid DNA constructs in HEK293 cells,
HEK125.3 cells and Neuro-2A cells,*

Human embryonic kidney HEK293 cells and mouse Neuro-2a cells were
15 transfected with expression constructs using the Lipofectamine Plus reagent from
Gibco/BRL. Cells were seeded in 24 well tissue culture plates to a density of 70-80%
confluence. Four wells per plate were transfected with 2 µg DNA (3:1,
APP:cotransfectant), 8 µl Plus reagent, and 4 µl Lipofectamine in OptiMEM.
OptiMEM was added to a total volume of 1 ml, distributed 200 µl per well and
20 incubated 3 hours. Care was taken to hold constant the ratios of the two plasmids used
for cotransfection as well as the total amount of DNA used in the transfection. The
transfection media was replaced with DMEM, 10%FBS, NaPyruvate, with
antibiotic/antimycotic and the cells were incubated under normal conditions (37°C,
5% CO₂) for 48 hours. The conditioned media were removed to polypropylene tubes
25 and stored at -80°C until assayed for the content of Aβ1-40 and Aβ1-42 by EIA as
described in the preceding examples. Transfection of antisense oligomers into
HEK125.3 cells was as described in Example 7.

Preparation of cell extracts, Western blot protocol

Cells were harvested after being transfected with plasmid DNA for about 60
30 hours. First, cells were transferred to 15-ml conical tube from the plate and

centrifuged at 1,500 rpm for 5 minutes to remove the medium. The cell pellets were washed once with PBS. We then lysed the cells with lysis buffer (10 mM HEPES, pH 7.9, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 0.1 mM sodium vanadate and 1% NP-40). The lysed cell mixtures were centrifuged at 5000 rpm and the supernatant was stored at -20°C as the cell extracts. Equal amounts of extracts from HEK125.3 cells transfected with the Asp2 antisense oligomers and controls were precipitated with antibody 369 that recognizes the C-terminus of APP and then CTF99 was detected in the immunoprecipitate with antibody 6E10. The experiment was repeated using C8, a second precipitating antibody that also recognizes the C-terminus of APP. For Western blot of extracts from mouse Neuro-2a cells cotransfected with Hu-Asp2 and APP-KK, APP-Sw-KK, APP-VF-KK or APP-VF, equal amounts of cell extracts were electrophoresed through 4-10% or 10-20% Tricine gradient gels (NOVEX, San Diego, CA). Full length APP and the CTF99 β -secretase product were detected with antibody 6E10.

Results

Transfection of HEK125.3 cells with Asp2-1 or Asp2-2 antisense oligomers reduces production of the CTF β -secretase product in comparison to cells similarly transfected with control oligomers having the reverse sequence (Asp2-1 reverse & Asp2-2 reverse), see Figure 9. Correspondingly, cotransfection of Hu-Asp2 into mouse Neuro-2a cells with the APP-KK construct increased the formation of CTF99. (See Fig. 10.) This was further increased if Hu-Asp2 was coexpressed with APP-Sw-KK, a mutant form of APP containing the Swedish KM-NL mutation that increases β -secretase processing.

Effects of Asp2 on the production of Ab peptides from endogenously expressed APP isoforms were assessed in HEK293 cells transfected with a construct expressing Asp2 or with the empty vector after selection of transformants with the antibiotic G418. A β 40 production was increased in cells transformed with the Asp2 construct in comparison to those transformed with the empty vector DNA. A β 40 levels in conditioned medium collected from the Asp2 transformed and control cultures was 424 ± 45 pg/ml and 113 ± 58 pg/ml, respectively ($p < 0.001$). A β 42

release was below the limit of detection by the EIA, while the release of sAPP α was unaffected, 112 ± 8 ng/ml versus 111 ± 40 ng/ml. This further indicates that Asp2 acts directly or indirectly to facilitate the processing and release of A β from endogenously expressed APP.

5 Co-transfection of Hu-Asp2 with APP has little effect on A β 40 production but increases A β 42 production above background (Table 4). Addition of the di-lysine motif to the C-terminus of APP increases A β peptide processing about two fold, although A β 40 and A β 42 production remain quite low (352 pg/ml and 21 pg/ml, respectively). Cotransfection of Asp2 with APP-KK further increases both A β 40 and
10 A β 42 production.

 The APP V717→F mutation has been shown to increase γ -secretase processing at the A β 42 cleavage site. Cotransfection of Hu-Asp2 with the APP-VF or APP-VF-KK constructs increased A β 42 production (a two fold increase with APP-VF and a four-fold increase with APP-VF-KK, Table 4), but had mixed effects on A β 40
15 production (a slight decrease with APP-VF, and a two fold increase with APP-VF-KK in comparison to the pcDNA cotransfection control. Thus, the effect of Asp2 on A β 42 production was proportionately greater leading to an increase in the ratio of A β 42/total Ab. Indeed, the ratio of A β 42/total A β reaches a very high value of 42% in HEK293 cells cotransfected with Hu-Asp2 and APP-VF-KK.

20

25

30

Table 4

Results of cotransfecting Hu-Asp2 or pcDNA plasmid DNA with various APP constructs containing the V717→F mutation that modifies γ -secretase processing.

5 Cotransfection with Asp2 consistently increases the ratio of A β 42/total A β . Values tabulated are A β peptide pg/ml.

		pcDNA Cotransfection			Asp2 Cotransfection		
		A β 40	A β 42	A β 42/Tot al	A β 40	A β 42	A β 42/Tot al
10							
	APP	192 \pm 1 8	<4	<2%	188 \pm 40	8 \pm 10	3.9%
15	APP-VF	118 \pm 1 5	15 \pm 19	11.5%	85 \pm 7	24 \pm 12	22.4%
	APP-KK	352 \pm 2 4	21 \pm 6	5.5%	1062 \pm 101	226 \pm 4 9	17.5%
20	APP-VF-K K	230 \pm 3 1	88 \pm 24	27.7%	491 \pm 35	355 \pm 3 6	42%

Example 9

Bacterial expression of human Asp2(a)

Expression of recombinant Hu-Asp2(a) in E. coli.

Hu-Asp2(a) can be expressed in *E. coli* after addition of N-terminal sequences
5 such as a T7 tag (SEQ ID No. 21 and No. 22) or a T7 tag followed by a caspase 8
leader sequence (SEQ ID No. 23 and No. 24). Alternatively, reduction of the GC
content of the 5' sequence by site directed mutagenesis can be used to increase the
yield of Hu-Asp2 (SEQ ID No. 25 and No. 26). In addition, Asp2(a) can be
engineered with a proteolytic cleavage site (SEQ ID No. 27 and No. 28). To produce
10 a soluble protein after expression and refolding, deletion of the transmembrane
domain and cytoplasmic tail, or deletion of the membrane proximal region,
transmembrane domain, and cytoplasmic tail is preferred. Any materials (vectors,
host cells, etc.) and methods described herein to express Hu-Asp2(a) should in
principle be equally effective for expression of Hu-Asp2(b).

15 *Methods*

PCR with primers containing appropriate linker sequences was used to
assemble fusions of Asp2(a) coding sequence with N-terminal sequence modifications
including a T7 tag (SEQ ID Nos. 21 and 22) or a T7-caspase 8 leader (SEQ ID Nos.
23 and 24). These constructs were cloned into the expression vector pet23a(+)
20 [Novagen] in which a T7 promoter directs expression of a T7 tag preceding a
sequence of multiple cloning sites. To clone Hu-Asp2 sequences behind the T7 leader
of pet23a+, the following oligonucleotides were used for amplification of the selected
Hu-Asp2(a) sequence: #553=GTGGATCCACCCAGCACGGCATCCGGCTG (SEQ
ID No. 35), #554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ
25 ID No. 36) which placed BamHI and HindIII sites flanking the 5' and 3' ends of the
insert, respectively. The Asp2(a) sequence was amplified from the full length Asp2(a)
cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech]
following the manufacturer's supplied protocol using annealing & extension at 68°C in
a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and
30 HindIII, purified by electrophoresis through an agarose gel, then ligated using the

Rapid DNA Ligation kit [Boehringer Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 (Promega) and colonies were picked for the purification of plasmid (Qiagen, Qiaprep minispin) and DNA sequence analysis. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli* strain BL21 (Statagene).
 5 Bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To clone Hu-Asp2 sequences behind the T7 tag and caspase leader (SEQ ID Nos. 23 and 24), the construct created above containing the T7-Hu-Asp2 sequence (SEQ ID Nos. 21 and 22) was opened at the BamHI site, and then the phosphorylated caspase 8 leader oligonucleotides
 #559=GATCGATGACTATCTCTGACTCTCCGCGTGAACAGGACG (SEQ ID No. 37), #560=GATCCGTCCTGTTCACGCGGAGAGTCAGAGATAGTCATC (SEQ
 15 ID No. 38) were annealed and ligated to the vector DNA. The 5' overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI. The ligation reaction was transformed into JM109 as above for analysis of protein expression after transfer to *E. coli* strain BL21.

In order to reduce the GC content of the 5' terminus of asp2(a), a pair of
 20 antiparallel oligos were designed to change degenerate codon bases in 15 amino acid positions from G/C to A/T (SEQ ID Nos. 25 and 26). The new nucleotide sequence at the 5' end of asp2 did not change the encoded amino acid and was chosen to optimize *E. Coli* expression. The sequence of the sense linker is 5'
 CGGCATCCGGCTGCCCCCTGCGTAGCGGTCTGGGTGGTGCTCCACTGGGTCT
 25 GCGTCTGCCCCGGGAGACCGACGAA G 3' (SEQ ID No. 39). The sequence of the antisense linker is : 5'
 CTTCGTCGGTCTCCCGGGGCAGACGCAGACCCAGTGGAGCACCACCCAGA
 CCGCTACGCAGGGGCAGCCGGATGCCG 3' (SEQ ID No. 40). After annealing the phosphorylated linkers together in 0.1 M NaCl-10 mM Tris, pH 7.4 they were
 30 ligated into unique Cla I and Sma I sites in Hu-Asp2 in the vector pTAC. For

inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

5 To create a vector in which the leader sequences can be removed by limited proteolysis with caspase 8 such that this liberates a Hu-Asp2 polypeptide beginning with the N-terminal sequence GSFV (SEQ ID Nos. 27 and 28), the following procedure was followed. Two phosphorylated oligonucleotides containing the caspase 8 cleavage site IETD, #571=5'
 10 GATCGATGACTATCTCTGACTCTCCGCTGGACTCTGGTATCGAAACCGACG (SEQ ID No. 41) and #572=
 GATCCGTCGGTTTCGATACCAGAGTCCAGCGGAGAGTCAGAGATAGTCAT C (SEQ ID No. 42) were annealed and ligated into pET23a+ that had been opened with BamHI. After transformation into JM109, the purified vector DNA was
 15 recovered and orientation of the insert was confirmed by DNA sequence analysis.

The following oligonucleotides were used for amplification of the selected Hu-Asp2(a) sequence: #573=5'AAGGATCCTTTGTGGAGATGGTGGACAACCTG, (SEQ ID No. 43) #554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ ID No. 44) which placed BamHI and HindIII sites flanking the 5' and 3' ends of
 20 the insert, respectively. The Hu-Asp2(a) sequence was amplified from the full length Hu-Asp2(a) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68°C in a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII, purified by electrophoresis through an agarose gel, then
 25 ligated using the Rapid DNA Ligation kit [Boehringer Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 [Promega] and colonies were picked for the purification of plasmid (Qiagen, Qiaprep minispin) and DNA sequence analysis. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli*
 30 strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of

ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To assist purification, a 6-His tag can be introduced into any of the above constructs following the T7 leader by opening the construct at the BamHI site and then ligating in the annealed, phosphorylated oligonucleotides containing the six histidine sequence #565=GATCGCATCATCACCATCACCATG (SEQ ID No. 45), #566=GATCCATGGTGATGGTGATGATGC (SEQ ID No. 46). The 5' overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI.

10 *Preparation of Bacterial Pellet:*

36.34g of bacterial pellet representing 10.8L of growth was dispersed into a total volume of 200ml using a 20mm tissue homogenizer probe at 3000 to 5000 rpm in 2M KCl, 0.1M Tris, 0.05M EDTA, 1mM DTT. The conductivity adjusted to about 193mMhos with water. After the pellet was dispersed, an additional amount of the KCl solution was added, bringing the total volume to 500 ml. This suspension was homogenized further for about 3 minutes at 5000 rpm using the same probe. The mixture was then passed through a Rannie high-pressure homogenizer at 10,000psi.

In all cases, the pellet material was carried forward, while the soluble fraction was discarded. The resultant solution was centrifuged in a GSA rotor for 1 hour at 12,500 rpm. The pellet was resuspended in the same solution (without the DTT) using the same tissue homogenizer probe at 2,000 rpm. After homogenizing for 5 minutes at 3000 rpm, the volume was adjusted to 500ml with the same solution, and spun for 1 hour at 12,500 rpm. The pellet was then resuspended as before, but this time the final volume was adjusted to 1.5L with the same solution prior to homogenizing for 5 minutes. After centrifuging at the same speed for 30 minutes, this procedure was repeated. The pellet was then resuspended into about 150ml of cold water, pooling the pellets from the six centrifuge tubes used in the GSA rotor. The pellet has homogenized for 5 minutes at 3,000 rpm, volume adjusted to 250ml with cold water, then spun for 30 minutes. Weight of the resultant pellet was 17.75g.

Summary: Lysis of bacterial pellet in KCl solution, followed by centrifugation in a GSA rotor was used to initially prepare the pellet. The same solution was then used an additional three times for resuspension/homogenization. A final water wash/homogenization was then performed to remove excess KCl and EDTA.

5 *Solubilization of Recombinant Hu-Asp2(a):*

A ratio of 9-10ml/gram of pellet was utilized for solubilizing the rHuAsp2L from the pellet previously described. 17.75g of pellet was thawed, and 150ml of 8M guanidine HCl, 5mM β ME, 0.1% DEA, was added. 3M Tris was used to titrate the pH to 8.6. The pellet was initially resuspended into the guanidine solution using a 20 mm tissue
10 homogenizer probe at 1000 rpm. The mixture was then stirred at 4°C for 1 hour prior to centrifugation at 12,500 rpm for 1 hour in GSA rotor. The resultant supernatant was then centrifuged for 30 minutes at 40,000 x g in an SS-34 rotor. The final supernatant was then stored at -20°C, except for 50 ml.

15 *Immobilized Nickel Affinity Chromatography of Solubilized Recombinant Hu-Asp2(a):*

The following solutions were utilized:

A) 6M Guanidine HCl, 0.1M NaP, pH 8.0, 0.01M Tris, 5mM β ME, 0.5mM Imidazole

20 A') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl

B') 6M Urea, 20mM NaP, pH 6.20, 50mM NaCl, 12mM Imidazole

C') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl, 300mM Imidazole

Note: Buffers A' and C' were mixed at the appropriate ratios to give intermediate concentrations of Imidazole.

25 The 50ml of solubilized material was combined with 50ml of buffer A prior to adding to 100-125ml Qiagen Ni-NTA SuperFlow (pre-equilibrated with buffer A) in a 5 x 10cm Bio-Rad econo column. This was shaken gently overnight at 4°C in the cold room.

Chromatography Steps:

30 Drained the resultant flow through.

Washed with 50ml buffer A (collecting into flow through fraction)

Washed with 250ml buffer A (wash 1)

- Washed with 250ml buffer A (wash 2)
 Washed with 250ml buffer A'
 Washed with 250ml buffer B'
 Washed with 250ml buffer A'
- 5 Eluted with 250ml 75mM Imidazole
 Eluted with 250ml 150mM Imidazole (150-1)
 Eluted with 250ml 150mM Imidazole (150-2)
 Eluted with 250ml 300mM Imidazole (300-1)
 Eluted with 250ml 300mM Imidazole (300-2)
- 10 Eluted with 250ml 300mM Imidazole (300-3)

Chromatography Results:

- The Hu-Asp(a) eluted at 75mM Imidazole through 300mM Imidazole. The 75mM fraction, as well as the first 150mM Imidazole (150-1) fraction contained
- 15 contaminating proteins as visualized on Coomassie Blue stained gels. Therefore, fractions 150-2 and 300-1 will be utilized for refolding experiments since they contained the greatest amount of protein as visualized on a Coomassie Blue stained gel.

Refolding Experiments of Recombinant Hu-Asp2(a):

20 *Experiment 1:*

- Forty ml of 150-2 was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 200ml of (4°C) cold 20mM NaP, pH 6.8, 150mM NaCl. This dilution gave a final Urea concentration of 1M. This solution remained clear, even if
- 25 allowed to set open to the air at room temperature (RT) or at 4°C .
- After setting open to the air for 4-5 hours at 4°C, this solution was then dialyzed overnight against 20mM NaP, pH 7.4, 150mM NaCl, 20% glycerol. This method effectively removes the urea in the solution without precipitation of the protein.

30

Experiment 2:

Some of the 150-2 eluate was concentrated 2x on an Amicon Centriprep, 10,000 MWCO, then treated as in Experiment 1. This material also stayed in solution, with no visible precipitation.

5 Experiment 3:

89ml of the 150-2 eluate was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 445ml of (4°C) cold 20mM NaP, pH 6.8, 150mM NaCl. This solution appeared clear, with no apparent precipitation. The solution was
10 removed to RT and stirred for 10 minutes prior to adding MEA to a final concentration of 0.1mM. This was stirred slowly at RT for 1 hour. Cystamine and CuSO₄ were then added to final concentrations of 1mM and 10 µM respectively. The solution was stirred slowly at RT for 10 minutes prior to being moved to the 4°C cold room and shaken slowly overnight, open to the air.

15 The following day, the solution (still clear, with no apparent precipitation) was centrifuged at 100,000 x g for 1 hour. Supernatants from multiple runs were pooled, and the bulk of the stabilized protein was dialyzed against 20mM NaP, pH 7.4, 150mM NaCl, 20% glycerol. After dialysis, the material was stored at -20°C.

Some (about 10 ml) of the protein solution (still in 1M Urea) was saved back
20 for biochemical analyses, and frozen at -20°C for storage.

Example 10**Expression of Hu-Asp2 and Derivatives in Insect Cells**

Any materials (vectors, host cells, etc.) and methods that are useful to express
25 Hu-Asp2(a) should in principle be equally effective for expression of Hu-Asp2(b).

Expression by baculovirus infection.

The coding sequence of Hu-Asp2(a) and Hu-ASp2(b) and several derivatives were engineered for expression in insect cells using the PCR. For the full-length sequence, a 5'-sense oligonucleotide primer that modified the translation initiation site
30 to fit the Kozak consensus sequence was paired with a 3'-antisense primer that

contains the natural translation termination codon in the Hu-Asp2 sequence. PCR amplification of the pcDNA3.1(hygro)/Hu-Asp2(a) template was used to prepare two derivatives of Hu-Asp2(a) or Hu-Asp(b) that delete the C-terminal transmembrane domain (SEQ ID Nos. 29-30 and 50-51, respectively) or delete the transmembrane domain and introduce a hexa-histidine tag at the C-terminus (SEQ ID Nos. 31-32 and 52-53) respectively, were also engineered using PCR. The same 5'-sense oligonucleotide primer described above was paired with either a 3'-antisense primer that (1) introduced a translation termination codon after codon 453 (SEQ ID No. 3) or (2) incorporated a hexa-histidine tag followed by a translation termination codon in the PCR using pcDNA3.1(hygro)/Hu-Asp-2(a) as the template. In all cases, the PCR reactions were performed amplified for 15 cycles using *Pwo*I DNA polymerase (Boehringer-Mannheim) as outlined by the supplier. The reaction products were digested to completion with *Bam*HI and *Not*I and ligated to *Bam*HI and *Not*I digested baculovirus transfer vector pVL1393 (Invitrogen). A portion of the ligations was used to transform competent *E. coli* DH5_ cells followed by antibiotic selection on LB-Amp. Plasmid DNA was prepared by standard alkaline lysis and banding in CsCl to yield the baculovirus transfer vectors pVL1393/Asp2(a), pVL1393/Asp2(a) Δ TM and pVL1393/Asp2(a) Δ TM(His)₆. Creation of recombinant baculoviruses and infection of sf9 insect cells was performed using standard methods.

Expression by transfection

Transient and stable expression of Hu-Asp2(a) Δ TM and Hu-Asp2(a) Δ TM(His)₆ in High 5 insect cells was performed using the insect expression vector pIZ/V5-His. The DNA inserts from the expression plasmids vectors pVL1393/Asp2(a), pVL1393/Asp2(a) Δ TM and pVL1393/Asp2(a) Δ TM(His)₆ were excised by double digestion with *Bam*HI and *Not*I and subcloned into *Bam*HI and *Not*I digested pIZ/V5-His using standard methods. The resulting expression plasmids, referred to as pIZ/Hu-Asp2 Δ TM and pIZ/Hu-Asp2 Δ TM(His)₆, were prepared as described above.

For transfection, High 5 insect cells were cultured in High Five serum free medium supplemented with 10 μ g/ml gentamycin at 27 °C in sealed flasks.

Transfections were performed using High five cells, High five serum free media supplemented with 10 µg/ml gentamycin, and InsectinPlus liposomes (Invitrogen, Carlsbad, CA) using standard methods.

For large scale transient transfections, 1.2×10^7 high five cells were plated in a 150 mm tissue culture dish and allowed to attach at room temperature for 15-30 minutes. During the attachment time the DNA/ liposome mixture was prepared by mixing 6 ml of serum free media, 60 µg Hu-Asp2(a)ΔTM/pIZ (+/- His) DNA and 120 µl of Insectin Plus and incubating at room temperature for 15 minutes. The plating media was removed from the dish of cells and replaced with the DNA/liposome mixture for 4 hours at room temperature with constant rocking at 2 rpm. An additional 6 ml of media was added to the dish prior to incubation for 4 days at 27 °C in a humid incubator. Four days post transfection the media was harvested, clarified by centrifugation at 500 x g, assayed for Hu-Asp2(a) expression by Western blotting. For stable expression, the cells were treated with 50 µg/ml Zeocin and the surviving pool used to prepared clonal cells by limiting dilution followed by analysis of the expression level as noted above.

Purification of Hu-Asp2(a)ΔTM and Hu-Asp2(a)ΔTM(His)₆

Removal of the transmembrane segment from Hu-Asp2(a) resulted in the secretion of the polypeptide into the culture medium. Following protein production by either baculovirus infection or transfection, the conditioned medium was harvested, clarified by centrifugation, and dialyzed against Tris-HCl (pH 8.0). This material was then purified by successive chromatography by anion exchange (Tris-HCl, pH 8.0) followed by cation exchange chromatography (Acetate buffer at pH 4.5) using NaCl gradients. The elution profile was monitored by (1) Western blot analysis and (2) by activity assay using the peptide substrate described in Example 12. For the Hu-Asp2(a)ΔTM(His)₆, the conditioned medium was dialyzed against Tris buffer (pH 8.0) and purified by sequential chromatography on IMAC resin followed by anion exchange chromatography.

Amino-terminal sequence analysis of the purified Hu-Asp2(a) Δ TM(His)₆ protein revealed that the signal peptide had been cleaved [TQHGIRLPLR, corresponding to SEQ ID NO: 32, residues 22-3].

5

Example 11

Expression of Hu-Asp2(a) and Hu-Asp(b) in CHO cells

The materials (vectors, host cells, etc.) and methods described herein for expression of Hu-Asp2(a) are intended to be equally applicable for expression of Hu-Asp2(b).

10 *Heterologous expression of Hu-Asp-2(a) in CHO-K1 cells*

The entire coding sequence of Hu-Asp2(a) was cloned into the mammalian expression vector pcDNA3.1(+)/Hygro (Invitrogen, Carlsbad, CA) which contains the CMV immediate early promoter and bGH polyadenylation signal to drive over expression. The expression plasmid, pcDNA3.1(+)/Hygro/Hu-Asp2(a), was prepared by alkaline lysis and banding in CsCl and completely sequenced on both strands to
15 verify the integrity of the coding sequence.

Wild-type Chinese hamster ovary cells (CHO-K1) were obtained from the ATCC. The cells were maintained in monolayer cultures in α -MEM containing 10% FCS at 37°C in 5% CO₂. Two 100 mm dishes of CHO-K1 cells (60% confluent) were
20 transfected with pcDNA3.1(+)/Hygro alone (mock) or pcDNA3.1(+)/Hygro/Hu-Asp2(a) or pcDNA3.1(+)/Hygro/Hu-Asp2(b) using the cationic liposome DOTAP as recommended by the supplier (Roche, Indianapolis, IN). The cells were treated with the plasmid DNA/liposome mixtures for 15 hours and then the medium replaced with growth medium containing 500 Units/ml hygromycin B. In
25 the case of pcDNA3.1(+)/Hygro/Hu-Asp2(a) or (b) transfected CHO-K1 cells, individual hygromycin B-resistant cells were cloned by limiting dilution. Following clonal expansion of the individual cell lines, expression of Hu-Asp2(a) or Hu-Asp2(b) protein was assessed by Western blot analysis using a polyclonal rabbit antiserum raised against recombinant Hu-Asp2 prepared by expression in *E. coli*. Near
30 confluent dishes of each cell line were harvested by scraping into PBS and the cells

recovered by centrifugation. The cell pellets were resuspended in cold lysis buffer (25 mM Tris-HCl (pH 8.0)/5 mM EDTA) containing protease inhibitors and the cells lysed by sonication. The soluble and membrane fractions were separated by centrifugation (105,000 x g, 60 min) and normalized amounts of protein from each fraction were then separated by SDS-PAGE. Following electrotransfer of the separated polypeptides to PVDF membranes, Hu-Asp-2(a) or Hu-Asp2(b) protein was detected using rabbit anti-Hu-Asp2 antiserum (1/1000 dilution) and the antibody-antigen complexes were visualized using alkaline phosphatase conjugated goat anti-rabbit antibodies (1/2500). A specific immunoreactive protein with an apparent Mr value of 65 kDa was detected in pcDNA3.1(+)/Hygro/Hu-Asp2 transfected cells and not mock-transfected cells. Also, the Hu-Asp2 polypeptide was only detected in the membrane fraction, consistent with the presence of a signal peptide and single transmembrane domain in the predicted sequence. Based on this analysis, clone #5 had the highest expression level of Hu-Asp2(a) protein and this production cell lines was scaled up to provide material for purification.

Purification of recombinant Hu-Asp-2(a) from CHO-K1/Hu-Asp2 clone #5

In a typical purification, clone #5 cell pellets derived from 20 150 mm dishes of confluent cells, were used as the starting material. The cell pellets were resuspended in 50 ml cold lysis buffer as described above. The cells were lysed by polytron homogenization (2 x 20 sec) and the lysate centrifuged at 338,000 x g for 20 minutes. The membrane pellet was then resuspended in 20 ml of cold lysis buffer containing 50 mM β -octylglucoside followed by rocking at 4 °C for 1 hour. The detergent extract was clarified by centrifugation at 338,000 x g for 20 minutes and the supernatant taken for further analysis.

The β -octylglucoside extract was applied to a Mono Q anion exchange column that was previously equilibrated with 25 mM Tris-HCl (pH 8.0)/50 mM β -octylglucoside. Following sample application, the column was eluted with a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β -secretase activity (see below). Fractions containing both Hu-Asp-2(a) immunoreactivity and β -secretase activity

were pooled and dialyzed against 25 mM NaOAc (pH 4.5)/50 mM β -octylglucoside. Following dialysis, precipitated material was removed by centrifugation and the soluble material chromatographed on a MonoS cation exchange column that was previously equilibrated in 25 mM NaOAc (pH 4.5)/ 50 mM β -octylglucoside. The column was eluted using a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β -secretase activity. Fractions containing both Hu-Asp2 immunoreactivity and β -secretase activity were combined and determined to be >95% pure by SDS-PAGE/Coomassie Blue staining.

10 The same methods were used to express and purify Hu-Asp2(b).

Example 12

Assay of Hu-Asp2 β -secretase activity using peptide substrates

β -secretase assay

15 Recombinant human Asp2(a) prepared in CHO cells and purified as described in Example 11 was used to assay Asp2(a) proteolytic activity directly. Activity assays for Asp2(a) were performed using synthetic peptide substrates containing either the wild-type APP β -secretase site (SEVKM↓DAEFR; SEQ ID NO: 64), the Swedish KM→NL mutation (SEVNL↓DAEFR; SEQ ID NO: 63), or the A β 40 and 42 γ -secretase sites (RRGGVV↓IA↓TVIVGER; SEQ ID NO: 65). Reactions were performed in 50 mM 2-[N-morpholino]ethane-sulfonate ("Na-MES," pH 5.5) containing 1% β -octylglucoside, 70 mM peptide substrate, and recombinant Asp2(a) (1-5 μ g protein) for various times at 37°C. The reaction products were quantified by RP-HPLC using a linear gradient from 0-70 B over 30 minutes (A=0.1% TFA in water, B=0.1%TFA/10%water/90%AcCN). The elution profile was monitored by absorbance at 214 nm. In preliminary experiments, the two product peaks which eluted before the intact peptide substrate, were confirmed to have the sequence DAEFR (SEQ ID NO: 72)and SEVNL (SEQ ID NO: 73) using both Edman sequencing and MADLI-TOF mass spectrometry. Percent hydrolysis of the peptide substrate was calculated by comparing the integrated peak areas for the two product

20

25

30

peptides and the starting material derived from the absorbance at 214 nm. The sequence of cleavage/hydrolysis products was confirmed using Edman sequencing and MADLI-TOF mass spectrometry.

5 The behavior of purified Asp2(a) in the proteolysis assays was consistent with the prior anti-sense studies which indicated that Asp2(a) possesses β -secretase activity. Maximal proteolysis was seen with the Swedish β -secretase peptide, which, after 6 hours, was about 10-fold higher than wild type APP.

10 The specificity of the protease cleavage reaction was determined by performing the β -secretase assay in the presence of 8 μ M pepstatin A and the presence of a cocktail of protease inhibitors (10 μ M leupeptin, 10 μ M E64, and 5 mM EDTA). Proteolytic activity was insensitive to both the pepstatin and the cocktail, which are inhibitors of cathepsin D (and other aspartyl proteases), serine proteases, cysteinyl proteases, and metalloproteases, respectively.

15 Hu-Asp2(b) when similarly expressed in CHO cells and purified using identical conditions for extraction with β -octylglucoside and sequential chromatography over Mono Q and Mono S also cleaves the Swedish β -secretase peptide in proteolysis assays using identical assay conditions.

20 Collectively, this data establishes that both forms of Asp2 (Hu-Asp2(a) and Hu-Asp2(b)) act directly in cell-free assays to cleave synthetic APP peptides at the β -secretase site, and that the rate of cleavage is greatly increased by the Swedish KM \rightarrow NL mutation that is associated with Alzheimer's disease.

25 An alternative β -secretase assay utilizes internally quenched fluorescent substrates to monitor enzyme activity using fluorescence spectroscopy in a single sample or multiwell format. Each reaction contained 50 mM Na-MES (pH 5.5), peptide substrate MCA-EVKMDAEF[K-DNP] (SEQ ID NO: 71; BioSource International) (50 μ M) and purified Hu-Asp-2 enzyme. These components were equilibrated to 37 $^{\circ}$ C for various times and the reaction initiated by addition of substrate. Excitation was performed at 330 nm and the reaction kinetics were monitored by measuring the fluorescence emission at 390 nm. To detect compounds
30 that modulate Hu-Asp-2 activity, the test compounds were added during the

preincubation phase of the reaction and the kinetics of the reaction monitored as described above. Activators are scored as compounds that increase the rate of appearance of fluorescence while inhibitors decrease the rate of appearance of fluorescence.

5 It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the invention. The entire disclosure of all publications cited herein are hereby incorporated by reference.

10

What is claimed is:

1. A polypeptide comprising the amino acid sequence of a mammalian amyloid protein precursor (APP) or fragment thereof containing an APP cleavage site recognizable by a mammalian β -secretase, and further comprising two lysine residues
5 at the carboxyl terminus of the amino acid sequence of the mammalian APP or APP fragment.
2. A polypeptide according to claim 1 comprising the amino acid sequence of a mammalian amyloid protein precursor (APP), and further comprising
10 two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian amyloid protein precursor.
3. A polypeptide according to claim 1 wherein the polypeptide further includes a marker.
15
4. A polypeptide according to claim 3 wherein the marker comprises a reporter protein amino acid sequence attached to the APP amino acid sequence.
5. A polypeptide according to claim 4 wherein the reporter protein
20 comprises an amino acid sequence of a fluorescing protein.
6. A polypeptide according to claim 1, wherein the mammalian APP is a human APP.
- 25 7. A polypeptide according to claim 6, wherein the human APP comprises at least one variation selected from the group consisting of a Swedish KM \rightarrow NL mutation and a London V717 \rightarrow F mutation.

8. A polypeptide according to claim 6, wherein the human APP is selected from the group consisting of: an APP695 isoform, an APP 751 isoform, and an APP770 isoform.

5 9. A polypeptide according to claim 1 wherein the APP protein or fragment thereof comprises the APP-Sw β -secretase peptide sequence NLDA.

10 10. A polypeptide according to claim 9 wherein the APP protein or fragment thereof comprises the APP-Sw β -secretase peptide sequence SEVNLDAEFR (SEQ ID NO: 63).

11. A polypeptide according to claim 9 wherein the APP protein or fragment thereof further includes an APP transmembrane domain carboxy-terminal to the APP-Sw β -secretase peptide sequence.

15 12. A polypeptide according to claim 9 wherein the APP protein or fragment thereof comprises a chimeric APP, said chimeric APP including partial APP amino acid sequences from at least two species.

20 13. A polypeptide according to claim 12 wherein the chimeric APP includes amino acid sequence of a human APP and a rodent APP.

25 14. A polynucleotide comprising a nucleotide sequence that encodes a polypeptide according to any one of claims 1.

15. A vector comprising a polynucleotide according to claim 14.

30 16. A vector according to claim 15 wherein said polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell.

17. A host cell transformed or transfected with a polynucleotide according to claim 14 or a vector according to claim 15 or 16.

18. A host cell according to claim 17 that is a mammalian cell.

5

19. A polypeptide useful for assaying for modulators of β -secretase activity, said polypeptide comprising an amino acid sequence of the formula $\text{NH}_2\text{-X-Y-Z-KK-COOH}$;

wherein X, Y, and Z each comprise an amino acid sequence of at least one amino acid;

wherein $\text{NH}_2\text{-X}$ comprises an amino-terminal amino acid sequence having at least one amino acid residue;

wherein Y comprises an amino acid sequence of a β -secretase recognition site of a mammalian amyloid protein precursor (APP); and

wherein Z-KK-COOH comprises a carboxy-terminal amino acid sequence ending in two lysine (K) residues.

20. A polypeptide according to claim 19 wherein the carboxyl-terminal amino acid sequence Z includes a hydrophobic domain that is a transmembrane domain in host cells that express the polypeptide.

21. A polypeptide according to claim 19 wherein the amino-terminal amino acid sequence X includes an amino acid sequence of a reporter protein.

22. A polypeptide according to claim 19 wherein the β -secretase recognition site Y comprises the human APP-Sw β -secretase peptide sequence NLDA.

23. A polynucleotide comprising a nucleotide sequence that encodes a polypeptide according to any one of claims 19-22.

24. A purified polypeptide comprising the murine Asp2 amino acid sequence set forth in SEQ ID NO: 8, or a fragment thereof that retains the β -secretase activity of said murine Asp2.
- 5 25. A polynucleotide comprising a nucleotide sequence that encodes the polypeptide of claim 24.
26. A polynucleotide according to claim 25 comprising the nucleotide sequence set forth in SEQ ID NO: 7.
- 10 27. A purified murine Asp2(b) polypeptide comprising the amino acid sequence set for in SEQ ID NO: 8 from residues 1-189 and 215-501, but lacking residues 190-214.
- 15 28. A polynucleotide comprising a nucleotide sequence that encodes the murine Asp2(b) polypeptide according to claim 27.
29. A vector comprising a polynucleotide according to claim 25.
- 20 30. A vector according to claim 29 wherein said polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell.
31. A host cell transformed or transfected with a vector according to claim
- 25 30.
32. A host cell according to claim 31 that is a mammalian cell.
33. A host cell according to claim 31 that expresses the polypeptide on its
- 30 surface.

34. A host cell according to claim 31, wherein the host cell is transfected with a nucleic acid comprising a nucleotide sequence that encodes an amyloid precursor protein (APP) that includes two carboxy-terminal lysine residues.

5

35. A host cell according to claim 34 that expresses the polypeptide and the APP on its surface.

36. A method of making a murine Asp2 polypeptide comprising steps of
10 culturing a host cell of claim 61 in a culture medium under conditions in which the cell produces the polypeptide that is encoded by the polynucleotide.

37. A method according to claim 36, further comprising a step of purifying the polypeptide from the cell or the culture medium.

15

38. A host cell transformed or transfected with a polynucleotide according to claim 25.

39. A host cell according to claim 38 that is a mammalian cell.

20

40. A host cell according to claim 38 that expresses the polypeptide on its surface.

41. A host cell according to claim 38, wherein the host cell is transfected
25 with a nucleic acid comprising a nucleotide sequence that encodes an amyloid precursor protein (APP) or fragment thereof containing a β -secretase cleavage site.

42. A host cell according to claim 41 wherein the APP includes two carboxy-terminal lysine residues.

30

43. A host cell according to claim 41 wherein the APP comprises the Swedish mutation (K→N, M→L) adjacent to the β-secretase cleavage site.

5 44. A host cell according to claim 41 that expresses the polypeptide and the APP on its surface.

45. A method of making a murine Asp2 polypeptide comprising steps of culturing a host cell of claim 38 in a culture medium under conditions in which the cell produces the polypeptide that is encoded by the polynucleotide.

10

46. A method according to claim 45, further comprising a step of purifying the polypeptide from the cell or the culture medium. –

15 47. A purified polypeptide comprising a fragment of a mammalian Asp2 protein, wherein said polypeptide lacks the Asp2 transmembrane domain of said Asp2 protein, and wherein the polypeptide and the fragment retain the β-secretase activity of said mammalian Asp2 protein.

20 48. A purified polypeptide according to claim 47 comprising a fragment of a human Asp2 protein that retains the β-secretase activity of said human Asp2 protein.

25 49. A purified polypeptide according to claim 48, wherein said polypeptide comprises a fragment of Asp2(a) having the amino acid sequence set forth in SEQ ID NO: 4, and wherein said polypeptide lacks transmembrane domain amino acids 455 to 477 of SEQ ID NO: 4.

50. A purified polypeptide according to claim 49, wherein said polypeptide further lacks cytoplasmic domain amino acids 478 to 501 of SEQ ID NO: 4.

51. A purified polypeptide according to claim 50, wherein said polypeptide further lacks amino acids 420-454 of SEQ ID NO: 4.

52. A purified polypeptide according to any one of claims 48-51, wherein
5 said polypeptide comprises an amino acid sequence:

that includes amino acids 58 to 419 of SEQ ID NO: 4, and
that lacks amino acids 22 to 57 of SEQ ID NO: 4.

53. A purified polypeptide according to any one of claims 48-51, wherein
10 said polypeptide comprises an amino acid sequence:

that includes amino acids 46 to 419 of SEQ ID NO: 4, and
that lacks amino acids 22 to 45 of SEQ ID NO: 4.

54. A purified polypeptide according to claim 49, wherein said polypeptide
15 comprises an amino acid sequence that includes amino acids 22 to 454 of SEQ ID NO: 4.

55. A purified polypeptide according to claim 47 comprising the amino
acid sequence of human Asp-2(b) protein set forth as SEQ ID NO: 6, or fragments
20 thereof that retain β -secretase activity.

56. A purified polypeptide according to claim 48, wherein said polypeptide
comprises a fragment of Asp2(b) having the amino acid sequence set forth in SEQ ID
NO: 6, and wherein said polypeptide lacks transmembrane domain amino acids 430 to
25 452 of SEQ ID NO: 6.

57. A purified polypeptide according to claim 56, wherein said polypeptide
further lacks cytoplasmic domain amino acids 453 to 476 of SEQ ID NO: 6.

58. A purified polypeptide according to claim 57, wherein said polypeptide further lacks amino acids 395-429 of SEQ ID NO: 4.

59. A purified polypeptide according to any one of claims 56-58, wherein
5 said polypeptide comprises an amino acid sequence:

that includes amino acids 58 to 394 of SEQ ID NO: 4, and
that lacks amino acids 22 to 57 of SEQ ID NO: 4.

60. A purified polypeptide according to any one of claims 56-58, wherein
10 said polypeptide comprises an amino acid sequence:

that includes amino acids 46 to 394 of SEQ ID NO: 4, and
that lacks amino acids 22 to 45 of SEQ ID NO: 4.

61. A purified polypeptide according to claim 56, wherein said polypeptide
15 comprises an amino acid sequence that includes amino acids 22 to 429 of SEQ ID
NO: 6.

62. A polypeptide comprising an amino acid sequence at least 95%
identical to a fragment of a human Asp2 protein, wherein said polypeptide and said
20 fragment lack a transmembrane domain and retain β -secretase activity of the human
Asp2 protein.

63. A purified polynucleotide comprising a nucleotide sequence that
encodes the polypeptide of any one of claims 47-63.
25

64. A polynucleotide of claim 47 wherein the polypeptide comprises a
fragment of human Asp2 protein.

65. A polynucleotide of claim 64 wherein the polypeptide comprises a
30 fragment of Asp2(a) having the amino acid sequence set forth as SEQ ID NO: 4, and

wherein the polypeptide lacks the transmembrane domain amino acids 455-477 of SEQ ID NO: 4.

5 66. A polynucleotide of claim 64, wherein the polypeptide further lacks cytoplasmic domain amino acids 478-501 of SEQ ID NO: 4.

67. A purified polynucleotide of claim 66, wherein said polypeptide further lacks amino acids 420-454 of SEQ ID NO: 4.

10 68. A polynucleotide of claim 65, wherein the polypeptide comprises an amino acid sequence:

that includes amino acids 58-419 of SEQ ID NO: 4, and
that lacks amino acids 22-57 of SEQ ID NO: 4.

15 69. A polynucleotide of claim 65, wherein the polypeptide comprises an amino acid sequence:

that includes amino acids 46-419 of SEQ ID NO: 4, and
that lacks amino acids 22-45 of SEQ ID NO: 4.

20 70. A polynucleotide of claim 65, wherein the polypeptide comprises an amino acid sequence that includes amino acids 22-454 of SEQ ID NO: 4.

25 71. A polynucleotide of claim 64, wherein the polypeptide comprises a fragment of human Asp2(b) having the amino acid set forth in SEQ ID NO: 6, and wherein the polypeptide lacks transmembrane domain amino acids 430-452 of SEQ ID NO: 6.

30 72. A polynucleotide of claim 71, wherein the polypeptide lacks cytoplasmic domain amino acids 453-476 of SEQ ID NO: 6.

73. A polynucleotide of claim 72, wherein the polypeptide further lacks amino acids 395-429 of SEQ ID NO: 6.

74. A polynucleotide of claim 71, wherein the polypeptide comprises an amino acid sequence:

that includes amino acids 58-394 of SEQ ID NO: 6, and
that lacks amino acids 22 to 57 of SEQ ID NO: 6.

75. A polynucleotide of claim 71, wherein the polypeptide comprises an amino acid sequence:

that includes amino acids 46-394 of SEQ ID NO: 6, and
that lacks amino acids 22-45 of SEQ ID NO: 6.

76. A polynucleotide of claim 71, wherein the polypeptide comprises an amino acid sequence that includes amino acids 22 to 429 of SEQ ID NO: 6.

77. A vector comprising a polynucleotide according to claim 63.

78. A host cell transformed or transfected with a polynucleotide according to claim 63.

79. A host cell transformed or transfected with a vector of claim 77.

80. A polynucleotide comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid comprising the sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6, wherein the nucleotide sequence encodes a polypeptide having β -secretase biological activity.

81. A vector comprising a polynucleotide of claim 80.

82. A host cell transformed or transfected with a polynucleotide of claim
80.

83. A method for assaying for modulators of β -secretase activity,
5 comprising the steps of:

- (a) contacting a first composition with a second composition both in the presence and in the absence of a putative modulator compound, wherein the first composition comprises a mammalian β -secretase polypeptide or biologically active fragment thereof, and wherein the second composition comprises a substrate
10 polypeptide having an amino acid sequence comprising a β -secretase cleavage site;
- (b) measuring cleavage of the substrate polypeptide in the presence and in the absence of the putative modulator compound; and
- (c) identifying modulators of β -secretase activity from a difference in cleavage in the presence versus in the absence of the putative modulator compound,
15 wherein a modulator that is a β -secretase antagonist reduces such cleavage and a modulator that is a β -secretase agonist increases such cleavage.

84. A method according to claim 83, wherein the first composition
20 comprises a purified human Asp2 polypeptide.

85. A method according to claim 83, wherein the first composition
comprises a soluble fragment of a human Asp2 polypeptide that retains Asp2 β -secretase activity.

86. A method according to claim 85 wherein the soluble fragment is a
25 fragment lacking an Asp2 transmembrane domain.

87. A method according to claim 83, wherein the substrate polypeptide of
the second composition comprises the amino acid sequence SEVNLDAEFR.

30

88. A method according to claim 83, wherein the substrate polypeptide of the second composition comprises the amino acid sequence EVKMDAEF.

89. A method according to claim 83, wherein the second composition comprises a polypeptide having an amino acid sequence of a human amyloid precursor protein (APP).

90. A method according to claim 89, wherein the human amyloid precursor protein is selected from the group consisting of: APP695, APP751, and APP770.

91. A method according to claim 90, wherein the human amyloid precursor protein includes at least one mutation selected from a KM-NL Swiss mutation and a V-F London mutation.

92. A method according to claim 89, wherein the polypeptide having an amino acid sequence of a human APP further comprises an amino acid sequence comprising a marker sequence attached amino-terminal to the amino acid sequence of the human amyloid precursor protein.

93. A method according to claim 89, wherein the polypeptide having an amino acid sequence of a human APP further comprises two lysine residues attached to the carboxyl terminus of the amino acid sequence of the human APP.

94. A method according to claim 82, wherein the second composition comprises a eukaryotic cell that expresses amyloid precursor protein (APP) or a fragment thereof containing a β -secretase cleavage site.

95. A method according to claim 94, wherein the APP expressed by the host cell is an APP variant that includes two carboxyl-terminal lysine residues.

96. A method for identifying agents that inhibit the activity of human Asp2 aspartyl protease (Hu-Asp2), comprising the steps of:

- (a) contacting amyloid precursor protein (APP) and purified and isolated Hu-Asp2 in the presence and absence of a test agent;
- 5 (b) determining the APP processing activity of the Hu-Asp2 in the presence and absence of the test agent; and
- (c) comparing the APP processing activity of the Hu-Asp2 polypeptide in the presence of the test agent to the activity in the absence of the test agent to identify
10 an agent that inhibits the APP processing activity of Hu-Asp2, wherein reduced activity in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.

97. A method according to claim 96, wherein the Hu-Asp2 comprises a
15 polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the Hu-Asp2.

98. A method according to claim 60 wherein the nucleotide sequence is selected from the group consisting of:

- 20 (a) a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4;
- (b) a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6;
- (c) a nucleotide sequence encoding a fragment of Hu-Asp2(a) (SEQ ID
25 NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b); and
- (d) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO:
30 5.

99. A method according to claim 97 wherein the Hu-Asp2 comprises the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4.

5 100. A method according to claim 97, wherein the Hu-Asp2 comprises the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6.

101. A method according to claim 97, wherein the Hu-Asp2 comprises a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein
10 said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b).

102. A method according to claim 96, wherein the APP comprises the Swedish mutation (K→N, M→L) adjacent to the β -secretase processing site.

15

103. A method according to claim 96, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).

20 104. A method for identifying agents that inhibit the activity of human Asp2 aspartyl protease (Hu-Asp2), comprising the steps of:

- (a) contacting Hu-Asp2 and amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the APP comprises a carboxy-terminal di-lysine (KK) and wherein the contacting comprises growing a host
25 cell that expresses the APP in the presence and absence of the test agent;
- (b) determining the APP processing activity of the Hu-Asp2 in the presence and absence of the test agent; and
- (c) comparing the APP processing activity of the Hu-Asp2 polypeptide in the presence of the test agent to the activity in the absence of the test agent to
30 identify an agent that inhibits the activity of Hu-Asp2, wherein reduced

activity in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.

105. A method according to claim 104, wherein the APP further comprises
5 the Swedish mutation (K→N, M→L) adjacent to the β-secretase processing site.

106. A method according to claim 104, wherein the host cell has been transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes a Hu-Asp2, wherein said nucleotide sequence is selected from the group
10 consisting of:

(a) a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4;

(b) a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6;

15 (c) a nucleotide sequence encoding a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b); and

(d) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding
20 polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.

107. A method according to claim 104, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to
25 steps (a)-(c).

108. A method for identifying agents that inhibit the activity of human Asp2 aspartyl protease (Hu-Asp2), comprising the steps of:

(a) contacting Hu-Asp2 and amyloid precursor protein (APP) in the
30 presence and absence of a test agent, wherein the contacting comprises

growing a host cell transformed or transfected with a polynucleotide comprising a nucleotide sequence encoding the Hu-Asp2 in the presence and absence of the test agent;

(b) determining the APP processing activity of the Hu-Asp2 in the presence and absence of the test agent; and

(c) comparing the APP processing activity of the Hu-Asp2 polypeptide in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the activity of Hu-Asp2, wherein reduced activity in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.

109. A method according to claim 108, wherein the host cell expresses APP.

110. A method according to claim 109 wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.

111. A method according to claim 109, wherein the host cell expresses an APP having an amino acid sequence that includes a carboxy-terminal di-lysine.

112. A method according to claim 109, wherein the host cell expresses an APP comprising the Swedish mutation (K→N, M→L) adjacent to the β -secretase processing site.

113. A method according to claim 108, wherein the host cell is a human embryonic kidney cell line 293 (HEK293) cell.

114. A method according to claim 108 wherein the nucleotide sequence is selected from the group consisting of:

(a) a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4;

5 (b) a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6;

(c) a nucleotide sequence encoding a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b); and

10 (d) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.

15 115. A method according to claim 108, wherein the host cell comprises a vector that comprises the polynucleotide.

116. A method according to claim 108 wherein the polynucleotide comprises a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set
20 forth in SEQ ID NO: 4.

117. A method according to claim 108 wherein the polynucleotide comprises a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6.

25 118. A method according to claim 108 wherein the polynucleotide comprises a nucleotide sequence encoding a polypeptide comprising a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b).

30

119. A method according to claim 108 wherein the Hu-Asp2 is encoded by a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.

5

120. A method according to claim 108, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).

10

121. A method for identifying agents that modulate the activity of Asp2 aspartyl protease, comprising the steps of:

(a) contacting an Asp2 aspartyl protease and amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the Asp2 aspartyl protease is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5;

15

(b) determining the APP processing activity of the Asp2 aspartyl protease in the presence and absence of the test agent; and

(c) comparing the APP processing activity of the Asp2 aspartyl protease in the presence of the test agent to the activity in the absence of the agent to identify agents that modulate the activity of the Asp2 aspartyl protease, wherein a modulator that is an Asp2 inhibitor reduces APP processing and a modulator that is an Asp2 agonist increases such processing.

20

122. A method according to claim 121, wherein the Asp2 aspartyl protease is purified and isolated.

25

123. A method according to claim 121, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).

30

124. A method for identifying an agent that inhibits APP processing activity of human Asp2 aspartyl protease, comprising steps of:

(a) contacting Hu-Asp2 with an APP substrate for the Hu-Asp2, in the presence and absence of a test agent;

5 (b) determining the proteolytic processing of the APP substrate by the Hu-Asp2 in the presence and absence of the test agent; and

(c) comparing the proteolytic processing of the APP substrate by the Hu-Asp2 in the presence and absence of the test agent to identify an agent that inhibits the APP processing activity of Hu-Asp2, wherein reduced proteolytic processing of the APP substrate by the Hu-Asp2 in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.

125. A method according to claim 124, wherein the APP substrate is a peptide comprising a β -secretase cleavage site of APP.

15

126. A method according to claim 125, wherein the β -secretase cleavage site comprises the formula P2-P1-P1'-P2', wherein

P2 is an amino acid selected from K and N;

P1 is an amino acid selected from M and L;

20 P1' is the amino acid D; and

P2' is the amino acid A.

127. A method according to claim 125, wherein the peptide comprises the amino acid sequence KMDA (SEQ ID NO: 64, positions 4-7).

25

128. A method according to claim 126, wherein the peptide comprises the amino acid sequence EVKMDAEF (SEQ ID NO: 67).

129. A method according to claim 125, wherein the peptide comprises the amino acid sequence NLDA (SEQ ID NO: 66).

30

130. A method of reducing cellular production of amyloid beta ($A\beta$) from amyloid precursor protein (APP), comprising step of transforming or transfecting cells with an anti-sense reagent capable of reducing Asp2 polypeptide production by
5 reducing Asp2 transcription or translation in the cells, wherein reduced Asp2 polypeptide production in the cells correlates with reduced cellular processing of APP into $A\beta$.

131. A method according to claim 130, wherein the cell is a neural cell.
10

132. A method according to claim 130, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp mRNA.

133. A method according to claim 130, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp DNA.
15

134. A method of reducing cellular production of amyloid beta ($A\beta$) from amyloid precursor protein (APP), comprising steps of:
20 (a) identifying mammalian cells that produce $A\beta$; and
(b) transforming or transfecting the cells with an anti-sense reagent capable of reducing Asp2 polypeptide production by reducing Asp2 transcription or translation in the cells, wherein reduced Asp2 polypeptide
25 production in the cells correlates with reduced cellular processing of APP into $A\beta$.

135. A method according to claim 134, wherein the cell is a neural cell.

136. A method according to claim 134, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp mRNA.

5 137. A method according to claim 133, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp DNA.

10 138. A method according to claim 133, wherein the identifying step comprises diagnosing Alzheimer's disease, where Alzheimer's disease correlates with the existence of cells that produce A β that forms amyloid plaques in the brain.

139. A vector comprising a polynucleotide according to claim 22.

15 140. A host cell comprising a vector according to claim 139.

141. A purified polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 8.

20 142. A polypeptide comprising an amino acid sequence at least 95% identical to a polypeptide according to any one of claims 42-61, wherein said polypeptide lacks a transmembrane domain and retains β -secretase activity of a human Asp2 protein.

25 143. A method according to claim 83, wherein the first composition comprises a human Asp2 polypeptide of any one of claims 1-13, 19-24, 26-27 or 47-62.

144. A method according to claim 124 wherein the Hu-Asp2 is purified and isolated.

5 145. A method according to claim 124, wherein the Hu-Asp2 is encoded by a nucleic acid that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.

10 146. A method according to claim 124, wherein the Hu-Asp2 is selected from the group consisting of:

- (a) Hu-Asp2(a) comprising the amino acid sequence set forth in SEQ ID NO: 4;
- (b) Hu-Asp2(b) comprising the amino acid sequence set forth in SEQ ID NO: 6; and
- 15 (c) fragments of Hu-Asp2(a) (SEQ ID NO: 4) and Hu-Asp2(b) (SEQ ID NO: 6) that cleave the APP substrate at a β -secretase cleavage site.

20 147. A method according to claim 87, wherein the Hu-Asp2 comprises an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOS: 4 and 6.

25 148. A method according to claim 146, wherein the Hu-Asp2 comprises a soluble fragment of Hu-Asp2(a) or Hu-Asp2(b) that lacks an Asp2 transmembrane domain.

149. A method according to claim 148, wherein the Hu-Asp2 has an amino acid sequence consisting of a sequence-selected from the group consisting of SEQ ID NOS: 30, 32, 51, and 53.

150. A method according to claim 148, wherein the Hu-Asp2 comprises a fragment of Hu-Asp2(a) or Hu-Asp2(b), wherein the Hu-Asp 2 lacks amino acids 1-45 of SEQ ID NOS: 4 or 6.

FIGURE 1A

ATGGGCGCACTGGCCCCG GCGCTGCTGCTG CCTCTGCTGGCC CAGTGGCTCCTG CGCGCC
 M G A L A R A L L L P L L A Q W L L R A
 CCCCAGAGCTGGCCCCCG CGCCCTTCACGC TGCCCTCCGGG TGGCCGCGGCCA CGAAC
 A P E L A P A P F T L P L R V A A A T N
 CGCGTAGTTGCGCCACC CCGGACCCGGG ACCCTGCCGAG CGCCACGCCGAC GGCCTG
 R V V A P T P G P G T P A E R H A D G L
 GCGCTCGCCCTGGAGCCT GCCCTGGCGTCC CCGCGGGCGCC GCCAACTTCTTG GCCATG
 A L A L E P A L A S P A G A A N F L A M
 GTAGACAACCTGCAGGGG GACTCTGGCCGC GGCTACTACCTG GAGATGCTGATC GGGACC
 V D N L Q G D S G R G Y Y L E M L I G T

 CCCCCGAGAAGCTACAG ATTCTCGTTGAC ACTGGAAGCAGT AACTTTGCCGTG GCAGGA
 P P Q K L Q I L V D T G S S N F A V A G

 ACCCCGCACTCCTACATA GACACGTACTTT GACACAGAGAGG TCTAGCACATAC CGCTCC
 T P H S Y I D T Y F D T E R S S T Y R S

 AAGGGCTTTGACGTCACA GTGAAGTACACA CAAGGAAGCTGG ACGGGCTTCGTT GGGGAA
 K G F D V T V K Y T Q G S W T G F V G E

 GACCTCGTCACCATCCCC AAAGGCTTCAAT ACTTCTTTCTT GTCAACATTGCC ACTATT
 D L V T I P K G F N T S F L V N I A T I

 TTTGAATCAGAGAATTTT TTTTGCCTGGG ATTAAATGGAAT GGAATACTTGGC CTAGCT
 F E S E N F F L P G I K W N G I L G L A

 TATGCCACACTTGCCAAG CCATCAAGTTCT CTGGAGACCTTC TTCGACTCCCTG GTGACA
 Y A T L A K P S S S L E T F F D S L V T

 CAAGCAAACATCCCCAAC GTTTTCTCCATG CAGATGTGTGGA GCCGGCTTGCCC GTTGCT
 Q A N I P N V F S M Q M C G A G L P V A

 GGATCTGGGACCAACGGA GGTAGTCTTGTC TTGGGTGGAATT GAACCAAGTTTG TATAAA
 G S G T N G G S L V L G G I E P S L Y K

 GGAGACATCTGGTATACC CCTATTAAGGAA GAGTGGTACTAC CAGATAGAAATT CTGAAA
 G D I W Y T P I K E E W Y Y Q I E I L K

 TTGGAAATTGGAGGCCAA AGCCTTAATCTG GACTGCAGAGAG TATAACGCAGAC AAGGCC
 L E I G G Q S L N L D C R E Y N A D K A

 ATCGTGACAGTGGCACC ACGCTGCTGCGC CTGCCCCAGAAG GTGTTTGATGCG GTGGTG
 I V D S G T T L L R L P Q K V F D A V V

 GAAGCTGTGGCCCGCGCA TCTCTGATTCCA GAATTCTCTGAT GGTTCCTGGACT GGGTCC
 E A V A R A S L I P E F S D G F W T G S

 CAGCTGGCGTGCTGGACG AATTTCGGAACA CCTTGGTCTTAC TTCCCTAAAATC TCCATC
 Q L A C W T N S E T P W S Y F P K I S I

 TACCTGAGAGATGAGAAC TCCAGCAGGTCA TTCCGTATCACA ATCCTGCCTCAG CTTTAC
 Y L R D E N S S R S F R I T I L P Q L Y

 ATTCAGCCCATGATGGGG GCCGGCCTGAAT TATGAATGTTAC CGATTCCGCATT TCCCCA
 I Q P M M G A G L N Y E C Y R F G I S P

 TCCACAAATGCGCTGGTG ATCGGTGCCACG GTGATGGAGGGC TTCTACGTCATC TTCGAC
 S T N A L V I G A T V M E G F Y V I F D

 AGAGCC CAGAAGAGGGTG GGCTTCGCAGCG AGCCCCTGTGCA GAAATTGCAGGT GCTGCA

FIGURE 1B

R A Q K R V G F A A S P C A E I A G A A
GTGTCTGAAATTTCCGGGCCTTTCTCAACAGAGGATGTAGCCAGCAACTGTGTCCCCGCT
V S E I S G P F S T E D V A S N C V P A
CAGTCTTTGAGCGAGCCCATTTTGTGGATTGTGTCTATGCGCTCATGAGCGTCTGTGGA
Q S L S E P I L W I V S Y A L M S V C G
GCCATCCTCCTTGTCTTAATCGTCCTGCTGCTGCTGCCGTTCCGGTGTGAGCGTCGCCCC
A I L L V L I V L L L L P F R C Q R R P
CGTGACCCTGAGGTCGTCAATGATGAGTCCTCTCTGGTCAGACATCGCTGGAAATGAATA
R D P E V V N D E S S L V R H R W K
GCCAGGCCTGACCTCAAGCAACCATGAACTCAGCTATTAAGAAAATCACATTTCCAGGGC
AGCAGCCGGGATCGATGGTGGCGCTTTCTCCTGTGCCCACCCGTCTTCAATCTCTGTTCT
GCTCCCAGATGCCTTCTAGATTCAGTGTCTTTTGATTCTTGATTTTCAAGCTTTCAAATC
CTCCCTACTTCCAAGAAAAATAATTAAAAAAAACCTTCATTCTAAACCAAAAAAAAAAAAA
AAAA

FIGURE 2A

ATGGCCCAAGCCCTGCCC TGCTCCTGCTG TGGATGGGCGCG GGAGTGCTGCCT GCCCAC
 M A Q A L P W L L L W M G A G V L P A H

 GGCACCAGCACGGCATC CGGCTGCCCCTG CGCAGCGGCCTG GGGGGCGCCCC CTGGGG
 G T Q H G I R L P L R S G L G G A P L G

 CTGCGGTGCCCCGGGAG ACCGACGAAGAG CCCGAGGAGCCC GGCCGGAGGGGC AGCTTT
 L R L P R E T D E E P E E P G R R G S F

 GTGGAGATGGTGGACAAC CTGAGGGGCAAG TCGGGGCAGGGC TACTACGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T

 GTGGGCAGCCCCCGCAG ACGCTCAACATC CTGGTGGATACA GGCAGCAGTAAC TTTGCA
 V G S P P Q T L N I L V D T G S S N F A

 GTGGGTGCTGCCCCCAC CCCTTCCTGCAT CGCTACTACCAG AGGCAGCTGTCC AGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T

 TACCGGGACCTCCGGAAG GGTGTGTATGTG CCCTACACCCAG GGCAAGTGGGAAGGGGAG
 Y R D L R K G V Y V P Y T Q G K W E G E

 CTGGGCACCGACCTGGTA AGCATCCCCAT GGCCCCAACGTC ACTGTGCGTGCC AACATT
 L G T D L V S I P H G P N V T V R A N I

 GCTGCCATCACTGAATCA GACAAGTTCTTC ATCAACGGCTCC AACTGGGAAGGC ATCCTG
 A A I T E S D K F F I N G S N W E G I L

 GGGCTGGCCTATGCTGAG ATTGCCAGGCTT TGTGGTGTGGC TTCCCCCTCAAC CAGTCT
 G L A Y A E I A R L C G A G F P L N Q S

 GAAGTGCTGGCCTCTGTC GGAGGGAGCATG ATCATTGGAGGT ATCGACCACTCG CTGTAT
 E V L A S V G G S M I I G G I D H S L Y

 ACAGGCAGTCTCTGGTAT ACACCCATCCGG CGGGAGTGGTAT TATGAGGTGATC ATTGTG
 T G S L W Y T P I R R E W Y Y E V I I V

 CGGGTGGAGATCAATGGA CAGGATCTGAAA ATGGA CTGCAAG GAGTACA ACTAT GACAAG
 R V E I N G Q D L K M D C K E Y N Y D K

 AGCATTGTGGACAGTGGC ACCACCAACCTT CGTTTGCCCAAG AAAGTGTTTGAA GCTGCA
 S I V D S G T T N L R L P K K V F E A A

 GTCAAATCCATCAAGGCA GCCTCCTCCACG GAGAAGTTCCTT GATGGTTTCTGG CTAGGA
 V K S I K A A S S T E K F P D G F W L G

 GAGCAGCTGGTGTGCTGG CAAGCAGGCACC ACCCCTTGGAAC ATTTTCCCAGTC ATCTCA
 E Q L V C W Q A G T T P W N I F P V I S

 CTCTACCTAATGGGTGAG GTTACCAACCAG TCCTTCCGCATC ACCATCCTTCCG CAGCAA
 L Y L M G E V T N Q S F R I T I L P Q Q

 TACCTGCGGCCAGTGGA GATGTGGCCACG TCCCAAGACGAC TGTTACAAGTTT GCCATC

FIGURE 2B

Y L R P V E D V A T S Q D D C Y K F A I
TCACAGTCATCCACGGGC ACTGTTATGGGA GCTGTATCATG GAGGGCTTCTAC GTTGTC
S Q S S T G T V M G A V I M E G F Y V V
TTTGATCGGGCCGAAAA CGAATTGGCTTT GCTGTCAGCGCT TGCCATGTGCAC GATGAG
F D R A R K R I G F A V S A C H V H D E
TTCAGGACGGCAGCGGTG GAAGGCCCTTTT GTCACCTTGGAC ATGGAAGACTGT GGCTAC
F R T A A V E G P F V T L D M E D C G Y
AACATTCCACAGACAGAT GAGTCAACCCCTC ATGACCATAGCC TATGTCATGGCT GCCATC
N I P Q T D E S T L M T I A Y V M A A I
TGCGCCCTCTTCATGCTG CCACTCTGCCTC ATGGTGTGTCAG TGGCGCTGCCTC CGCTGC
C A L F M L P L C L M V C Q W R C L R C
CTGCGC CAGCAGCATGAT GACTTTGCTGAT GACATCTCCCTG CTGAAGTGAGGA GGCCCA
L R Q Q H D D F A D D I S L L K
TGGGCA GAAGATAGAGAT TCCCCTGGACCA CACCTCCGTGGT TCACTTTGGTCA CAAGTA
GGAGACACAGATGGCACC TGTGGCCAGAGC ACCTCAGGACCC TCCCCACCCACC AAATGC
CTCTGC CTTGATGGAGAA GGAAAAGGCTGG CAAGGTGGGTTC CAGGGACTGTAC CTGTAG
GAAACA GAAAAGAGAAGA AAGAAGCACTCT GCTGGCGGGAAT ACTCTTGGTCAC CTCAAA
TTTAAGTCGGGAAATTCT GCTGCTTGAAAC TTCAGCCCTGAA CCTTTGTCCACC ATTCCT
TTAAAT TCTCCAACCCAA AGTATTCTTCTT TTCTTAGTTTCA GAAGTACTGGCA TCACAC
GCAGGT TACCTTGGCGTG TGTCCCTGTGGT ACCCTGGCAGAG AAGAGACCAAGC TTGTTT
CCCTGCTGGCCAAAGTCA GTAGGAGAGGAT GCACAGTTTGCT ATTTGCTTTAGA GACAGG
GACTGTATAACAAGCCT AACATTGGTGCA AAGATTGCCTCT TGAAAAAAAAA AAA

FIGURE 3A

ATGGCCCAAGCCCTGCCCTGGCTCCTGCTG TGGATGGGCGCG GGAGTGCTGCCTGCCAC
M A Q A L P W L L L W M G A G V L P A H

GGCACC CAGCAGGCATC CGGCTGCCCTG CGCAGCGGCCTG GGGGGCGCCCC CTGGG
G T Q H G I R L P L R S G L G G A P L G

CTGCGGCTGCCCCGGGAGACCGACGAAGAG CCCGAGGAGCCC GGCCGGAGGGGC AGCTTT
L R L P R E T D E E P E E P G R R G S F

GTGGAGATGGTGGACAAC CTGAGGGGCAAG TCGGGGCAGGGC TACTACGTGGAGATGACC
V E M V D N L R G K S G Q G Y Y V E M T

GTGGGCAGCCCCCGCAGACGCTCAACATC CTGGTGGATACA GGCAGCAGTAAC TTTGCA
V G S P P Q T L N I L V D T G S S N F A

GTGGGTGCTGCCCCCAC CCCTTCCTGCAT CGCTACTACCAG AGGCAGCTGTCC AGCACA
V G A A P H P F L H R Y Y Q R Q L S S T

TACCGGGACCTCCGAAG GGTGTGTATGTG CCCTACACCCAG GGCAAGTGGGAA GGGGAG
Y R D L R K G V Y V P Y T Q G K W E G E

CTGGGCACCGACCTGGTA AGCATCCCCAT GGCCCCAACGTC ACTGTGCGTGCC AACATT
L G T D L V S I P H G P N V T V R A N I

GCTGCCATCACTGAATCA GACAAGTTCTTC ATCAACGGCTCC AACTGGGAAGGC ATCCTG
A A I T E S D K F F I N G S N W E G I L

GGGCTGCGCTATGCTGAG ATTGCCAGGCCT GACGACTCCCTG GAGCCTTTCTTT GACTCT
G L A Y A E I A R P D D S L E P F F D S

CTGGTAAGCAGACCCAC GTTCCCAACCTC TTCTCCCTGCAG CTTTGTGGTGCT GGCTTC
L V K Q T H V P N L F S L Q L C G A G F

CCCCTAACCAAGTCTGAA GTGCTGGCCTCT GTCGGAGGGAGC ATGATCATTGGA GGTATC
P L N Q S E V L A S V G G S M I I G G I

GACCAC TCGCTGTACACA GGCAGTCTCTGG TATACACCCATC CGGCGGGAGTGG TATTAT
D H S L Y T G S L W Y T P I R R E W Y Y

GAGGTCATCATTGTGCGG GTGGAGATCAAT GGACAGGATCTG AAAATGGACTGC AAGGAG
E V I I V R V E I N G Q D L K M D C K E

TACAAC TATGACAAGAGC ATTGTGGACAGT GGCACCACCAAC CTTGTTTGGCC AAGAAA
Y N Y D K S I V D S G T T N L R L P K K

GTGTTTGAAGCTGCAGTC AAATCCATCAAG GCAGCCTCCTCC ACGGAGAAGTTC CCTGAT
V F E A A V K S I K A A S S T E K F P D

FIGURE 3B

GGTTCCTGGCTAGGAGAG CAGCTGGTGTGC TGGCAAGCAGGC ACCACCCCTTGG AACATT
 G F W L G E Q L V C W Q A G T T P W N I

 TTCCCAAGTCATCTCACTCTACCTAATGGGT GAGGTTACCAAC CAGTCCTTCCGC ATCACC
 F P V I S L Y L M G E V T N Q S F R I T

 ATCCTTCCGCAGCAATAC CTGCGGCCAGTG GAAGATGTGGCC ACGTCCCAAGAC GACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C

 TACAAGTTTGCCATCTCA CAGTCATCCACG GGCAGTGTATG GGAGCTGTTATC ATGGAG
 Y K F A I S Q S S T G T V M G A V I M E

 GGCTTCTACGTTGTCTTT GATCGGGCCCGA AAACGAATTGGCTTTGCTGTCAGC GCTTGC
 G F Y V V F D R A R K R I G F A V S A C

 CATGTGCACGATGAGTTC AGGACGGCAGCG GTGGAAGGCCCT TTTGTCACCTTG GACATG
 H V H D E F R T A A V E G P F V T L D M

 GAAGACTGTGGCTACAAC ATTCCACAGACA GATGAGTCAACC CTCATGACCATA GCCTAT
 E D C G Y N I P Q T D E S T L M T I A Y

 GTCATGGCTGCCATCTGC GCCCTCTTCATG CTGCCACTCTGC CTCATGGTGTGT CAGTGG
 V M A A I C A L F M L P L C L M V C Q W

 CGCTGCCTCCGCTGCCTG CGCCAGCAGCAT GATGACTTTGCT GATGACATCTCC CTGCTG
 R C L R C L R Q Q H D D F A D D I S L L

 AAGTGAGGAGGCCCATGG GCAGAAGATAGA GATCCCCTGGA CCACACCTCCGT GGTTC A
 K

 CTTTGGTCACAAGTAGGA GACACAGATGGC ACCTGTGGCCAG AGCACCTCAGGA CCCTCC
 CCACCCACCAATGCCTC TGCCTTGATGGA GAAGGAAAAGGC TGGCAAGGTGGG TTCCAG
 GGACTGTACCTGTAGGAA ACAGAAAAGAGA AGAAAGAAGCAC TCTGCTGGCGGG AATACT
 CTTGGTCACCTCAAATTT AAGTCGGGAAAT TCTGCTGCTTGA AACTTCAGCCCT GAACCT
 TTGTCCACCATTTCCTTA AATTCTCCAACC CAAAGTATTCTT CTTTCTTAGTT TCAGAA
 GTACTGGCATCACACGCA GGTACCTTGGC GTGTGTCCCTGT GGTACCCTGGCA GAGAAG
 AGACCAAGCTTGTTTCCC TGCTGGCCAAAG TCAGTAGGAGAG GATGCACAGTTT GCTATT
 TGCTTTAGAGACAGGGAC TGTATAAACAAG CCTAACATTGGT GCAAAGATTGCC TCTTGA
 ATTAATAAAAAAAAAA AAAAAAAAAA

FIGURE 4

ATGGCCCCAGCGTGCA CTGGCTCCTGCT ATGGGTGGGCTC GGAATGCTGCC TGCCCAG
 M A P A L H W L L L W V G S G M L P A Q
 GGAACCCATCTCGGCAT CCGGCTGCCCCCT TCGCAGCGGCCT GGCAGGGCCACC CCTGGGC
 G T H L G I R L P L R S G L A G P P L G
 CTGAGGCTGCCCCGGA GACTGACGAGGA ATCGGAGGAGCCTGGCCGGAGAGG CAGCTTT
 L R L P R E T D E E S E E P G R R G S F
 GTGGAGATGGTGGACAA CCTGAGGGGAAA GTCCGGCCAGGG CTAATATGTGGA GATGACC
 V E M V D N L R G K S G Q G Y Y V E M T
 GTAGGCAGCCCCCACA GACGCTCAACAT CCTGGTGGACAC GGGCAGTAGTAA CTTTGCA
 V G S P P Q T L N I L V D T G S S N F A
 GTGGGGGCTGCCCCACA CCCTTTCCTGCA TCGCTACTACCA GAGGCAGCTGTC CAGCACA
 V G A A P A P H P F L H R Y Y Q R Q L S S T
 TATCGAGACCTCCGAAA GGGTGTGTATGT GCCCTACACCCA GGGCAAGTGGGA GGGGGAA
 Y R D L R K G V Y V P Y T Q G K W E G E
 CTGGGCACCGACCTGGT GAGCATCCCTCA TGGCCCCAACGT CACTGTGCGTGC CAACATT
 L G T D L V S I P H G P N V T V R A N I
 GCTGCCCATCACTGAATC GGACAAGTTCTT CATCAATGGTTC CAACTGGGAGGG CATCCTA
 A A I T E S D K F F I N G S N W E G I L
 GGGCTGGCCTATGCTGA GATTGCCAGGCC CGACGACTCTTT GGAGCCCTTCTT TGACTCC
 G L A Y A E I A R P D D S L E P F F D S
 CTGGTGAAGCAGACCCA CATTCCCAACAT CTTTCCCTGCAGCTCTGTGGCGC TGGCTTC
 L V K Q T H I P N I F S L Q L C G A G F
 CCCCTCAACCAGACCGA GGCACCTGGCCTC GGTGGGAGGGAG CATGATCATTGG TGGTATC
 P L N Q T E A L A S V G G S M I I G G I
 GACCACTCGCTATACAC GGGCAGTCTCTG GTACACACCCAT CCGGCGGGAGTG GTATTAT
 D H S L Y T G S L W Y T P I R R E W Y Y
 GAAGTGATCATTGTACG TGTGGAAATCAA TGGTCAAGATCT CAAGATGGACTG CAAGGAG
 E V I I V R V E I N G Q D L K M D C K E
 TACAACTACGACAAGAG CATTGTGGACAG TGGGACCACCAA CCTTCGCTTGCC CAAGAAA
 Y N Y D K S I V D S G T T N L R L P K K
 GTATT TGAAGCTGCCGT CAAGTCCATCAA GGCAGCCTCCTC GACGGAGAAGTT CCCGGAT
 V F E A A V K S I K A A S S T E K F P D
 GGCTTTTGGCTAGGGGA GCAGCTGGTGTG CTGGCAAGCAGG CACGACCCCTTG GAACATT
 G F W L G E Q L V C W Q A G T T P W N I
 TTCCAGTCATTTCACT TTACCTCATGGG TGAAGTCACCAA TCAGTCCTTCCG CATCACC
 F P V I S L Y L M G E V T N Q S F R I T
 ATCTT TCTCAGCAATA CCTACGGCCGGT GGAGGACGTGGC CACGTCCCAAGA CGACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C
 TACAAGTTCGCTGTCTC ACAGTCATCCAC GGGCACTGTTAT GGGAGCCGTCAT CATGGAA
 Y K F A V S Q S S T G T V M G A V I M E
 GGTTT CTATGTCGCTT CGATCGAGCCCG AAAGCGAATTGG CTTTGCTGTGAG CGCTTGC
 G F Y V V F D R A R K R I G F A V S A C
 CATGTGCACGATGAGTT CAGGACGGCGGC AGTGAAGGTCC GTTGTACGGC AGACATG
 H V H D E F R T A A V E G P F V T A D M
 GAAGACTGTGGCTACAA CATTCCCCAGAC AGATGAGTCAAC ACTTATGACCAT AGCCTAT
 E D C G Y N I P Q T D E S T L M T I A Y
 GTCATGGCGGCCATCTG CGCCCTCTTCAT GTTGCCACTCTG CCTCATGGTATG TCAGTGG
 V M A A I C A L F M L P L C L M V C Q W
 CGCTGCCTGCGTTGCCT GCGCCACCAGCA CGATGACTTTGC TGATGACATCTC CCTGCTC
 R C L R C L R H Q H D D F A D D I S L L
 AAGTAAGGAGGCTCGTG GGCAGATGATGG AGACGCCCCTGG ACCACATCTGGG TGGTTCC
 K
 CTTTGGTCACATGAGTT GGAGCTATGGAT GGTACCTGTGGC CAGAGCACCTCA GGACCCT
 CACCAACCTGCCAATGC TTCTGGCGTGAC AGAACAGAGAAA TCAGGCAAGCTG GATTACA
 GGGCTTGCACCTGTAGG ACACAGGAGAGG GAAGGAAGCAGC GTTCTGGTGGCA GGAATAT
 CCTTAGGCACCACAAAC TTGAGTTGGAAA TTTTGCTGCTTG AAGCTTCAGCCC TGACCCCT
 CTGCCCAGCATCCTTTA GAGTCTCCAACC TAAAGTATTCTT TATGTCCTTCCA GAAGTAC
 TGGCGTCATACTCAGGC TACCCGGCATGT GTCCCTGTGGTA CCCTGGCAGAGA AAGGGCC
 AATCT CATTCCCTGCTG GCCAAAGTCAGC AGAAGAAGGTGA AGTTTGCCAGTT GCTTTAG
 TGATA GGGACTGCAGAC TCAAGCCTACAC TGGTACAAAGAC TGCGTCTTGAGA TAAACAA
 GAA

1	MAQALPWLLLLWMGAGVLPAGHTQHGIRLPLRSGLGGAPLGLRLPRETDEE	50
1	MAPALHWLLLLWVGSGMLPAQGTHLGIRLPLRSGLAGPPLGLRLPRETDEE	50
51	PEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSPQTLNILVDTGSSNFA	100
51	SEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSPQTLNILVDTGSSNFA	100
101	VGAAPHFPLHRYYQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLVSIPH	150
101	VGAAPHFPLHRYYQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLVSIPH	150
151	GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS	200
151	GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS	200
201	LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW	250
201	LVKQTHIPNIFSLQLCGAGFPLNQTEALASVGGSMIIGGIDHSLYTGSLW	250
251	YTPIRREWYVEVIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRPLPKK	300
251	YTPIRREWYVEVIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRPLPKK	300
301	VFEAAVKSIIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNI F PVISLYLMG	350
301	VFEAAVKSIIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNI F PVISLYLMG	350
351	EVTNQSFRTILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME	400
351	EVTNQSFRTILPQQYLRPVEDVATSQDDCYKFAVSQSSTGTVMGAVIME	400
401	GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT	450
401	GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTADMEDCGYNIPQT	450
451	DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRQHHDDFADDISLL	500
451	DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRHQHHDDFADDISLL	500
501	K 501	
501	K 501	

FIGURE 6A

ATGGCTAGC ATGACTGGTGA CAGCAAATGGGT CGCGGATCCACC CAGCACGGCATC CGG
 M A S M T G G Q Q M G R G S T Q H G I R
 CTGCCCCTG CGCAGCGGCTG GGGGGCGCCCC CTGGGGCTGCGG CTGCCCCGGGAG ACC
 L P L R S G L G G A P L G L R L P R E T
 GACGAAGAG CCCGAGGAGCCC GGCCGGAGGGC AGCTTTGTGGAG ATGGTGGACAAC CTG
 D E E P E E P G R R G S F V E M V D N L
 AGGGGCAAG TCGGGGAGGGC TACTACGTGGAG ATGACCGTGGG AGCCCCCGCAG ACG
 R G K S G Q G Y Y V E M T V G S P P Q T
 CTCAACATC CTGGTGGATACA GGCAGCAGTAAC TTTGCAGTGGGT GCTGCCCCCAC CCC
 L N I L V D T G S S N F A V G A A P H P
 TTCCTGCAT CGCTACTACCAG AGGCAGCTGTCC AGCACATACCGG GACCTCCGGAAG GGC
 F L H R Y Y Q R Q L S S T Y R D L R K G
 GTGTATGTG CCCTACACCCAG GGCAAGTGGAA GGGGAGCTGGG ACCGACCTGGTA AGC
 V Y V P Y T Q G K W E G E L G T D L V S
 ATCCCCCAT GGCCCCAACGTC ACTGTGCGTGCC AACATTGCTGCC ATCACTGAATCA GAC
 I P H G P N V T V R A N I A A I T E S D
 AAGTTCTTC ATCAACGGCTCC AACTGGGAAGGC ATCCTGGGCTG GCCTATGCTGAG ATT
 K F F I N G S N W E G I L G L A Y A E I
 GCCAGGCCT GACGACTCCCTG GAGCCTTTCTTT GACTCTCTGGTA AAGCAGACCCAC GTT
 A R P D D S L E P F F D S L V K Q T H V
 CCCAACCTC TTCTCCCTGCAG CTTTGTGGTGCT GGCTTCCCCCTC AACAGTCTGAA GTG
 P N L F S L Q L C G A G F P L N Q S E V
 CTGGCCTCT GTCGGAGGGAGC ATGATCATTGGA GGTATCGACCAC TCGCTGTACACA GGC
 L A S V G G S M I I G G I D H S L Y T G
 AGTCTCTGG TATACACCCATC CGGCGGGAGTGG TATTATGAGGTC ATCATTGTGCGG GTG
 S L W Y T P I R R E W Y Y E V I I V R V
 GAGATCAAT GGACAGGATCTG AAAATGGACTGC AAGGAGTACAAC TATGACAAGAGC ATT
 E I N G Q D L K M D C K E Y N Y D K S I
 GTGGACAGT GGCAACCAAC CTTGTTTTGCCC AAGAAAGTGTTT GAAGCTGCAGTC AAA
 V D S G T T N L R L P K K V F E A A V K
 TCCATCAAG GCAGCCTCCTCC ACGGAGAAGTTC CCTGATGGTTTC TGGCTAGGAGAG CAG
 S I K A A S S T E K F P D G F W L G E Q
 CTGGTGTGC TGGCAAGCAGGC ACCACCCCTTGG AACATTTCCCA GTCATCTCACTC TAC
 L V C W Q A G T T P W N I F P V I S L Y
 CTAATGGGT GAGGTTACCAAC CAGTCCTTCCGC ATCACCATCCTT CCGCAGCAATAC CTG
 L M G E V T N Q S F R I T I L P Q Q Y L
 CGGCCAGTGG AAGATGTGGCCA CGTCCCAAGACG ACTGTTACAAGT TTGCCATCTCAC AG

FIGURE 6B

R P V E D V A T S Q D D C Y K F A I S Q
TCATCCACGG GCACTGTTATGG GAGCTGTTATCA TGGAGGGCTTCTACGTTGTCTTTGAT
S S T G T V M G A V I M E G F Y V V F D
CGGGCCCGAA AACGAATTGGCT TTGCTGTCAGCG CTTGCCATGTGC ACGATGAGTTCAGG
R A R K R I G F A V S A C H V H D E F R
ACGGCAGCGG TGGAAGGCCCTT TTGTCACCTTGG ACATGGAAGACT GTGGCTACAACATT
T A A V E G P F V T L D M E D C G Y N I
CCACAGACAG ATGAGTCATGA
P Q T D E S *

FIGURE 7A

ATGGCTAGC ATGACTGGTGGG CAGCAAATGGGT CGCGGATCGATG ACTATCTCTGAC TCT
 M A S M T G G Q Q M G R G S M T I S D S

CCGCGTGAA CAGGACGGATCC ACCCAGCACGGC ATCCGGCTGCCC CTGCGCAGCGGC CTG
 P R E Q D G S T Q H G I R L P L R S G L

GGGGCGGCC CCCCTGGGGCTG CGGCTGCCCCGG GAGACCGACGAA GAGCCCAGGAG CCC
 G G A P L G L R L P R E T D E E P E E P

GGCCGGAGG GGCAGCTTTGTG GAGATGGTGGAC AACCTGAGGGGC AAGTCGGGGCAG GGC
 G R R G S F V E M V D N L R G K S G Q G

TACTACGTG GAGATGACCGTG GGCAGCCCCCG CAGACGCTCAAC ATCCTGGTGGAT ACA
 Y Y V E M T V G S P P Q T L N I L V D T

GGCAGCAGT AACTTTGCAGTG GGTGCTGCCCC CACCCCTTCTTG CATCGTACTAC CAG
 G S S N F A V G A A P H P F L H R Y Y Q

AGGCAGCTG TCCAGCACATAC CGGGACCTCCGG AAGGGCGTGTAT GTGCCCTACACC CAG
 R Q L S S T Y R D L R K G V Y V P Y T Q

GGCAAGTGG GAAGGGGAGCTG GGCACCGACCTG GTAAGCATCCCC CATGGCCCCAAC GTC
 G K W E G E L G T D L V S I P H G P N V

ACTGTGCGT GCCAACATTGCT GCCATCACTGAA TCAGACAAGTTC TTCATCAACGGC TTC
 T V R A N I A A I T E S D K F F I N G S

AACTGGGAA GGCATCCTGGGG CTGGCCTATGCT GAGATTGCCAGG CCTGACGACTCC CTG
 N W E G I L G L A Y A E I A R P D D S L

GAGCCTTTC TTTGACTCTCTG GTAAAGCAGACC CACGTTCCCAAC CTCTTCTCCCTG CAG
 E P F F D S L V K Q T H V P N L F S L Q

CTTTGTGGT GCTGGCTTCCCC CTCAACCAGTCT GAAGTGCTGGCC TCTGTGCGAGGG AGC
 L C G A G F P L N Q S E V L A S V G G S

ATGATCATT GGAGGTATCGAC CACTCGCTGTAC ACAGGCAGTCTC TGGTATACACCC ATC
 M I I G G I D H S L Y T G S L W Y T P I

CGGCGGGAG TGGTATTATGAG GTCATCATTGTG CGGGTGGAGATC AATGGACAGGAT CTG
 R R E W Y Y E V I I V R V E I N G Q D L

AAAATGGAC TGCAAGGAGTAC AACTATGACAAG AGCATTGTGGAC AGTGGCACCACC AAC
 K M D C K E Y N Y D K S I V D S G T T N

CTTCTGTTG CCCAAGAAAGTG TTTGAAGCTGCA GTCAAATCCATC AAGGCAGCCTCC TCC
 L R L P K K V F E A A V K S I K A A S S

ACGGAGAAG TTCCCTGATGGT TTCTGGCTAGGA GAGCAGCTGGTG TGCTGGCAAGCA GGC
 T E K F P D G F W L G E Q L V C W Q A G

ACCACCCCTT GGAACATTTTCC CAGTCATCTCAC TCTACCTAATGG GTGAGGTTACCA AC
 T T P W N I F P V I S L Y L M G E V T N

FIGURE 7B

CAGTCCTTCCGCATCACCATCC TTCCGCAGCAAT ACCTGCGGCCAG TGGAAGATGTGG CC
Q S F R I T I L P Q Q Y L R P V E D V A

ACGTCCCAAGACGACTGTTACA AGTTTGCCATCT CACAGTCATCCA CGGGCACTGTTA TG
T S Q D D C Y K F A I S Q S S T G T V M

GGAGCTGTTA TCATGGAGGGCT TCTACGTTGTCT TTGATCGGGCCC GAAAACGAATTG GC
G A V I M E G F Y V V F D R A R K R I G

TTTGCTGTCA GCGCTTGCCATG TGCACGATGAGT TCAGGACGGCAG CGGTGGAAGGCC CT
F A V S A C H V H D E F R T A A V E G P

TTTGTCACCT TGGACATGGAAG ACTGTGGCTACA ACATTCCACAGA CAGATGAGTCAT GA
F V T L D M E D C G Y N I P Q T D E S *

FIGURE 8A

ATGACTCAGCATGGTATTCGTCTGCCACTGCGTAGCGGTCTGGGTGGTGC TCCACTGGGT
 M T Q H G I R L P L R S G L G G A P L G -
 CTGCGTCTGCCCCGGAGACCGACGAAGAGCCCCGAGGA GCGCGCCGGAG GGGCAGCTTT
 L R L P R E T D E E P E E P G R R G S F -
 GTGGAGATGGTGGACAACTGAGGGGCAAGTCGGGGCA GGGCTACTACGT GGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T -
 GTGGGCAGCCCCGCAGACGCTCAA CATCCTGGTGGATACAGGCAGCAG TAACTTTGCA
 V G S P P Q T L N I L V D T G S S N F A -
 GTGGGTGCTGCCCC CCACCCCTTCCT GCATCGCTACTA CCAGAGGCAGCT GTCCAGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T -
 TACCGGGACCTCCG GAAGGGCGTGTA TGTGCCCTACAC CCAGGGCAAGTG GGAAGGGGAG
 Y R D L R K G V Y V P Y T Q G K W E G E -
 CTGGGCACCGACCT GGTAAGCATCCC CCATGGCCCCAA CGTCACTGTGCG TGCCAACATT
 L G T D L V S I P H G P N V T V R A N I -
 GCTGCCATCACTGA ATCAGACAAGTT CTTTCATCAACGG CTCCAAGTGGGA AGGCATCCTG
 A A I T E S D K F F I N G S N W E G I L -
 GGGCTGGCCTATGC TGAGATTGCCAG GCCTGACGACTC CCTGGAGCCTTT CTTTGACTCT
 G L A Y A E I A R P D D S L E P F F D S
 CTGTTAAAGCAGAC CCACGTTCCCAA CCTCTTCTCCCT GCAGCTTTGTGG TGCTGGCTTC
 L V K Q T H V P N L F S L Q L C G A G F -
 CCCCTCAACCAGTC TGAAGTGCTGGC CTCTGTGCGAGG GAGCATGATCAT TGGAGGTATC
 P L N Q S E V L A S V G G S M I I G G I -
 GACCACTCGCTGTA CACAGGCAGTCT CTGGTATACACC CATCCGGCGGGA GTGGTATTAT
 D H S L Y T G S L W Y T P I R R E W Y Y -
 GAGGTATCATTTGT GCGGCTGGAGAT CAATGGACAGGA TCTGAAAATGGA CTGCAAGGAG
 E V I I V R V E I N G Q D L K M D C K E
 TACAACTATGACAA GAGCATTGTGGA CAGTGGCACCAC CAACCTTCGTTT GCCCAAGAAA
 Y N Y D K S I V D S G T T N L R L P K K -
 GTGTTTGAAGCTGC AGTCAAATCCAT CAAGGCAGCCTC CTCCACGGAGAA GTTCCCTGAT
 V F E A A V K S I K A A S S T E K F P D -
 GGTTCCTGGCTAGG AGAGCAGCTGGT GTGCTGGCAAGC AGGCACCACCCC TTGGAACATT
 G F W L G E Q L V C W Q A G T T P W N I -
 TTCCCAGTCATCTC ACTCTACCTAAT GGGTGAGGTTAC CAACCAGTCCTT TCGCATCACC
 F P V I S L Y L M G E V T N Q S F R I T -
 ATCCTTCCGCAGCA ATACCTGCGGCC AGTGGAAGATGT GGCCACGTCCCA AGACGACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C -

FIGURE 8B

TACAAGTTGCCAT CTCACAGTCATC CACGGGCACTGT TATGGGAGCTGT TATCATGGAG
Y K F A I S Q S S T G T V M G A V I M E -
GGCTTCTACGTGT CTTTGATCGGGC CCGAAAACGAAT TGGCTTTGCTGT CAGCGCTTGC
G F Y V V F D R A R K R I G F A V S A C -
CATTAG
H *

FIGURE 9




FIGURE 10




FIGURE 11

MAQALPWLLLWMGAGVLPPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEE
PEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSPQTNLILVDTGSSNFA
VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLVSI PH
GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS
LVKQTHVFNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW
YTPIRREWYYEVIIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKK
VFEEAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMG
EVTNQSFRTILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME
GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT
DES

FIGURE 12

MAQALPWLLWMGAGVLPAGHTQHGI RLP LRSGLGGAPLGLRLPRETDEE
PEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSPPQTLN ILVDTGSSNFA
VGAAPHPFLHRY YQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLVSI PH
GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPPFDS
LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW
YTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLR LPKK
VFEAAVKS IKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMG
EVTNQSF RITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME
GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT
DESHHHHHH

- 1 -

SEQUENCE LISTING

<110> Beinkowski et al.

<120> ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES THEREFOR

<130> 28341/6280M

<140>

<141>

<150> 09/416,901

<151> 1999-10-13

<150> 60/155,493

<151> 1999-09-23

<150> 09/404,133

<151> 1999-09-23

<150> PCT/US99/20881

<151> 1999-09-23

<150> 60/101,594

<151> 1998-09-24

<160> 73

<170> PatentIn Ver. 2.0

<210> 1

<211> 1804

<212> DNA

<213> Homo sapiens

<400> 1

```

atggggcgac tggcccgggc gctgctgctg cctctgctgg cccagtgggt cctgcgcgcc 60
gccccggagc tggcccccgc gcccttcacg ctgcccctcc ggggtggcgc ggccacgaac 120
cgcgtagttg cgcccacccc gggaccgggg acccctgccc agcgccacgc cgacggcttg 180
gcgctcgccc tggagcctgc cctggcgctc ccgcggggcg ccgccaactt cttggccatg 240
gtagacaacc tgcaggggga ctctggccgc ggctactacc tggagatgct gatcgggacc 300
cccccgcaga agctacagat tctcgttgac actggaagca gtaactttgc cgtggcagga 360
accccgcact cctacataga cacgtacttt gacacagaga ggtctagcac ataccgctcc 420
aagggctttg acgtcacagt gaagtacaca caaggaagct ggacgggctt cgttggggaa 480
gacctcgtea ccatcccaa aggcttcaat acttcttttc ttgtcaacat tgccactatt 540
tttgaatcag agaatttctt tttgcctggg attaaatgga atggaatact tggcctagct 600
tatgccacac ttgccaagcc atcaagttct ctggagacct tottogactc cctggtgaca 660
caagcaaaca tccccaaagt tttctccatg cagatgtgtg gagccggctt gcccgttgct 720
ggatctggga ccaacggagg tagtcttgct ttgggtggaa ttgaaccaag tttgtataaa 780
ggagacatct ggtatacccc tattaaggaa gagtggtact accagataga aattctgaaa 840
ttggaaattg gaggccaaag ccttaatctg gactgcagag agtataacgc agacaaggcc 900
atcgctggaca gtggcaccac gctgctgcgc ctgccccaga aggtgtttga tgcggtggtg 960
gaagctgtgg ccgcgcgcat tctgattcca gaattctctg atggtttctg gactgggtcc 1020
cagctggcgt gctggacgaa ttcggaacaa ccttgggtctt acttccctaa aatctccatc 1080
tacctgagag atgagaactc cagcaggtca ttccgtatca caatcctgcc tcagctttac 1140
attcagccca tgatgggggc cggcctgaat tatgaatgtt accgattcgg catttcccca 1200
tccacaaatg cgctggtgat cgggtgccacg gtgatggagg gcttctacgt catcttcgac 1260
agagcccaga agagggtggg cttcgcagcg agccctgtg cagaaattgc aggtgctgca 1320
gtgtctgaaa tttccggggc tttctcaaca gaggatgtag ccagcaactg tgtcccgcgt 1380
cagtctttga gcgagcccat tttgtggatt gtgtcctatg cgctcatgag cgtctgtgga 1440
gccatcctcc ttgtcttaat cgtcctgctg ctgctgccgt tccggtgtca gcgtcgcccc 1500

```

- 2 -

```

cgtgaccctg aggtcgtcaa tgatgagtcc tctctgggtca gacatcgctg gaaatgaata 1560
gccaggcctg acctcaagca accatgaact cagctattaa gaaaatcaca tttccagggc 1620
agcagccggg atcgatgggtg gcgctttctc ctgtgccac ccgtcttcaa tctctgttct 1680
gtccccagat gccttctaga ttcactgtct ttgtattctt gatcttcaag ctttcaaatac 1740
ctccctactt ccaagaaaaa taattaaaaa aaaaacttca ttctaaacca aaaaaaaaaa 1800
aaaaa 1804

```

<210> 2
 <211> 518
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Gly Ala Leu Ala Arg Ala Leu Leu Leu Pro Leu Leu Ala Gln Trp
 1 5 10 15
 Leu Leu Arg Ala Ala Pro Glu Leu Ala Pro Ala Pro Phe Thr Leu Pro
 20 25 30
 Leu Arg Val Ala Ala Ala Thr Asn Arg Val Val Ala Pro Thr Pro Gly
 35 40 45
 Pro Gly Thr Pro Ala Glu Arg His Ala Asp Gly Leu Ala Leu Ala Leu
 50 55 60
 Glu Pro Ala Leu Ala Ser Pro Ala Gly Ala Ala Asn Phe Leu Ala Met
 65 70 75 80
 Val Asp Asn Leu Gln Gly Asp Ser Gly Arg Gly Tyr Tyr Leu Glu Met
 85 90 95
 Leu Ile Gly Thr Pro Pro Gln Lys Leu Gln Ile Leu Val Asp Thr Gly
 100 105 110
 Ser Ser Asn Phe Ala Val Ala Gly Thr Pro His Ser Tyr Ile Asp Thr
 115 120 125
 Tyr Phe Asp Thr Glu Arg Ser Ser Thr Tyr Arg Ser Lys Gly Phe Asp
 130 135 140
 Val Thr Val Lys Tyr Thr Gln Gly Ser Trp Thr Gly Phe Val Gly Glu
 145 150 155 160
 Asp Leu Val Thr Ile Pro Lys Gly Phe Asn Thr Ser Phe Leu Val Asn
 165 170 175
 Ile Ala Thr Ile Phe Glu Ser Glu Asn Phe Phe Leu Pro Gly Ile Lys
 180 185 190
 Trp Asn Gly Ile Leu Gly Leu Ala Tyr Ala Thr Leu Ala Lys Pro Ser
 195 200 205
 Ser Ser Leu Glu Thr Phe Phe Asp Ser Leu Val Thr Gln Ala Asn Ile
 210 215 220
 Pro Asn Val Phe Ser Met Gln Met Cys Gly Ala Gly Leu Pro Val Ala
 225 230 235 240
 Gly Ser Gly Thr Asn Gly Gly Ser Leu Val Leu Gly Gly Ile Glu Pro
 245 250 255

- 3 -

Ser Leu Tyr Lys Gly Asp Ile Trp Tyr Thr Pro Ile Lys Glu Glu Trp
 260 265 270
 Tyr Tyr Gln Ile Glu Ile Leu Lys Leu Glu Ile Gly Gly Gln Ser Leu
 275 280 285
 Asn Leu Asp Cys Arg Glu Tyr Asn Ala Asp Lys Ala Ile Val Asp Ser
 290 295 300
 Gly Thr Thr Leu Leu Arg Leu Pro Gln Lys Val Phe Asp Ala Val Val
 305 310 315 320
 Glu Ala Val Ala Arg Ala Ser Leu Ile Pro Glu Phe Ser Asp Gly Phe
 325 330 335
 Trp Thr Gly Ser Gln Leu Ala Cys Trp Thr Asn Ser Glu Thr Pro Trp
 340 345 350
 Ser Tyr Phe Pro Lys Ile Ser Ile Tyr Leu Arg Asp Glu Asn Ser Ser
 355 360 365
 Arg Ser Phe Arg Ile Thr Ile Leu Pro Gln Leu Tyr Ile Gln Pro Met
 370 375 380
 Met Gly Ala Gly Leu Asn Tyr Glu Cys Tyr Arg Phe Gly Ile Ser Pro
 385 390 395 400
 Ser Thr Asn Ala Leu Val Ile Gly Ala Thr Val Met Glu Gly Phe Tyr
 405 410 415
 Val Ile Phe Asp Arg Ala Gln Lys Arg Val Gly Phe Ala Ala Ser Pro
 420 425 430
 Cys Ala Glu Ile Ala Gly Ala Ala Val Ser Glu Ile Ser Gly Pro Phe
 435 440 445
 Ser Thr Glu Asp Val Ala Ser Asn Cys Val Pro Ala Gln Ser Leu Ser
 450 455 460
 Glu Pro Ile Leu Trp Ile Val Ser Tyr Ala Leu Met Ser Val Cys Gly
 465 470 475 480
 Ala Ile Leu Leu Val Leu Ile Val Leu Leu Leu Leu Pro Phe Arg Cys
 485 490 495
 Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu Ser Ser Leu
 500 505 510
 Val Arg His Arg Trp Lys
 515

<210> 3

<211> 2070

<212> DNA

<213> Homo sapiens

<400> 3

atggcccaag ccctgccttg gctcctgctg tggatgggag cgggagtgcg gcctgcccac 60
 ggcacccagc acggcatccg gctgcctctg cgcagcggcc tggggggcgc cccctggggg 120
 ctgcggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240

- 4 -

```

gtgggcagcc cccgcagac gctcaacatc ctgggtggata caggcagcag taactttgca 300
gtgggtgctg cccccacccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tcgggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420
ctgggcaccg acctggttaag catcccccat ggccccaacg tcaactgtgc tgccaacatt 480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcatcctg 540
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 600
ctggtaaaagc agaccacagt tcccaacctc ttctccctgc acctttgtgg tggaggcttc 660
cccccaacc agtctgaagt gctggcctct gtccggaggga gcatgatcat tggaggatc 720
gaccactcgc tgtacacagg cagtctctgg tatacaccca tccggcggga gtggtattat 780
gaggtcacatc ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gttccctgat 960
ggtttctggc taggagagca gctgggtgtgc tggcaagcag gcaccacccc ttggaacatt 1020
ttcccagtc tctcactcta cctaattgggt gaggttacca accagtcctt ccgcatcacc 1080
atccttccgc agcaatacct ggggccagtg gaagatgtgg ccacgtccca agacgactgt 1140
tacaagtttg ccatctcaca gtcatccacg ggcactgtta tgggagctgt tatcatggag 1200
ggcttctacg ttgtctttga tggggcccg aaacgaattg gctttgtgtg cagcgcttgc 1260
catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
gaagactgtg gctacaacat tccacagaca gatgagtcaa cctcatgac catagcctat 1380
gtcatggctg ccatctgcgc cctcttcacg ctgccactct gctcatgggt gtgtcagtg 1440
cgctgcctcc gctgcctgcg ccagcagcat gatgactttg ctgatgacat ctccctgctg 1500
aagtgaggag gccatgggc agaagataga gattccccctg gaccacacct ccgtgggttc 1560
ctttggtcac aagtaggaga cacagatggc acctgtggcc agagcacctc aggaccctcc 1620
ccaccaccca aatgcctctg ccttgatgga gaagggaaaag gctggcaagg tgggttccag 1680
ggactgtacc ttaggaaac agaaaagaga agaaaagaagc actctgctgg cgggaatact 1740
cttggtcacc tcaaatttaa gtccggaaat tctgctgctt gaaacttcag cctgaaacct 1800
ttgtccacca ttcttttaa ttctccaacc caaagtattc ttcttttctt agtttcagaa 1860
gtactggcat cacgcagcgg ttacctggc gtgtgtccct gtggtaccct ggcagagaag 1920
agaccaagct tgtttccctg ctggccaaag tcagtaggag aggatgcaca gtttgctatt 1980
tgcttttagag acagggactg tataaacaag cctaacattg gtgcaaagat tgctctctga 2040
attaaaaaaaa aaaaaaaaaa aaaaaaaaaa

```

<210> 4

<211> 501

<212> PRT

<213> Homo sapiens

<400> 4

```

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
  1              5              10              15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
      20              25              30

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
      35              40              45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
      50              55              60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
      65              70              75              80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
      85              90              95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
      100             105             110

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
      115             120             125

```


- 5 -

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140
 Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160
 Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175
 Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp
 180 185 190
 Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro
 195 200 205
 Asn Leu Phe Ser Leu His Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln
 210 215 220
 Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
 225 230 235 240
 Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg
 245 250 255
 Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
 260 265 270
 Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val
 275 280 285
 Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala
 290 295 300
 Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp
 305 310 315 320
 Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr
 325 330 335
 Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val
 340 345 350
 Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg
 355 360 365
 Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala
 370 375 380
 Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu
 385 390 395 400
 Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala
 405 410 415
 Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu
 420 425 430
 Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro
 435 440 445
 Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met Ala Ala
 450 455 460

- 6 -

Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp
 465 470 475 480

Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp
 485 490 495

Ile Ser Leu Leu Lys
 500

<210> 5
 <211> 1977
 <212> DNA
 <213> Homo sapiens

<400> 5
 atggcccaag ccctgccctg gctcctgctg tggatggggc cgggagtgtt gcttgcacac 60
 ggcaccacag acggcatccg gctgccccctg cgcagcgggc tggggggcgc ccccttgggg 120
 ctgcggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
 gtggagatgg tggacaacct gaggggcaag tgggggcagg gctactacgt ggagatgacc 240
 gtgggcagcc cccgcagac gctcaacatc ctgggtggata caggcagcag taactttgca 300
 gtgggtgctg cccccaccc ctctcctgcat cgctactacc agaggcagct gtccagcaca 360
 taccgggacc tccggaaggg tgtgtatgtg cctacacccc agggcaagtg ggaaggggag 420
 ctgggcaccg acctggtaag catcccccat ggccccaacg tcaactgtgc tgccaacatt 480
 gctgccatca ctgaatcaga caagtctctt atcaacggct ccaactggga aggcacacct 540
 gggctggcct atgctgagat tgccaggctt tgtggtgctg gcttccccct caaccagtct 600
 gaagtgtctg cctctgtcgg agggagcatg atcattggag gtatcgacca ctcgctgtac 660
 acaggcagtc tctggtatac acccatccgg cgggagtggg attatgaggt gatcattgtg 720
 cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
 agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagctgca 840
 gtcaaatcca tcaaggcagc ctctccacg gagaagttcc ctgatgggtt ctggctagga 900
 gagcagctgg tgtgctggca agcaggcacc accccttggg acattttccc agtcattctca 960
 ctctacctaa tgggtgaggt taccaaccag tcttccgca tcaccatcct tccgcagcaa 1020
 tacctgcygc cagtggaaaga tgtggccacg tcccaagacg actgttacaa gtttgccatc 1080
 tcacagtcac ccacgggcac tgttatggga gctgttatca tggagggctt ctacgttgtc 1140
 tttgatcggg ccgaaaaacg aattggcttt gctgtcagcg ctgtccatgt gcacgatgag 1200
 ttcaggacgg cagcgggtga aggccctttt gtcaccttgg acatggaaga ctgtggctac 1260
 aacattccac agacagatga gtcaacctc atgacctag cctatgtcat ggctgccatc 1320
 tgcgccctct tcatgtgcc actctgcctc atggtgtgtc agtggcgctg cctccgctgc 1380
 ctgcgccagc agcatgatga ctttgcctgt gacatctccc tgctgaagtg aggaggccca 1440
 tgggcagaag atagagattc ccttggaacca cactccgtg gttcactttg gtcacaagta 1500
 ggagacacag atggcacctg tggccagagc acctcaggac cctccccacc caccaaatgc 1560
 ctctgccttg atggagaagg aaaaggctgg caaggtgggt tccagggaact gtacctgtat 1620
 gaaacagaaa agagaagaaa gaagcactct gctggcggga atactcttgg tcacctcaaa 1680
 ttttaagtcg gaaattctgc tgcttgaaac ttcagccctg aacctttgtc caccattcct 1740
 ttaaattctc caacccaaag tattcttctt ttcttagttt cagaagtact ggcatcacac 1800
 gcaggttacc ttggcgtgtg tccctgtggg acctggcag agaagagacc aagcttgttt 1860
 ccctgctggc caaagtcagt aggagaggat gcacagtttg ctatttgctt tagagacagg 1920
 gactgtataa acaagcctaa cattggtgca aagattgcct cttgaaaaaa aaaaaaa 1977

<210> 6
 <211> 476
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
 1 5 10 15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30

- 7 -

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
 100 105 110

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Leu Cys Gly
 180 185 190

Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly
 195 200 205

Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu
 210 215 220

Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val
 225 230 235 240

Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr
 245 250 255

Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu
 260 265 270

Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser
 275 280 285

Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val
 290 295 300

Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser
 305 310 315 320

Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile
 325 330 335

Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln
 340 345 350

Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val
 355 360 365

- 8 -

Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala
 370 375 380

Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu
 385 390 395 400

Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu
 405 410 415

Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser Thr Leu Met Thr
 420 425 430

Ile Ala Tyr Val Met Ala Ala Ile Cys Ala Leu Phe Met Leu Pro Leu
 435 440 445

Cys Leu Met Val Cys Gln Trp Arg Cys Leu Arg Cys Leu Arg Gln Gln
 450 455 460

His Asp Asp Phe Ala Asp Asp Ile Ser Leu Leu Lys
 465 470 475

<210> 7

<211> 2043

<212> DNA

<213> Mus musculus

<400> 7

```

atggccccag cgctgcactg gctcctgcta tgggtgggct cgggaatget gcctgcccag 60
ggaaccatcc tgggcatccg gctgcccctt cgcagcggcc tggcagggcc acccctgggc 120
ctgaggctgc cccgggagac tgacgaggaa tcggaggagc ctggccggag aggcagcttt 180
gtggagatgg tggacaacct gaggggaaaag tccggccagg gctactatgt ggagatgacc 240
gtaggcagcc cccacagac gctcaacatc ctggtggaca cgggcagtag taactttgca 300
gtgggggctg cccacacccc ttctctgcat cgctactacc agaggcagct gtccagcaca 360
tatcgagacc tccgaaaggg tgtgtatgtg ccctacaccc agggcaagtg ggagggggaa 420
ctgggcaccg acctggtgag catccctcat ggccccaacg tcaactgtgc tgccaacatt 480
gctgccatca ctgaatcgga caagtctctc atcaatgggt ccaactggga gggcatccta 540
gggctggcct atgctgagat tgccaggccc gacgactctt tggagccctt ctttgactcc 600
ctggtgaagc agaccacat tcccaacatc ttttccctgc agctctgtgg cgctggcttc 660
cccctcaacc agaccgaggc actggcctcg gtgggagggg gcatgatcat tgggtggtatc 720
gaccactcgc tatacacggg cagtctctgg tacacaccca tccggcggga gtggtattat 780
gaagtgatca ttgtacgtgt ggaaatcaat ggtcaagatc tcaagatgga ctgcaaggag 840
tacaactacg acaagagcat tgtggacagt ggacacacca acctcgctt gcccaagaaa 900
gtatttgaag ctgccgtcaa gtccatcaag gcagcctcct cgacggagaa gttcccggat 960
ggcttttggc taggggagca gctggtgtgc tggcaagcag gcacgacccc ttggaacatt 1020
ttcccagtca ttccacttta cctcatgggt gaagtcacca atcagtcctt ccgcatcacc 1080
atccttcttc agcaatacct acggccgggtg gaggacgtgg ccacgtccca agacgactgt 1140
tacaagttcg ctgtctcaca gtcacccacg ggcactgtta tgggagccgt catcatggaa 1200
ggtttctatg tcgtcttcga tcgagcccgaa aagcgaattg gctttgctgt cagcgcttgc 1260
catgtgcacg atgagttcag gacggcggca gtggaaggtc cgtttgttac ggcagacatg 1320
gaagactgtg gctacaacat tcccagaca gatgagtaa cacttatgac catagcctat 1380
gtcatggcgg ccatctgcgc cctcttcatg ttgccactct gcctcatggt atgtcagtgg 1440
cgctgectgc gttgcctgcg ccaccagcac gatgactttg ctgatgacat ctccttgctc 1500
aagtaaggag gctcgtgggc agatgatgga gacgcccctg gaccacatct ggggtggtcc 1560
ctttggtcac atgagttgga gctatggatg gtacctgtgg ccagagcacc tcaggacctt 1620
caccaacctg ccaatgcttc tggcgtgaca gaacagagaa atcaggcaag ctggattaca 1680
gggcttgcac ctgtaggaca caggagaggg aaggaagcag cgttctggtg gcaggaatat 1740
ccttaggcac cacaaacttg agttggaaat tttgctgctt gaagcttcag ccctgacctt 1800
ctgcccagca tcccttagag tctccaacct aaagtattct ttatgtcctt ccagaagtac 1860
tggcgtcata ctcaggctac ccggcatgtg tccctgtggt accctggcag agaaagggcc 1920
aatctcattc cctgctggcc aaagtcagca gaagaagggt aagtttgcca gttgctttag 1980
tgatagggac tgcagactca agcctacact ggtacaaaga ctgcgtcttg agataaacia 2040
gaa 2043

```

- 9 -

<210> 8

<211> 501

<212> PRT

<213> Mus musculus

<400> 8

Met Ala Pro Ala Leu His Trp Leu Leu Leu Trp Val Gly Ser Gly Met
 1 5 10 15

Leu Pro Ala Gln Gly Thr His Leu Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30

Gly Leu Ala Gly Pro Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45

Glu Glu Ser Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
 100 105 110

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp
 180 185 190

Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Ile Pro
 195 200 205

Asn Ile Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln
 210 215 220

Thr Glu Ala Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
 225 230 235 240

Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg
 245 250 255

Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
 260 265 270

Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val
 275 280 285

Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala
 290 295 300

- 10 -

Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp
 305 310 315 320

Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr
 325 330 335

Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val
 340 345 350

Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg
 355 360 365

Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala
 370 375 380

Val Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu
 385 390 395 400

Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala
 405 410 415

Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu
 420 425 430

Gly Pro Phe Val Thr Ala Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro
 435 440 445

Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met Ala Ala
 450 455 460

Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp
 465 470 475 480

Arg Cys Leu Arg Cys Leu Arg His Gln His Asp Asp Phe Ala Asp Asp
 485 490 495

Ile Ser Leu Leu Lys
 500

<210> 9

<211> 2088

<212> DNA

<213> Homo sapiens

<400> 9

atgctgcccc gtttggcact gctcctgctg gccgcctgga cggtcgggc gctggaggta 60
 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggacccaa 180
 acctgcattg ataccaagga aggcacctcg cagtattgcc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtgcaagac ccaccccccac tttgtgattc cctaccgctg cttagtgtgg 360
 gagttttgtaa gtgatgccct tctcgttccg gacaagtgca aattcttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttactcgg cacaccgtcg ccaaagagac atgcagttag 480
 aaaggtacca acttgcata ctacggcatg ttgctgccct gcggaattga caagttccga 540
 ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
 gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
 ccctacgaag aagccacaga gagaaccacc agcattgccca ccaccaccac caccaccaca 840
 gagtctgtgg aagaggtggg tcgagtccct acaacagcag ccagtacccc tgatgccgtt 900
 gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
 gagaggcttg aggccaaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020

- 11 -

```

gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaaag tggaaatcttt ggaacaggaa gcagccaacg agagacagca gctgggtggag 1140
acacacatgg ccagagtggg agccatgctc aatgaccgcc gccgcctggc cctggagaaac 1200
tacatcaccc ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cgcatgggtg atcccaagaa agccgctcag atccgggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcagtaa tcagtctctc tccttgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaaacta ttcagatgac 1500
gtcttggtgcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctcttcccg tgaatggaga gttcagcctg 1620
gacgatctcc agcgtgggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctgttgatgc ccgcctgct gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
ggttcaaaca aaggtgcaat cattggactc atgggtggcg gtgttgatc atgcacagtg 1920
atcgatcatc ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
gtggaggttg acgccgctgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaacctt caagttcttt gagcagatgc agaactag 2088

```

<210> 10

<211> 695

<212> PRT

<213> Homo sapiens

<400> 10

```

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
  1             5             10             15

```

```

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
      20             25             30

```

```

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
      35             40             45

```

```

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
      50             55             60

```

```

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
      65             70             75             80

```

```

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
      85             90             95

```

```

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
      100            105            110

```

```

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
      115            120            125

```

```

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
      130            135            140

```

```

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
      145            150            155            160

```

```

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
      165            170            175

```

```

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
      180            185            190

```

- 12 -

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300
 Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320
 Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335
 Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350
 Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365
 Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380
 Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400
 Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415
 Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430
 Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445
 Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460
 Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480
 Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495
 Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
 500 505 510

- 14 -

```

acacacatgg ccagagtggg agccatgctc aatgaccggc gccgcctggc cctggagaac 1200
tacatcaccc ctctgcaggc tgttctctct cggcctcgct acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cgcattgggtg atcccaagaa agccgctcag atccgggtccc aggttatgac acacctccgt 1380
gtgattttatg agcgcataaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaacta ttcagatgac 1500
gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaaac caccgtggag ctcttctccc tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tccagccaa cacagaaaac 1680
gaagttgagc ctgttgatgc ccgccctgct gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaatctgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
ggttcaaaca aagtgcaat cattggactc atggtgggcg gtgttgatc atgcacagtg 1920
atcgatcatc ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
gtggagggtg acgccgctgt caccacagag gaggccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaaccta caagttcttt gagcagatgc agaactag 2088

```

<210> 12

<211> 695

<212> PRT

<213> Homo sapiens

<400> 12

```

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1              5              10              15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
      20              25              30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
      35              40              45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
      50              55              60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
      65              70              75              80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
      85              90              95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
      100              105              110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
      115              120              125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
      130              135              140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
      145              150              155              160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
      165              170              175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
      180              185              190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
      195              200              205

```

- 15 -

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300
 Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320
 Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335
 Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350
 Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365
 Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380
 Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400
 Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415
 Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430
 Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445
 Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460
 Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480
 Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495
 Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
 500 505 510
 Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
 515 520 525
 Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
 530 535 540

- 16 -

Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
 545 550 555 560

Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
 565 570 575

Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
 580 585 590

Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
 625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
 645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
 660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
 675 680 685

Phe Phe Glu Gln Met Gln Asn
 690 695

<210> 13
 <211> 2088
 <212> DNA
 <213> Homo sapiens

<400> 13
 atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
 ccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
 acctgcattg ataccaagga aggcattcctg cagtattgcc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtgcaagac ccattccccac tttgtgattc cctaccgctg cttagtgtgt 360
 gaggttgtaa gtgatgcct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagttag 480
 aagagtacca acttgcattg ctacggcatg ttgctgacct gcggaattga caagttccga 540
 ggggtagagt ttgtgtgttg ccactggct gaagaaagtg acaatgtgga ttctgtgat 600
 gcggaggagg atgactcgga tgtctggtgg gccggagcag acacagacta tgcagatggg 660
 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
 gagtctgtgg aagaggtggt tctgattcct acaacagcag ccagtacccc tgatgccgtt 900
 gacaagtatc tctgacacac tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
 gagaggcttg aggcacaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
 gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
 caggagaaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
 acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200
 tacatcaccg ctctgcaggc tgttctctct cggcctcgtc acgtgttcaa tatgctaaag 1260
 aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
 cgcattgttg atcccaagaa agccgctcag atccgggtccc aggttatgac acacctccgt 1380
 gtgatttatg agcgcattgaa tcatgtctct tccctgctct acaacgtgcc tgcagtggcc 1440
 gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500
 gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560

- 17 -

```

tctttgaccg aaacgaaaac caccgtggag ctcttcccg tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctggtgatgc ccgccctgct gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tggtctttgc agaagatgtg 1860
ggttcaaaca aaggtgcaat cattggactc atgggtggcg gtgttgtcat agcgacagtg 1920
atcttcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
gtggagggtg acgcgcgtgt caccocagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaacctc caagttcttt gacgagatgc agaactag 2088

```

<210> 14

<211> 695

<212> PRT

<213> Homo sapiens

<400> 14

```

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
  1              5              10              15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
      20              25              30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
      35              40              45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
      50              55              60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
      65              70              75              80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
      85              90              95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
      100              105              110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
      115              120              125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
      130              135              140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
      145              150              155              160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
      165              170              175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
      180              185              190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
      195              200              205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
      210              215              220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
      225              230              235              240

```

- 18 -

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270

Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300

Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320

Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335

Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350

Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365

Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380

Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400

Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415

Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430

Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445

Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460

Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480

Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495

Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
 500 505 510

Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
 515 520 525

Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
 530 535 540

Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
 545 550 555 560

- 19 -

Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
 565 570 575
 Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
 580 585 590
 Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 595 600 605
 His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 610 615 620
 Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
 625 630 635 640
 Ile Phe Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
 645 650 655
 His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
 660 665 670
 His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
 675 680 685
 Phe Phe Glu Gln Met Gln Asn
 690 695

<210> 15
 <211> 2094
 <212> DNA
 <213> Homo sapiens

<400> 15
 atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatggt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaa 180
 acctgcattg ataccaagga aggcatacctg cagtattgcc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtgcaagac ccatccccac tttgtgatcc cctaccgctg cttagtgggt 360
 gagtttgtaa gtgatgccct tctcgttccg gacaagtgca aattcttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtggg 480
 aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagtccga 540
 ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
 gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
 gagtctgtgg aagaggtggg tcgagttcct acaacagcag ccagtacccc tgatgccgtt 900
 gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
 gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
 gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
 caggagaaag tggaaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
 acacacatgg ccagagtggg agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200
 tacatcaccg ctctgcaggc tgcttcctct cggcctcgct acgtgttcaa tatgtctaaag 1260
 aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
 cgcattggtg atcccaagaa agccgctcag atccgggtccc aggttatgac acacctccgt 1380
 gtgatttatg agcgcagtaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
 gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaaacta ttcagatgac 1500
 gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
 tctttgaccg aaacgaaaac caccgtggag ctccctcccc tgaatggaga gttcagcctg 1620
 gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680

- 20 -

gaagttgagc ctgttgatgc ccgccctgct gccgaccgag gactgaccac tcgaccaggt 1740
 tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
 cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
 ggttcaaaca aaggtgcaat cattggactc atggtgggag gtgttgcac agcgacagtg 1920
 atcgatcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
 gtggaggttg acgccgctgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
 ggctacgaaa atccaacctt caagttcttt gagcagatgc agaacaagaa gtag 2094

<210> 16

<211> 697

<212> PRT

<213> Homo sapiens

<400> 16

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255

- 21 -

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270

Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300

Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320

Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335

Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350

Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365

Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380

Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400

Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415

Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430

Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445

Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460

Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480

Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495

Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
 500 505 510

Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
 515 520 525

Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
 530 535 540

Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
 545 550 555 560

Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
 565 570 575

- 22 -

Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
580 585 590

Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
690 695

<210> 17

<211> 2094

<212> DNA

<213> Homo sapiens

<400> 17

```

atgctgcccc gtttggcact gtcctgctg gccgctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
acctgcattg ataccaagga aggcacctct cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgaaca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggg 360
gagtttgtaa gtgatgcctt tctcgttctt gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttacttgg cacaccgtcg ccaaagagac atgcagttag 480
aagagtacca acttgcatga ctacggcatg ttgctgccc gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcgaggaggg atgactcgga tgtctggttg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtctgttg aagaggtggg tcgagttcct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
gcagaacgtc aagcaaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaaag tggaaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtggg agccatgctc aatgaccgcc gccgctggc cctggagaac 1200
tacatcaccc ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cgcatgggtg atcccaagaa agccgctcag atccggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaacta ttcagatgac 1500
gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctccctccc tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctgttgatgc ccgcctgct gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaaggag atctctgaag tgaatctgga tgcagaattc 1800

```

- 23 -

cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
 gggtcaaaca aagggtgcaat cattggactc atgggtggcg gtgttgcat agcgacagtg 1920
 atcgatcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
 gtggaggttg acgccgtgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
 ggctacgaaa atccaaccta caagttcttt gagcagatgc agaacaagaa gtag 2094

<210> 18

<211> 697

<212> PRT

<213> Homo sapiens

<400> 18

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270

- 24 -

Ala Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300
 Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320
 Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335
 Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350
 Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365
 Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380
 Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400
 Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415
 Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430
 Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445
 Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460
 Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480
 Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495
 Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
 500 505 510
 Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
 515 520 525
 Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
 530 535 540
 Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
 545 550 555 560
 Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
 565 570 575
 Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
 580 585 590

- 25 -

Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
690 695

<210> 19

<211> 2094

<212> DNA

<213> Homo sapiens

<400> 19

```

atgctgcccc gtttggcaat gctcctgctg gccgcctgga cggctcgggc gctggaggtta 60
ccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
acctgcattg ataccaagga aggcattcctg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccatccccac tttgtgattc cttaccgctg cttagtgggt 360
gagtttgtaa gtgatgcctt tctcgttctt gacaagtga aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttactggt cacaccgtcg ccaaagagac atgcagtga 480
aagagtacca acttgcctga ctacggcatg ttgctgcctt gcggaattga caagtccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gctggaggagg atgactcgga tgtctgggtg gccggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtcgtgtg aagaggtggt tctgagttctt acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tctgagacac tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
gagaggcttg aggccaaagc ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaaag tggaaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtggg agccatgtct aatgaaccgcc gccgcctggc cctggagaac 1200
tacatcaccg ctctgcaggc tgttctctct cggcctcgtc acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cgcatggttg atcccaagaa agccgtctag atccgggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcatgaa ttagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaaacta ttcagatgac 1500
gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctcttcccg tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgcagccaa cacagaaaac 1680
gaagttgagc ctgttgatgc ccgcctgct gccgaccgag gactgaccac tgcaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
ggttcaaaca aaggtgcaat cattggactc atgggtgggc gtgttgctat agcgacagt 1920
atcttcata ccttgggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
gtggaggttg ccgcgctgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaaccta caagttcttt gagcagatgc agaacaagaa gtag 2094

```

- 26 -

<210> 20

<211> 697

<212> PRT

<213> Homo sapiens

<400> 20

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270

Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285

- 27 -

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300
 Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320
 Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335
 Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350
 Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365
 Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380
 Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400
 Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415
 Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430
 Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445
 Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460
 Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480
 Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495
 Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
 500 505 510
 Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
 515 520 525
 Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
 530 535 540
 Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
 545 550 555 560
 Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
 565 570 575
 Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
 580 585 590
 Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 595 600 605
 His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 610 615 620

- 28 -

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Phe Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
690 695

<210> 21
<211> 1341
<212> DNA
<213> Homo sapiens

<400> 21
atggctagca tgactggtgg acagcaaattg ggtagcggtt ccacccagca cggcatccgg 60
ctgccccctgc gcagcggcct gggggggcgcc cccctggggc tgcggctgcc ccgggagacc 120
gacgaagagc cggaggagcc cggcgggagg ggcagctttg tggagatggt ggacaacctg 180
aggggcaagt cggggcaggg ctactacgtg gagatgaccg tgggcagccc cccgcagacg 240
ctcaacatcc tgggtggatac aggcagcagt aactttgcag tgggtgctgc cccccacccc 300
ttctgcacgc gctactacca gaggcagctg tccagcacat accgggacct ccggaagggt 360
gtgtatgtgc cctacaccca gggcaagtgg gaaggggagc tgggcaccga cctggttaagc 420
atcccccatg gccccaacgt cactgtgcgt gccaacattg ctgccatcac tgaatcagac 480
aagtcttcca tcaacggctc caactgggaa ggcacacctg ggctggccta tgctgagatt 540
gccaggcctg acgactccct ggagcctttc tttgactctc tggtaagca gaccacgtt 600
cccaacctct tctccctgca cctttgtggt gctggcttcc cctcaacca gtctgaagtg 660
ctggcctctg tccggaggag catgatcatt ggaggtatcg accactcgct gtacacaggc 720
agtctctggt atacacccat ccggcgggag tggattatg aggtcatcat tgtgcgggtg 780
gagatcaatg gacaggatct gaaaatggac tgcaaggagt acaactatga caagagcatt 840
gtggacagtg gcaccaccaa ccttcgtttg cccaagaaag tgtttgaagc tgcagtcaaa 900
tccatcaagg cagcctctc caccggagaag ttcctgatg gtttctggct aggagagcag 960
ctggtgtgct ggcaagcagg caccacccct tggaaacatt tcccagtcac ctactctac 1020
ctaattgggtg aggttaccaa ccagtccttc cgcacacca tcttccgca gcaatacctg 1080
cggccagtgg aagatgtggc caggtcccaa gacgactgtt acaagtttgc catctcacag 1140
tcacccacgg gcactgttat gggagctggt atcatggagg gcttctacgt tgtctttgat 1200
cgggcccgaa aacgaattgg ctttgcgtgc agcgttgcc atgtgcacga tgagttcagg 1260
acggcagcgg tggaaggccc ttttgtcacc ttggacatgg aagactgtgg ctacaacatt 1320
ccacagacag atgagtcatt a 1341

<210> 22
<211> 446
<212> PRT
<213> Homo sapiens

<400> 22

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Thr Gln
1 5 10 15

His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu
20 25 30

Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly
35 40 45

- 29 -

Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser
 50 55 60
 Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr
 65 70 75 80
 Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala
 85 90 95
 Ala Pro His Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser
 100 105 110
 Thr Tyr Arg Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly
 115 120 125
 Lys Trp Glu Gly Glu Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly
 130 135 140
 Pro Asn Val Thr Val Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp
 145 150 155 160
 Lys Phe Phe Ile Asn Gly Ser Asn Trp Glu Gly Ile Leu Gly Leu Ala
 165 170 175
 Tyr Ala Glu Ile Ala Arg Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp
 180 185 190
 Ser Leu Val Lys Gln Thr His Val Pro Asn Leu Phe Ser Leu His Leu
 195 200 205
 Cys Gly Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val
 210 215 220
 Gly Gly Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly
 225 230 235 240
 Ser Leu Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile
 245 250 255
 Ile Val Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys
 260 265 270
 Glu Tyr Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu
 275 280 285
 Arg Leu Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala
 290 295 300
 Ala Ser Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln
 305 310 315 320
 Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val
 325 330 335
 Ile Ser Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile
 340 345 350
 Thr Ile Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr
 355 360 365
 Ser Gln Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly
 370 375 380

- 30 -

Thr Val Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp
 385 390 395 400

Arg Ala Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His
 405 410 415

Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp
 420 425 430

Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 435 440 445

<210> 23
 <211> 1380
 <212> DNA
 <213> Homo sapiens

<400> 23
 atggctagca tgactggtgg acagcaaagt ggtcgcggtat cgatgactat ctctgactct 60
 ccgcgtgaac aggacggatc caccagcac ggcacccggc tgccctgccc cagcggcctg 120
 gggggcgccc ccttggggct gggcgtgccc ggggagaccg acgaagagcc cgaggagccc 180
 ggccggaggg gcagctttgt ggagatggtg gacaacctga ggggcaagtc ggggcagggc 240
 tactacgtgg agatgaccgt gggcagcccc ccgcagacgc tcaacatcct ggtggatata 300
 ggcagcagta actttgcagt ggggtgctgcc cccacccctt tcttgcacgc ctactaccag 360
 aggcagctgt ccagcacata ccgggacctc cggaagggtg tgtatgtgcc ctacacccag 420
 ggcaagtggg aaggggagct gggcaccgac ctggttaagca tccccatgg ccccaacgtc 480
 actgtgcgtg ccaacattgc tgccatcact gaatcagaca agttcttcat caacggctcc 540
 aactgggaag gcacccctgg gctggcctat gctgagattg ccaggcctga cgactccctg 600
 gagcctttct ttgactctct ggtaaagcag acccacgttc ccaacctctt ctccctgcac 660
 ctttgtgggtg ctggcttccc cctcaaccag tctgaagtgc tggcctctgt cggagggagc 720
 atgatcattg gaggtatcga ccactcgtg tacacaggca gtctctggta tacacccatc 780
 cggcgggagt ggtattatga ggtcatcatt gtgcgggtgg agatcaatgg acaggatctg 840
 aaaatggact gcaaggagta caactatgac aagagcattg tggacagtgg caccaccaac 900
 cttcgtttgc ccaagaaagt gtttgaagct gcagtcfaat ccatcaaggc agcctcctcc 960
 acggagaagt tccctgatgg tttctggcta ggagagcagc tgggtgtgctg gcaagcaggc 1020
 accacccctt ggaacatttt ccagtcac tcaactctacc taatgggtga ggttaccac 1080
 cagtccttcc gcacaccat ccttcgcag caatacctgc ggcagtgga agatgtggcc 1140
 acgtcccaag acgactgtta caagtttgcc atctcacagt catccacggg cactgttatg 1200
 ggagctgtta tcatggaggg cttctacgtt gtctttgatc gggcccgaaa acgaattggc 1260
 tttgtgtca gcgcttgcca tgtgcacgat gaggtcagga cggcagcggg ggaaggccct 1320
 tttgtcacct tggacatgga agactgtggc tacaacattc cacagacaga tgagtcatga 1380

<210> 24
 <211> 459
 <212> PRT
 <213> Homo sapiens

<400> 24
 Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr
 1 5 10 15

Ile Ser Asp Ser Pro Arg Glu Gln Asp Gly Ser Thr Gln His Gly Ile
 20 25 30

Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg
 35 40 45

Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly
 50 55 60

- 31 -

Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly
 65 70 75 80
 Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile
 85 90 95
 Leu Val Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His
 100 105 110
 Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg
 115 120 125
 Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu
 130 135 140
 Gly Glu Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val
 145 150 155 160
 Thr Val Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe
 165 170 175
 Ile Asn Gly Ser Asn Trp Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu
 180 185 190
 Ile Ala Arg Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp Ser Leu Val
 195 200 205
 Lys Gln Thr His Val Pro Asn Leu Phe Ser Leu His Leu Cys Gly Ala
 210 215 220
 Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly Ser
 225 230 235 240
 Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp
 245 250 255
 Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg
 260 265 270
 Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn
 275 280 285
 Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro
 290 295 300
 Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser
 305 310 315 320
 Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys
 325 330 335
 Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu
 340 345 350
 Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu
 355 360 365
 Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp
 370 375 380
 Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met
 385 390 395 400

- 32 -

Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg
 405 410 415

Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe
 420 425 430

Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp
 435 440 445

Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 450 455

<210> 25
 <211> 1302
 <212> DNA
 <213> Homo sapiens

<400> 25
 atgactcagc atggtattcg tctgccactg cgtagcggtc tgggtggtgc tccactgggt 60
 ctgcgtctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 120
 gtggagatgg tggacaacct gaggggcaag tgggggcagg gctactacgt ggagatgacc 180
 gtgggcagcc ccccgagac gctcaacatc ctggtggata caggcagcag taactttgca 240
 gtgggtgctg cccccaccc ctctctgcat cgctactacc agaggcagct gtccagcaca 300
 taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 360
 ctgggcaccg acctggtaag catccccat ggccccaacg tcaactgtgc tgccaacatt 420
 gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcattctg 480
 gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 540
 ctggtaaagc agaccacgt tccaacctc ttctccctgc acctttgtgg tgettgcttc 600
 cccctcaacc agtctgaagt gctggcctct gtccggaggga gcatgatcat tggaggtatc 660
 gaccactcgc tgtacacagg cagtctctgg tatacaccca tccggcggga gtggtattat 720
 gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 780
 tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 840
 gtgtttgaag ctgcagtcaa atccatcaag gcagctcctt ccacggagaa gttccctgat 900
 ggtttctggc taggagagca gctggtgtgc tggcaagcag gcaccacccc ttggaacatt 960
 ttcccagtc tctactcta cctaattgggt gaggtacca accagtcctt ccgcatacc 1020
 atccttcgc agcaatacct gcggccagtg gaagatgtgg ccacgtccca agacgactgt 1080
 tacaagtttg ccatctcaca gcatccacg ggcactgtta tgggagctgt tatcatggag 1140
 ggcttctacg ttgtctttga tcgggcccga aaacgaattg gctttgctgt cagcgcttgc 1200
 catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1260
 gaagactgtg gctacaacat tccacagaca gatgagtcac ga 1302

<210> 26
 <211> 433
 <212> PRT
 <213> Homo sapiens

<400> 26
 Met Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly
 1 5 10 15

Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu
 20 25 30

Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg
 35 40 45

Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro
 50 55 60

Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala
 65 70 75 80

- 34 -

Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu
 420 425 430

Ser

<210> 27

<211> 1278

<212> DNA

<213> Homo sapiens

<400> 27

```

atggctagca tgactgggtg acagcaaagt ggtgcgggat cgatgactat ctctgactct 60
ccgctggact ctggtatcga aaccgacgga tcctttgttg agatgggtgga caacctgagg 120
ggcaagtcgg ggcaaggccta ctacgtggag atgaccgtgg gcagccccc gcagacgctc 180
aacatcctgg tggatacagg cagcagtaac tttgcagtgg gtgctgcccc ccacccttc 240
ctgcatcgct actaccagag gcagctgtcc agcacatacc gggacctccg gaaggggtgtg 300
tatgtgccct acacccaggg caagtgggaa ggggagctgg gcaccgacct ggtaagcatc 360
ccccatggcc ccaacgtcac tgtgcgtgcc aacattgctg ccatactga atcagacaag 420
ttcttcacga acggctccaa ctgggaaggc atcctggggc tggcctatgc tgagattgcc 480
aggcctgacg actccctgga gcctttcttt gactctctgg taaagcagac ccacgttccc 540
aacctcttct ccctgcacct ttgtgggtgt ggcctcccc tcaaccagtc tgaagtgtgt 600
gcctctgtcg gagggagcat gatcattgga ggtatcgacc actcgctgta cacaggcagt 660
ctctgggtata caccatccg gcgggagtggt tattatgagg tcatcattgt gcgggtggag 720
atcaatggac aggatctgaa aatggactgc aaggagtaca actatgacaa gagcattgtg 780
gacagtggca ccaccaacct tcgtttgcc aagaaagtgt ttgaagctgc agtcaaatcc 840
atcaaggcag cctcctccac ggagaagttc cctgatgggt tctggctagg agagcagctg 900
gtgtgctggc aagcaggcac cacccttgg aacattttcc cagtcacttc actctacct 960
atgggtgagg ttaccaacca gtccctccgc atcaccatcc ttccgcagca atacctgccg 1020
ccagtggaa atgtggccac gtcccaagac gactgttaca agtttgccat ctcacagtca 1080
tccacgggca ctgttatggg agctgttacc atggagggct tctacgttgt ctttgatcgg 1140
gccgaaaaac gaattggctt tgctgtcagc gcttgccatg tgcacgatga gttcaggacg 1200
gcagcgggtg aaggcccttt tgtcaccttg gacatggaag actgtggcta caacattcca 1260
cagacagatg agtcatga 1278

```

<210> 28

<211> 425

<212> PRT

<213> Homo sapiens

<400> 28

```

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr
  1 5 10 15
Ile Ser Asp Ser Pro Leu Asp Ser Gly Ile Glu Thr Asp Gly Ser Phe
 20 25 30
Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr
 35 40 45
Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val
 50 55 60
Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Pro His Pro Phe
 65 70 75 80
Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu
 85 90 95
Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu
100 105 110
Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val
115 120 125

```

- 35 -

Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn
 130 135 140
 Gly Ser Asn Trp Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala
 145 150 155 160
 Arg Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln
 165 170 175
 Thr His Val Pro Asn Leu Phe Ser Leu His Leu Cys Gly Ala Gly Phe
 180 185 190
 Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile
 195 200 205
 Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr
 210 215 220
 Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu
 225 230 235 240
 Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp
 245 250 255
 Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys
 260 265 270
 Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu
 275 280 285
 Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln
 290 295 300
 Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu
 305 310 315 320
 Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln
 325 330 335
 Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys
 340 345 350
 Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala
 355 360 365
 Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg
 370 375 380
 Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr
 385 390 395 400
 Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly
 405 410 415
 Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 420 425

<210> 29

<211> 1362

<212> DNA

<213> Homo sapiens

- 36 -

<400> 29

```

atggcccaag ccctgccctg gctcctgctg tggatgggag cgggagtgct gcctgcccac 60
ggcaccacag acggcatccg gctgcccctg cgcagcggcc tggggggcgc ccccttgggg 120
ctggggctgc cccgggagac cgcagaagag cccgaggagc cgggcccggag gggcagcttt 180
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
gtgggcagcc ccccgagac gctcaacatc ctgggtggata caggcagcag taactttgca 300
gtgggtgctg cccccacccc ctccctgcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420
ctgggcaccg acctggtaag catcccccat ggcccacaacg tcaactgtgc tgccaacatt 480
gctgccatca ctgaatcaga caagtctctt atcaacggct ccaactggga aggcacacct 540
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 600
ctggtaaagc agaccacagt tcccaacctc ttctccctgc acctttgtgg tgctggcttc 660
cccccaacc agtctgaagt gctggcctct gtccggaggga gcatgatcat tggaggtatc 720
gaccactcgc tgtacacagg cagtctctgg tatacaccca tcgggcggga gtggatttat 780
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gttccctgat 960
ggttttctggc taggagagca gctgggtgtg tggcaagcag gcaccacccc ttggaacatt 1020
ttcccagtca tctcactcta cctaattgggt gaggttacca accagtctt ccgcatacc 1080
atccttccgc agcaataacct gcggccagtg gaagatgtgg ccacgtccca agacgactgt 1140
tacaagtttg ccattctaca gtcattccag ggcactgtta tgggagctgt tatcatggag 1200
ggcttctacg ttgtctttga tcgggcccga aaacgaattg gctttgctgt cagcgcttgc 1260
catgtgcag atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
gaagactgtg gctacaacat tccacagaca gatgagtcat ga 1362

```

<210> 30

<211> 453

<212> PRT

<213> Homo sapiens

<400> 30

```

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
 1             5             10             15

```

```

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
          20             25             30

```

```

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
          35             40             45

```

```

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
          50             55             60

```

```

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
          65             70             75             80

```

```

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
          85             90             95

```

```

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
          100            105            110

```

```

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
          115            120            125

```

```

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
          130            135            140

```

```

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
          145            150            155            160

```


- 37 -

[illegible]

<210> 31
<211> 1380
<212> DNA

- 38 -

<213> Homo sapiens

<400> 31

```

atggcccaag ccctgccctg gctcctgctg tggatgggag cgggagtgct gcctgcccac 60
ggcaccacag acggcatccg gctgcccctg cgcagcggcc tggggggcgc cccctgggg 120
ctgcggctgc cccgggagac cgcagaagag cccgaggagc ccggccggag gggcagcttt 180
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
gtgggcagcc ccccgagac gctcaacatc ctggtggata caggcagcag taactttgca 300
gtgggtgctg cccccaccc ctctctgcat cgtactacc agaggcagct gtccagcaca 360
taccgggacc tccggaaggg tgtgtatgtg ccctacacc agggcaagtg ggaaggggag 420
ctgggcaccc acctggttaag catcccccat ggccccaacg tcaactgtgc tgccaacatt 480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcattctg 540
gggctggcct atgctgagat tggcaggcct gacgactccc tggagccttt ctttgactct 600
ctggtaaaagc agaccacgt tcccaacctc ttctccctgc acctttgtgg tgctggcttc 660
ccctcaacc agtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggtatc 720
gaccactcgc tgtacacagg cagtctctgg tatacacca tccggcgagg gtggtattat 780
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gccaagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gtccctgat 960
ggtttctggc taggagagca gctggtgtgc tggcaagcag gcaccacccc ttggaacatt 1020
ttcccgatca tctactcta cctaattgggt gaggttacca accagtcctt ccgcatcacc 1080
atcttccgc agcaatacct gcggccagtg gaagatgtgg ccacgtccca agacgactgt 1140
tacaagtttg ccattctaca gtcattccag ggcactgtta tgggagctgt tatcatggag 1200
ggcttctacg ttgtctttga tcgggcccga aaacgaattg gctttgctgt cagcgcttgc 1260
catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
gaagactgtg gctacaacat tccacagaca gatgagtcac agcagcagca gcagcagtga 1380

```

<210> 32

<211> 459

<212> PRT

<213> Homo sapiens

<400> 32

```

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
  1                      5                      10                      15

```

```

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
      20                      25                      30

```

```

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
      35                      40                      45

```

```

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
      50                      55                      60

```

```

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
      65                      70                      75                      80

```

```

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
      85                      90                      95

```

```

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
      100                      105                      110

```

```

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
      115                      120                      125

```

```

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
      130                      135                      140

```

```

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
      145                      150                      155                      160

```

- 39 -

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
165 170 175

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp
180 185 190

Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro
195 200 205

Asn Leu Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln
210 215 220

Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
225 230 235 240

Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg
245 250 255

Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
260 265 270

Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val
275 280 285

Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala
290 295 300

Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp
305 310 315 320

Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr
325 330 335

Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val
340 345 350

Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg
355 360 365

Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala
370 375 380

Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu
385 390 395 400

Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala
405 410 415

Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu
420 425 430

Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro
435 440 445

Gln Thr Asp Glu Ser His His His His His His
450 455

<210> 33

<211> 25

- 40 -

<212> PRT

<213> Homo sapiens

<400> 33

Ser Glu Gln Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu
 1 5 10 15

Ser Ser Leu Val Arg His Arg Trp Lys
 20 25

<210> 34

<211> 19

<212> PRT

<213> Homo sapiens

<400> 34

Ser Glu Gln Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp Ile Ser
 1 5 10 15

Leu Leu Lys

<210> 35

<211> 29

<212> DNA

<213> Homo sapiens

<400> 35

gtggatccac ccagcacggc atccggctg 29

<210> 36

<211> 36

<212> DNA

<213> Homo sapiens

<400> 36

gaaagctttc atgactcatc tgtctgtgga atgttg 36

<210> 37

<211> 39

<212> DNA

<213> Homo sapiens

<400> 37

gatcgatgac tatctctgac tctccgctg aacaggacg 39

<210> 38

<211> 39

<212> DNA

<213> Homo sapiens

<400> 38

gatccgtcct gttcacgcgg agagtcagag atagtcac 39

<210> 39

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2

- 41 -

<400> 39
cggcacccgg ctgccctgc gtagcgggtct ggggtgggtc cactggggtc tgcgtctgcc 60
ccgggagacc gacgaag 77

<210> 40
<211> 77
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Hu-Asp2

<400> 40
cttcgtcggg ctcccggggc agacgcagac ccagtggagc accaccaga ccgctacgca 60
ggggcagccg gatgccg 77

<210> 41
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Caspase 8
Cleavage Site

<400> 41
gatcgatgac tatctctgac tctccgctgg actctgggtat cgaaaccgac g 51

<210> 42
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Caspase 8
Cleavage Site

<400> 42
gatccgtcgg ttccgatacc agagtccagc ggagagtcag agatagtcac c 51

<210> 43
<211> 32
<212> DNA
<213> Homo sapiens

<400> 43
aaggatcctt tgtggagatg gtggacaacc tg 32

<210> 44
<211> 36
<212> DNA
<213> Homo sapiens

<400> 44
gaaagctttc atgactcatc tgtctgtgga atgttg 36

<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 6-His tag

47
accac tcgaccaggt tc 22

48
51
DNA
Artificial Sequence

Description of Artificial Sequence: primer

48
-aaat tccagcacac tggctacttc ttgttctgca tctcaaagaa c 51

49
26
DNA
Artificial Sequence

Description of Artificial Sequence: primer

49
-aaat tccagcacac tggcta 26

50
1287
DNA
Artificial Sequence

Description of Artificial Sequence: Hu-Asp2(b)
delta TM

50
ccaag cctgccttg gctcctgctg tggatgggag cgggagtgct gctgcccac 60
ccagc acggcatccg gctgcccctg cgcagcggcc tggggggcgc cccctgggg 120
gctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
gatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
cagcc cccgcagac gctcaacatc ctgggggata caggcagcag taactttgca 300
tgctg cccccaccc ctctctgcat cgctactacc agaggcagct gtccagcaca 360

1/49097

PCT/IB01/00797

- 42 -

45
atca tcaccatcac catg 24

46
24
DNA
Artificial Sequence

Description of Artificial Sequence: 6-His tag

46
-tggt gatggtgatg atgc 24

47
22
DNA
Artificial Sequence

Description of Artificial Sequence: primer

- 43 -

```

taccgggacc tccggaaggg tgtgtatgtg cccacacccc agggcaagtg ggaaggggag 420
ctgggcaccg acctggtaag catcccccat ggccccaacg tcaactgtgcg tgccaacatt 480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcattctg 540
gggctggcct atgctgagat tgccaggctt tgtggtgctg gcttccccct caaccagtct 600
gaagtgtctg cctctgtcgg agggagcatg atcattggag gtatcgacca ctcgctgtac 660
acaggcagtc tctgttatac acccatccgg cgggagtggg attatgaggt catcattgtg 720
cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagtgcga 840
gtcaaattcca tcaaggcagc ctctccacg gagaagttcc ctgatgggtt ctggctagga 900
gagcagctgg tgtgctggca agcaggcacc accccttggg acattttccc agtcatctca 960
ctctacctaa tgggtgaggt taccaaccag tcttccgca tcaccatcct tccgcagcaa 1020
tacctgcggc cagtgaaga tgtggccacg tcccaagacg actgttacaa gtttgccatc 1080
tcacagtcac ccacgggcac tggtatggga gctgttatca tggagggctt ctacgttgtc 1140
tttgatcggg ccgaaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200
ttcaggacgg cagcgggtgga aggcctttt gtcaccttgg acatggaaga ctgtggctac 1260
aacattccac agacagatga gtcatga 1287

```

<210> 51

<211> 428

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2(b)
delta TM

<400> 51

```

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
  1                      5                      10                      15

```

```

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
          20                      25                      30

```

```

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
          35                      40                      45

```

```

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
          50                      55                      60

```

```

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
          65                      70                      75                      80

```

```

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
          85                      90                      95

```

```

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
          100                      105                      110

```

```

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
          115                      120                      125

```

```

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
          130                      135                      140

```

```

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
          145                      150                      155                      160

```

```

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
          165                      170                      175

```

```

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Leu Cys Gly
          180                      185                      190

```

- 44 -

Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly
 195 200 205

Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu
 210 215 220

Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val
 225 230 235 240

Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr
 245 250 255

Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu
 260 265 270

Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser
 275 280 285

Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val
 290 295 300

Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser
 305 310 315 320

Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile
 325 330 335

Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln
 340 345 350

Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val
 355 360 365

Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala
 370 375 380

Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu
 385 390 395 400

Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu
 405 410 415

Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 420 425

<210> 52

<211> 1305

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2(b)
 delta TM

<400> 52

atggcccaag cctgcccctg gctcctgctg tggatgggag cgggagtgct gcctgcccac 60
 ggaccccagc acggcatccg gctgcccctg cgcagcggcc tggggggcgc cccctggggg 120
 ctgcggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
 gtgggcagcc ccccgagac gctcaacatc ctgggtggata caggcagcag taactttgca 300
 gtgggtgctg ccccccaccc cttcctgcat cgtactacc agaggcagct gtccagcaca 360
 taccgggacc tccggaaggg tgtgtatgtg cctacaccc agggcaagtg ggaaggggag 420

- 45 -

```

ctggggcaccg acctggtaag catcccccat ggccccaacg tcaactgtgcg tgccaacatt 480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcattcctg 540
gggctggcct atgctgagat tgccaggctt tgtggtgctg gcttccccct caaccagtct 600
gaagtgtcgg cctctgtcgg agggagcatg atcattggag gtatcgacca ctgcgtgtac 660
acaggcagtc tctggtatac acccatccgg cgggagtggg attatgaggt catcattgtg 720
cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagtgcga 840
gtcaaatcca tcaaggcagc ctctccacg gagaagttcc ctgatggttt ctggctagga 900
gagcagctgg tgtgctggca agcaggcacc accccttggg acattttccc agtcattctca 960
ctctacctaa tgggtgaggt taccaaccag tccttcgca tcaccatcct tccgcagcaa 1020
tacctgcggc cagtggaaga tgtggccacg tcccaagacg actgttacia gtttgccatc 1080
tcacagtcac ccacgggcac tggttatggg gctgttatca tggagggctt ctacgttgtc 1140
tttgatcggg cccgaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200
ttcaggacgg cagcgggtga aggccctttt gtcaccttgg acatggaaga ctgtggctac 1260
aacattccac agacagatga gtcacagcag cagcagcagc agtga 1305

```

<210> 53

<211> 434

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2(b)
delta TM

<400> 53

```

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
  1             5             10             15

```

```

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
          20             25             30

```

```

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
          35             40             45

```

```

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
          50             55             60

```

```

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
          65             70             75             80

```

```

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
          85             90             95

```

```

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
          100            105            110

```

```

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
          115            120            125

```

```

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
          130            135            140

```

```

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
          145            150            155            160

```

```

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
          165            170            175

```

```

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Leu Cys Gly
          180            185            190

```

- 46 -

Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly
 195 200 205

Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu
 210 215 220

Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val
 225 230 235 240

Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr
 245 250 255

Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu
 260 265 270

Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser
 275 280 285

Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val
 290 295 300

Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser
 305 310 315 320

Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile
 325 330 335

Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln
 340 345 350

Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val
 355 360 365

Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala
 370 375 380

Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu
 385 390 395 400

Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu
 405 410 415

Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser His His His His
 420 425 430

His His

<210> 54

<211> 2310

<212> DNA

<213> Homo sapiens

<400> 54

atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
 cccactgatg gtaatgctgg cctgctggct gaacccaga ttgccatgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
 acctgcattg ataccaagga aggcacctcg cagtattgcc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgaacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtgcaagac ccatcccac tttgtgattc cctaccgctg cttagtgtgt 360

- 47 -

```

gagtttgttaa gtgatgccct tctcgttccct gacaagtgtca aattctttaca ccaggagagg 420
atggatgtttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagttag 480
aagagtacca acttgcattga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcggg tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggtgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgccca ccaccaccac caccaccaca 840
gagtctgtgg aagaggtggt tcgagaggtg tgctctgaac aagccgagac ggggccgtgc 900
cgagcaatga tctcccgtcg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
tacggcggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
tgtggcagcg ccatgtccca aagtttactc aagactaccc aggaacctct tggccgagat 1080
cctgttaaac ttctacaac agcagccagt acccctgatg ccgttgacaa gtatctcgag 1140
acacctgggg atgagaatga acatgcccat ttccagaaag ccaaagagag gcttgaggcc 1200
aagcaccgag agagaatgtc ccaggtcatg agagaatggg aagaggcaga acgtcaagca 1260
aagaacttgc ctaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa 1320
tctttggaac aggaagcagc caacgagaga cagcagctgg tggagacaca catggccaga 1380
gtggaagcca tgctcaatga ccgccgcgc ctggccctgg agaactacat caccgctctg 1440
caggtgttct ctcctcggcc tcgtcacgtg ttcaatatgc taaagaagta tgtccgcgca 1500
gaacagaagg acagacagca caccctaaag catttcgagc atgtgcgcat ggtggatccc 1560
aagaaagccg ctcatatccg gtcccaggtt atgacacacc tccgtgtgat ttatgagcgc 1620
atgaatcagt ctctctccct gctctacaac gtgcttcgag tggccgagga gattcaggat 1680
gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg 1740
attagtgaac caaggtatcag ttacggaaac gatgtcttca tgccatcttt gaccgaaacg 1800
aaaaccaccg tggagctcct tcccgtgaat ggagagttca gcttgacga tctccagccg 1860
tggcattctt ttggggctga ctctgtgccca ggcaacacag azaacgaagt tgagcctgtt 1920
gatgcccgcc ctgctgccga ccgaggactg accactcgac caggttcttg gttgacaaat 1980
atcaagacgg aggagatctc tgaagtgaag atggatgcaq aattccgaca tgactcagga 2040
tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 2100
gcaatcattg gactcatggt gggcgggtgtt gtcatacgca cagtgatcgt catcaccttg 2160
gtgatgctga agaagaaca gtacacatcc attcatcatg gtgtggtgga gggtgacgcc 2220
gctgtcaccc cagaggagcg ccacctgtcc aagatgcagc agaacggcta cgaaaatcca 2280
acctacaagt tctttgagca gatgcagaac 2310

```

<210> 55

<211> 770

<212> PRT

<213> Homo sapiens

<400> 55

```

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
  1             5             10            15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
      20             25            30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
      35             40            45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
      50             55            60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
      65             70            75            80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
      85             90            95

Trp Cys Lys Arg Gly Arg Lys Cln Cys Lys Thr His Pro His Phe Val
      100            105            110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
      115            120            125

```

- 48 -

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300
 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 305 310 315 320
 Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335
 Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
 340 345 350
 Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
 355 360 365
 Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
 370 375 380
 Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
 385 390 395 400
 Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
 405 410 415
 Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
 420 425 430
 Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
 435 440 445
 Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
 450 455 460

- 49 -

Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
 465 470 475 480
 Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
 485 490 495
 Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
 500 505 510
 Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
 515 520 525
 Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
 530 535 540
 Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
 545 550 555 560
 Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
 565 570 575
 Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
 580 585 590
 Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
 595 600 605
 Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
 610 615 620
 Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
 625 630 635 640
 Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
 645 650 655
 Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
 660 665 670
 Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
 675 680 685
 Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
 690 695 700
 Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
 705 710 715 720
 Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
 725 730 735
 Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
 740 745 750
 Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
 755 760 765
 Gln Asn
 770

- 50 -

<210> 56
 <211> 2253
 <212> DNA
 <213> Homo sapiens

<400> 56
 atgctgcccc gtttggcact gctcctgctg gccgctgga cggctcgggc gctggaggtg 60
 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
 acctgcattg ataccaagga aggcacccct cagtattgcc aagaagtcta cctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgaacca tccagaactg gtgcaagcgg 300
 ggcgcgaage agtgcaagac ccacccccac tttgtgattc cctaccgctg cttagttggg 360
 gagtttgtaa gtgatgccct tctogttcct gacaagtga aattcttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttccactg cacaccgtcg ccaaagagac atgcagttag 480
 aagagtacca acttgcctga ctaccggcatg ttgctgccct gcggaattga caagttccga 540
 ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
 gcggaggagg atgactcgga tgtctgggtg gccggagcag acacagacta tgcagatggg 660
 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
 cccacgaag aagccacaga gagaaccacc agcattgcc caccaccac caccaccaca 840
 gagtctgtgg aagaggtggg tgcagaggtg tgcctgaac aagccgagac ggggcccgtg 900
 cgagcaatga tctcccgtg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
 tacggcggat gtggcggcaa ccggaacaa tttgacacag aagagtactg catggccgtg 1020
 tgtggcagcg ccatttctac aacagcagcc agtaccctg atgccgttga caagtatctc 1080
 gagacacctg gggatgagaa tgaacatgcc catttccaga aagccaaaga gaggtttgag 1140
 gccaaagcacc gagagagaat gtcccaggtc atgagagaat ggggaagaggc agaactgcaa 1200
 gcaaagaact tgctaaagc tgataagaag gcagttatcc agcatttcca ggagaaagtg 1260
 gaatctttgg aacaggaagc agccaacgag agacagcagc tgggtggagac acacatggcc 1320
 agagtggaaag ccattgctcaa tgaccgcccgc cgcttggccc tggagaacta catcaccgct 1380
 ctgcaggctg tctctctctg gcctcgtcac gtgttcaata tgctaaagaa gtatgtccgc 1440
 gcagaacaga ccacaccta aagcatttcc agcatgtgcg catggtggat 1500
 cccaagaaag ccgctcagat ccggtcccag gttatgacac acctccgtgt gatttatgag 1560
 cgcattgaatc agtctctctc cctgctctac aacgtgcctg cagtggccga ggagattcag 1620
 gatgaagtgt atgagctgct tcagaaagag caaaactatt cagatgacgt cttggccaac 1680
 atgattagtg aaccaaggat cagttacgga aacgatgctc tcatgccatc tttgaccgaa 1740
 acgaaaacca ccgtggagct ccttcccgtg aatggagagt tcagcctgga cgatctccag 1800
 ccgtggcatt cttttggggc tgactctgtg ccagccaaca cagaaaacga agttgagcct 1860
 gttgatgcc gccctgctgc cgaccgagga ctgaccactc gaccagggtc tgggttgaca 1920
 aatatcaaga cggaggagat ctctgaagtg aagatggatg cagaattccg acatgactca 1980
 ggatatgaag ttcattcatc aaaattggtg ttctttgcag aagatgtggg ttcaaacaaa 2040
 ggtgcaatca ttggactcat ggtgggcggg gttgtcatag cgacagtgat cgtcatcacc 2100
 ttggtgatgc tgaagaagaa acagtaacaa tccattcatc atggtgtggg ggaggttgac 2160
 gccgctgtca ccccagagga gcgccacctg tccaagatgc agcagaacgg ctacgaaaat 2220
 ccaacctaca agttctttga gcagatgcag aac 2253

<210> 57
 <211> 751
 <212> PRT
 <213> Homo sapiens

<400> 57
 Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60

- 51 -

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300
 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 305 310 315 320
 Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335
 Cys Met Ala Val Cys Gly Ser Ala Ile Pro Thr Thr Ala Ala Ser Thr
 340 345 350
 Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp Glu Asn Glu
 355 360 365
 His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala Lys His Arg
 370 375 380
 Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln
 385 390 395 400

- 52 -

Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile Gln His Phe
 405 410 415
 Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln
 420 425 430
 Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met Leu Asn Asp
 435 440 445
 Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu Gln Ala Val
 450 455 460
 Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys Tyr Val Arg
 465 470 475 480
 Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe Glu His Val
 485 490 495
 Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser Gln Val Met
 500 505 510
 Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu
 515 520 525
 Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp
 530 535 540
 Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn
 545 550 555 560
 Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro
 565 570 575
 Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro Val Asn Gly
 580 585 590
 Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp
 595 600 605
 Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val Asp Ala Arg
 610 615 620
 Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr
 625 630 635 640
 Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe
 645 650 655
 Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe
 660 665 670
 Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val
 675 680 685
 Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu
 690 695 700
 Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp
 705 710 715 720
 Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn
 725 730 735

- 53 -

Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met Gln Asn
740 745 750

<210> 58
<211> 2316
<212> DNA
<213> Homo sapiens

<400> 58
atgctgcccc gtttggcaact gctcctgctg gccgcctgga cggtcggggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggacccaaa 180
acctgcattg ataccaagga aggcacccctg cagtattgcc aagaagtcta cctgaactcg 240
cagatcacca atgtggtaga agccaaccaa ccagtaccca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccaccccac tttgtgattc cctaccgctg cttagttggg 360
gagtttgtaa gtgatgcccc tctcgttccg gacaagtgc aattctttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgcg 480
aagagtacca acttgcctga ctacggcatg ttgctgcccc gccgaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcccaggagg atgactcgga tgtctgtggg gccggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcc aaccaccac caccaccaca 840
gagctctgtg aagaggtggg tccgagagtg tgcctggaac aagccgagac gggcccggtg 900
cgagcaatga tctcccgctg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
tacggcggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
tgtggcagcg ccatgtccca aagtttactc aagactacct aggaacctct tggccgagat 1080
cctgttaaac ttccctacaac agcagccagt acccctgatg ccgttgacaa gtatctcgag 1140
acacctgggg atgagaatga acatgcccat ttccagaaag ccaaagagag gcttgaggcc 1200
aagcaccgag agagaatgtc ccaggtcatg aagaatggg aagaggcaga acgtcaagca 1260
aagaacttgc ctaaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa 1320
tctttggaac aggaagcagc caacgagaga cagcagctgg tggagacaca catggccaga 1380
gtggaagcca tgcctaatga ccgcgcgcgc ctggccctgg agaactacat caccgctctg 1440
caggtgttcc ctccctcgcc tgcctcagtg ttcaatatgc taaagaagta tgtccgcgca 1500
gaacagaagg acagacagca caccctaaag catctcgagc atgtgcgcac ggtggatccc 1560
aagaaagccg ctccagatccg gtcccaggtt atgacacacc tccgtgtgat ttatgagcgc 1620
atgaatcagt ctctctccct gctctacaac gtgcctgcag tggccgagga gattcaggat 1680
gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg 1740
attagtgaac caaggatcag ttacggaaac gatgctctca tgccatcttt gaccgaaacg 1800
aaaaccaccg tggagctcct tcccgtgaat ggagagttca gcctggacga tctccagccg 1860
tggcattctt ttggggctga ctctgtgcca gccaacacag aaaacgaagt tgagcctgtt 1920
gatgcccgcc ctgctgcgca ccgaggactg accactcgac caggttctgg gttgacaaat 1980
atcaagacgg aggagatctc tgaagtgaag atggatgcag aattccgaca tgactcagga 2040
tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 2100
gcaatcattg gactcatggt gggcgggtgt gtcatagcga cagtgatcgt catcaccttg 2160
gtgatgctga agaagaaaca gtacacatcc attcatcatg gtgtgggtga ggttgacgcc 2220
gctgtcacc cagaggagcg ccacctgtcc aagatgcagc agaacggcta cgaatatcca 2280
acctacaagt tctttgagca gatgcagaac aagaag 2316

<210> 59
<211> 772
<212> PRT
<213> Homo sapiens

<400> 59
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
1 5 10 15
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30

- 54 -

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300
 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 305 310 315 320
 Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335
 Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
 340 345 350
 Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
 355 360 365

- 55 -

Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
 370 375 380
 Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
 385 390 395 400
 Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
 405 410 415
 Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
 420 425 430
 Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
 435 440 445
 Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
 450 455 460
 Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
 465 470 475 480
 Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
 485 490 495
 Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
 500 505 510
 Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
 515 520 525
 Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
 530 535 540
 Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
 545 550 555 560
 Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
 565 570 575
 Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
 580 585 590
 Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
 595 600 605
 Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
 610 615 620
 Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
 625 630 635 640
 Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
 645 650 655
 Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
 660 665 670
 Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
 675 680 685
 Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
 690 695 700

- 56 -

Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
705 710 715 720

Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
725 730 735

Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
740 745 750

Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
755 760 765

Gln Asn Lys Lys
770

<210> 60

<211> 2259

<212> DNA

<213> Homo sapiens

<400> 60

```

atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
ccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
acctgcattg ataccaagga aggcacccct cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgaacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccaccccac tttgtgattc cctaccgctg cttagttygt 360
gagtttgtaa gtgatgccct tctcgttcct gacaagtgca aattccttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcactgg cacacccgtc ccaaagagac atgcagttag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
gggtagaggt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcggg tgtctgggtg ggccggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag ttgctgaggt ggaagaagaa 720
gaagccgacg atgacgagga cgatgaggaa tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtcgtgtg aagaggtggt tcgagaggtg tgctctgaac aagccgagac ggggcccgtg 900
cgagcaatga tctcccgtg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
tacggcggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
tgtggcagcg ccattcctac aacagcagcc agtacccttg atgccgttga caagtatctc 1080
gagacacctg gggatgagaa tgaacatgcc cattccaga aagccaaaga gaggcttag 1140
gccaagcacc gagagagaat gtcccaggtc atgagagaat ggaagaggc agaactcaa 1200
gcaaagaact rgcctaaagc tgataagaag gcagttatcc agcatttcca ggagaaagt 1260
gaatctttgg aacaggaagc agccaacgag agacagcagc tggtaggagc acacatggcc 1320
agagtgggag ccattgctcaa tgaccgcgcg cgcctggccc tggagaacta catcaccgct 1380
ctgcaggctg ttctcctcgt gcctcgtcac gtgttcaata tgctaaagaa gtatgtccgc 1440
gcagaacaga aggacagaca gcacacccta aagcatttcg agcatgtgcg catggtggat 1500
cccaagaaaag ccgctcagat ccggtcccag gttatgacac acctccgtgt gatttatgag 1560
cgcatgaatc agtctctctc cctgctctac aacgtgcctg cagtggccga ggagattcag 1620
gatgaagttg atgagctgct tcagaaagag caaaactatt cagatgacgt cttggccaac 1680
atgattagtg aaccaaggat cagttacgga aacgatgctc tcatgccatc tttgaccgaa 1740
acgaaaacca ccgtggagct ccttcccgtg aatggagagt tcagcctgga cgatectcag 1800
ccgtggcatt cttttggggc tgactctgtg ccagccaaca cagaaaacga agttgacct 1860
gttgatgcc gccctgctgc cgaccgagga ctgaccactc gaccagggtc tgggttgaca 1920
aatatcaaga cggaggagat ctctgaagtg aagatggatg cagaattccg acatgactca 1980
ggatatgaag ttcacatca aaaattggtg ttctttgcag aagatgtggg ttcaaacaaa 2040
ggtgcaatca ttggactcat ggtgggcggg gttgtcatag cgacagtgat cgtcatcacc 2100
ttggtgatgc tgaagaagaa acagtaacac tccattcatc atggtgtggt ggaggttgac 2160
gccgctgtca ccccagagga gccccacctg tccaagatgc agcagaacgg ctacgaaaat 2220
ccaacctaca agttctttga gcagatgcag aacaagaag 2259

```

- 57 -

<210> 61
 <211> 753
 <212> PRT
 <213> Homo sapiens

<400> 61
 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300

- 58 -

Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe	305	310	315	320
Tyr	Gly	Gly	Cys	Gly	Gly	Asn	Arg	Asn	Asn	Phe	Asp	Thr	Glu	Glu	Tyr	325	330	335	
Cys	Met	Ala	Val	Cys	Gly	Ser	Ala	Ile	Pro	Thr	Thr	Ala	Ala	Ser	Thr	340	345	350	
Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	355	360	365	
His	Ala	His	Phe	Gln	Lys	Ala	Lys	Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	370	375	380	
Glu	Arg	Met	Ser	Gln	Val	Met	Arg	Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	385	390	395	400
Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	Lys	Lys	Ala	Val	Ile	Gln	His	Phe	405	410	415	
Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu	Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	420	425	430	
Gln	Leu	Val	Glu	Thr	His	Met	Ala	Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	435	440	445	
Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn	Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	450	455	460	
Pro	Pro	Arg	Pro	Arg	His	Val	Phe	Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	465	470	475	480
Ala	Glu	Gln	Lys	Asp	Arg	Gln	His	Thr	Leu	Lys	His	Phe	Glu	His	Val	485	490	495	
Arg	Met	Val	Asp	Pro	Lys	Lys	Ala	Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	500	505	510	
Thr	His	Leu	Arg	Val	Ile	Tyr	Glu	Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	515	520	525	
Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala	Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	530	535	540	
Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn	Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	545	550	555	560
Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser	Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	565	570	575	
Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr	Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	580	585	590	
Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln	Pro	Trp	His	Ser	Phe	Gly	Ala	Asp	595	600	605	
Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn	Glu	Val	Glu	Pro	Val	Asp	Ala	Arg	610	615	620	
Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	Gly	Leu	Thr	625	630	635	640

- 59 -

Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Lys	Met	Asp	Ala	Glu	Phe	
				645					650							655
Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys	Leu	Val	Phe	Phe	
				660					665							670
Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile	Gly	Leu	Met	Val	
				675					680							685
Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Ile	Val	Ile	Thr	Leu	Val	Met	Leu	
				690					695							700
Lys	Lys	Lys	Gln	Tyr	Thr	Ser	Ile	His	His	Gly	Val	Val	Glu	Val	Asp	
705					710					715						720
Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser	Lys	Met	Gln	Gln	Asn	
				725					730							735
Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu	Gln	Met	Gln	Asn	Lys	
				740					745							750

Lys

```
<210> 62
<211> 8
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: synthetic

<400> 62
Leu Glu Val Leu Phe Gln Gly Pro
1 5

```
<210> 63
<211> 10
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: synthetic

```
<400> 63
Ser Glu Val Asn Leu Asp Ala Glu Phe Arg
 1             5             10
```

```
<210> 64
<211> 10
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: synthetic

```
<400> 64
Ser Glu Val  Lys Met  Asp Ala  Glu Phe  Arg
   1                   5                   10
```

- 60 -

<210> 65
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 65
Arg Arg Gly Gly Val Val Ile Ala Thr Val Ile Val Gly Glu Arg
1 5 10 15

<210> 66
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 66
Asn Leu Asp Ala
1

<210> 67
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 67
Glu Val Lys Met Asp Ala Glu Phe
1 5

<210> 68
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 68
Gly Arg Arg Gly Ser
1 5

<210> 69
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 69

- 61 -

Thr Gln His Gly Ile Arg
1 5

<210> 70
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 70

Glu Thr Asp Glu Glu Pro
1 5

<210> 71
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 71
Met Cys Ala Glu Val Lys Met Asp Ala Glu Phe Lys Asp Asn Pro
1 5 10 15

<210> 72
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 72

Asp Ala Glu Phe Arg
1 5

<210> 73
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 73

Ser Glu Val Asn Leu
1 5